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THESIS OUTLINE
The aims of the studies presented in this thesis are to:
1. Evaluate (long-term) toxicity after treatment with 177Lu-DOTATATE regarding:
a. Renal function
b. Subacute effects on the bonemarrow: prognostic factors, incidence and 
course
c. Hematological malignancies: incidence, course & predicting factors
d. Spleen volume decrease after PRRT: clinical and dosimetric correlation 
2. Evaluate a novel gastrin-releasing peptide receptor (GRPR) antagonist in patients 
with prostate or breast cancer
The first chapter is a general introduction. Chapter 1.1 is an opening text about 
neuroendocrine tumors and the different treatment modalities, including peptide 
radionuclide receptor therapy (PRRT). Chapter 1.2 gives a theoretical outline of 
dosimetry used in PRRT. Furthermore practical dosimetric aspects of the critical organs 
will be discussed. Chapter 1.3 describes the current literature on peptide radionuclide 
receptor therapy.
The second chapter covers (long-term) toxicity after PRRT with 177Lu-DOTATATE.  In 
Chapter 2.1 the renal function over time, the incidence of nephrotoxicity and associated 
risk factors are investigated in patients treated with 177Lu-DOTATATE. Also, the radiation 
dose to the kidneys is evaluated and compared to the accepted dose limits in external 
beam radiotherapy and PRRT with 90Y radiolabelled somatostatin analogues. Chapter 
2.2 describes the incidence, duration and risk factors of (sub)acute hematological 
toxicity in patients treated with PRRT. Absorbed bonemarrow dose estimates are 
evaluated and compared with the approved dose limit of 2 Gy. In Chapter 2.3 the 
incidence and clinical course of long-term hematological toxicity is analyzed in patients 
with (suspected) hematological malignancies after PRRT. In Chapter 2.4 the clinical 
implications of spleen volume loss and decreased lymphocyte count are studied.
The third chapter deals with targeted nuclear imaging of prostate and breast cancer. 
Chapter 3.1 gives an introduction to prostate/breast cancer and the possible targets for 
nuclear imaging. Chapter 3.2 characterizes a novel gastrin-releasing peptide receptor 
(GRPR) antagonist, 68Ga-SB3, in patients with prostate or breast cancer. 
Chapter 4.1 provides an English and Dutch summary of the presented data in this 
thesis whereas Chapter 4.2 concludes with a general discussion and future remarks. 
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1.1 PRRT & NETs
Neuroendocrine tumors (NETs) are a varied group of neoplasms that arise from 
neuroendocrine cells throughout the body. They most commonly occur in the 
intestines, but they are also frequently found in the pancreas and lungs. The term 
“carcinoid”, introduced by Siegfried Oberndorfer in 1907, is still wrongly used in the 
clinic and literature (1). The World Health Organization (WHO) replaced the term 
carcinoid by NET including the degree of differentiation and proliferation (2-5). For the 
bronchopulmonary NETs, the terminology remains “typical” and “atypical carcinoid” (6).
NETs can have special secretory granules and often produce biogenic amines and 
polypeptide hormones causing tumor-related symptoms (7). The peptide somatostatin 
inhibits the secretion of hormones by binding to the complementary somatostatin 
receptor (sst), which are expressed on most NETs (8). Five subtypes of the sst are known, 
sst1 - sst5 (9). Somatostatin analogs, like octreotide and lanreotide, can reduce symptoms 
(10), but can also be labeled with a radionuclide, like [111Indium-DTPA0]octreotide 
(OctreoScan®), for visualization and therapy (11,12). 
EPIDEMIOLOGY OF NETS
NETs are relatively rare tumors with an incidence of 2-5 cases per 100,000 persons (13-15). 
In the Netherlands (between 1989-1996), the incidence of NETs was 1.8 and 1.9 cases per 
100,000 persons for men and women, respectively (16). The highest incidence of NETs 
occurs in the 6th and 7th decade of life (15,16). A strong increase in incidence of NETS has 
been reported. This increase may reflect the improvement in diagnostic modalities, but 
also increased awareness of NETs by clinicians can explain this rise in incidence. Survival 
for all NETs has improved over time, especially for distantly metastasized gastrointestinal 
NETs and pancreatic NETs in particular, reflecting improvement in therapies (17). 
DIAGNOSIS
Clinical Aspects
The clinical presentation of NETs varies according to the anatomic site of origin, tumor 
size, function and extent of metastatic disease (18). Functioning NETs give hormone-
related symptoms, whereas non-functioning NETs are often clinically silent and found 
by coincidence (19). The hormone-related symptoms (carcinoid syndrome) consist of 
secretory diarrhea, flushing, wheezing and right sided valvular heart disease, which is 
caused by serotonin production. Serotonin production can cause small bowel ischemia, 
due to mesenteric fibrosis. Specific occasional hormone production of insulin, gastrine 
or VIP can cause hypoglycemia, peptic ulcer disease, and Verner-Morrison syndrome, 
respectively, in patients with NETs.
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Non-specific tumor related symptoms are (localized) pain, loss of weight and/or 
anorexia. 
Biomarkers
Important diagnostics for NETs are biochemical testing, imaging procedures and 
pathological findings. Frequent laboratory tests used in monitoring therapy and follow-
up include Chromogranine A (CgA), urinary 5-Hydroxyindoleacetic acid (5-HIAA) and 
Neuron-specific enolase (NSE), particularly in patients with functioning NETs. Also liver 
function tests are routinely performed in patients with liver metastasis.
An important serum marker is CgA, which is found in the secretory granules of 
neuroendocrine cells. Depending on the extent of disease, serum CgA is elevated in > 
60% of the patients with functioning or non-functioning NETs (20). The sensitivity and 
specificity of CgA for the detection of NETs is between 53-85% and 84-98% respectively 
(21). CgA levels can also be elevated due to use of medication (proton pump inhibitor), 
chronic kidney failure or gastritis, therefore medical history and use of medication 
should be asked. CgA can as well be used as a prognostic factor. Patients with a high 
serum CgA (> 5,000 μg/l) have a shorter median overall survival (OS) than patients with 
a low serum CgA (< 5,000 μg/l), 33 versus 57 months (22).
Measurement of the 5-HIAA is relevant in patients with the carcinoid syndrome. 5-HIAA 
is a breakdown metabolite of serotonin, making it an indirect marker for serotonin 
production by the tumor. Levels of 24-hour urinary 5-HIAA are correlated with extend of 
carcinoid heart disease (23). The sensitivity of urinary 5-HIAA in patients with carcinoid 
syndrome is 90%. However, certain medications and types of food can effect levels of 
5-HIAA in the urine and should be abstained during the 24-hour urine collection (24).
NSE levels can be used as a biomarker for both functioning and non-functioning NETs. 
Serum NSE is a cell-specific isoenzyme and is present in the cytoplasm of neurons 
and neuroendocrine cells. The marker is elevated in 30-50% of the patients with 
gastroenteropancreatic NETs (25-27). 
Since current biomarkers have clinical limitations, two major types of novel biomarkers 
have been considered: multigene signatures and circulating tumor cells. Multigene 
signatures provide characterization of NETs on a molecular level and can provide up-
to-date information about tumor activity and treatment response (28). Measurement of 
circulating tumor cells (CTCs) can be used to accurately identify and acquire genomic 
information of the NET. Limited data on the use of CTCs is available, but one study 
demonstrated promising results linking CTC to tumor burden in metastasized NET 
patients (29).
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Imaging
Medical imaging generally can be divided into two categories, anatomical and 
functional. 
Anatomical imaging of NETs can be performed with conventional (film) radiography, 
ultrasonography, angiography, computed tomography (CT) and magnetic resonance 
imaging (MRI) (30-33). Primary, (multi-phasic) CT and MRI are performed giving 
information about tumor localization, size and degree of invasion with surrounding 
tissue. A major limitation of these two latter imaging modalities is that only a part of 
the body is scanned, also small (< 10mm) non-pathological lymph nodes cannot be 
considered 100% tumor-free. 
Functional imaging can visualize the distribution of a specific target throughout the 
body. In case of NETs, somatostatin receptor scintigraphy (SRS) can provide information 
about the presence of sst’s on the tumor. Octreoscan® ([111In-DTPA0]octreotide) was one 
of the first successful radiotracers for imaging the somatostatin receptor (mainly sst2 
and sst5). The overall sensitivity of OctreoScan® in NET patients is 60-90% (34). SRS can 
be improved by the co-use of CT, combing functional- with anatomical information (35). 
SRS is more effective for screening the total body for primary lesions and metastasis. 
Furthermore, Octreoscan® is used to evaluate radioactivity uptake in the tumor for 
potential peptide receptor radionuclide therapy (PRRT) (36).
Recently, PET imaging with gallium-68-somatostatin analogs has improved somatostatin 
receptor imaging (37). It has been demonstrated that a 68Ga-DOTATATE or 68Ga-DOTATOC 
PET-scan can increase the spatial resolution and lesion detectability compared to 
Octreoscan® (37,38). Also 68Ga-DOTATATE has a major advantage for patients since 
imaging can be completed in less than 2 hours versus 2 days for OctreoScan® and 68Ga-
DOTATATE involves lower radiation exposure (39). Another gallium-68-somatostatin 
analog, 68Ga-DOTATOC, has also improved imaging of neuroendocrine tumors (40). 
[18F]-fluorodeoxyglucose (FDG)-PET can be used for imaging of poorly differentiated 
neuroendocrine carcinomas (NECs) or when the Octreoscan® is negative or equivocal 
(41). Recent studies have demonstrated that intermediate-moderate grade NETs with 
FDG positive lesions can progress more aggressively (42). Therefore a combination of 
FDG-PET and 68Ga-DOTATATE is increasingly being used prior and during therapy in 
patients with well- and moderately differentiated NETs (43,44).
Pathology, Staging and Grading
The final diagnosis of NET is mainly based on the pathology report. Therefore, a biopsy 
of the primary tumor and/or metastasis is fundamental in the workup. Various types 
of staining are available like hematoxylin and eosin (HE), also immunostaining with 
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CgA, synaptophysin and sst2 can be assessed. Additional immunostaining for specific 
hormones (e.g. insulin, glucagon, gastrin or vasoactive intestinal polypeptide) can be 
performed in a small group of patients with uncommon functional NETs. Also the rate of 
tumor growth can be estimated using Ki-67 index and/or mitotic count (45). 
For staging NETs, current guidelines utilize the tumor-node-metastasis (TNM) 
classification and the 2010 WHO grading system. The TNM system of NETs is site-specific 
and describes the stage according to size, lymph node involvement and presence 
of distant metastasis (46,47). The TNM system is also incorporated in the WHO 2010 
classification. The WHO grading system (48) is based on examining tumor-cells and 
-tissue. A grade 1-3 is given according to the mitotic count or proliferative activity (ki-
67), resulting in a NET or NEC, see Table 1. The prognostic validity of both TNM stage and 
proliferative rate has been demonstrated in several studies (49-51).
Table 1: Pathological grading of Neuroendocrine tumors. Neuroendocrine tumor (NET), 
Neuroendocrine carcinoma (NEC), High-power field (HPF)
Type of tumour
Degree of 
differentiation
Grade
Mitotic Count  
(per 10 HPF)
Ki-67 Index  
(%)
NET Well
G1 < 2 < 3
G2 2 - 20 3 - 20
NEC Poor G3 > 20 > 20
TREATMENT
Surgery
Surgery is the only curative treatment option in patients with localized 
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) (19,52). However, most 
of the patients often present with tumor-related symptoms and widespread disease. 
Nonetheless, surgical intervention can be a treatment option in patients with advanced 
disease. Resection of the primary tumor is associated with an increased overall survival 
in patients with NETs of pancreatic origin (53,54).  Surgery can also be performed 
for control of hormonal symptoms (55) and can prevent small bowel obstruction 
or ischemia in patients with mesenteric involvement (56). A combination of surgery, 
(chemo)embolization and/or radiofrequency ablation (RFA) can be an option for 
patients with advanced disease (19,56). As for patients without extrahepatic metastasis, 
liver transplantation can be considered (57). 
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Interventional radiology
Liver metastases of neuroendocrine tumors are often hypervascular and derive their 
blood supply mostly from the hepatic artery, as opposed to normal liver parenchyma, 
which mainly depends on the portal vein. Therefore occlusion of the hepatic arterial 
branches by (chemo)particles can induce tumor necrosis and volume reduction (58). 
Transcatheter arterial chemoembolization (TACE) can decrease tumor-related symptoms 
and has tumor response rates of 33-80% (59).  A recent study demonstrated no difference 
in survival rate for hepatic arterial embolization with or without chemotherapy coated 
particles (60). Radioembolization of neuroendocrine liver metastases can also be 
performed with radioactive 90Yttrium (90Y) microspheres. A median response rate of 63% 
(range 13-100%) has been reported with this technique (61). Local heating of the tumor 
with Radio frequency ablation (RFA) is used in patients with limited (< 5 liver lesions) and 
small tumors (<5 cm) (62). RFA is associated with relief of symptoms and can be used in 
combination with (partial) hepatic resection (62,63). Other local ablative techniques for 
neuroendocrine liver metastasis include alcohol ablation or (intraoperative) cryotherapy 
(63).
Somatostatin analogues
Somatostatin analogues (SSAs) are currently the first line therapy for grade 1-2 GEP-
NETs (64). SSAs inhibit hormone production (serotonin and growth hormone) by 
binding to the sst2, resulting in symptom control in up to 71% of the patients (65,66). 
Also an increase in time to progression with SSAs was demonstrated when compared to 
placebo in patients with NETs (67). Preoperative and perioperative octreotide therapy 
are essential to protect against carcinoid crises that can arise from anesthesia and/or 
tumor manipulation (68). However, long-term use of SSAs can desensitize the tumor, 
resulting in recurrence of hormone-related symptoms. 
Molecular targets
Various molecular targeted therapies have been developed for NETs in the past decade. 
In a recent study, patients treated with the tyrosine kinase inhibitor Sunitinib (Sutent; 
Pfizer Inc, New York, NY) had a longer median progression free survival (PFS) than placebo, 
11.4 versus 5.5 months (69). Also treatment with the mammalian target of rapamycin 
(mTOR)-inhibitor everolimus (Affinitor; Novartis Pharmaceuticals, Basel, Switzerland) 
resulted in a longer median PFS compared to placebo (11.0 versus 4.6 months) (70). 
A phase II study, combining the angiogenesis inhibitor bevacizumab (Avastin) and 
the antiviral drug interferon alpha-2b (Intron-A), demonstrated that bevacizumab 
decreased blood flow and had a tumor stabilizing effect (71). However, objective tumor 
responses with these new targeted therapies are rare (69,70,72), therefore molecular 
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targeted therapies are currently not first line therapies, despite the fact that sunitinib 
and everolimus are both registered therapies for pancreatic NETs in the Netherlands.   
Interferon-α and chemotherapy
Inteferon-α is another targeted therapy and binds specifically to surface receptors of 
NETs, reducing symptoms in patients with carcinoid syndrome (73). Also antiproliferative 
effects of Inteferon-α in combination with octreotide long-acting release (LAR) have been 
demonstrated in a prospective randomized study (71). However inteferon-α has serious 
side effects, like fatigue, fever, myelosuppression and auto-immune disorders (74). 
Other types of Inteferon are explored in (future) experimental studies, like Inteferon-β, 
which might be a successor of a more potent anti-tumor agent for NETs (75-77).
Poorly differentiated grade 3 neuroendocrine carcinomas (NEC) are usually treated 
with cisplatin-based chemotherapy regimens, usually a combination of cisplatinum 
and etoposide. Moertel et al. described an overall remission rate of 67% and a 
median survival of 19 months. A more recent study reported a response rate around 
50% for chemotherapy with cisplatinum and etoposide (78). An objective response 
or stabilization was observed in 71% of the NEC patients after temozolomide 
(with/without Capecitabine (Xeloda)), who failed on first-line chemotherapy (79). 
Alternatively, streptozocin-based chemotherapies in combination with 5-fluorouacil or 
doxorubicin result in objective tumor response rates in 35-40% of the patients (78,80). 
First line temozolomide-based chemotherapy (with or without capecitabine) seems to 
be promising in pancreatic NETs giving partial remission in 40-70% of the patients (81).
External beam Radiotherapy
External beam radiotherapy (EBRT) has a limited role in the treatment of NETs. EBRT 
can be performed in case of brain metastases, spinal cord compression or pain due to 
bone metastases. Furthermore, EBRT can have additional value in localized bronchial 
NETs (82). Another application of radiotherapy may be its use in combination with 
chemotherapy (i.e. chemoradiation), which has been performed in a few patients with 
locally advanced pancreatic NETs (83). Pheochromocytomas and paraganglioma are 
both a different type of neuroendocrine tumors. In these patients, EBRT can also be 
considered when the tumor is symptomatic, localized and progressive (84,85). 
Peptide Receptor Radionuclide Therapy (PRRT)
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs 
plays an increasing role in the treatment of patients with inoperable and/or metastasized 
NETs.
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21 
1.1 PRRT & NETs
In PRRT, a cell-targeting protein (or peptide) is combined with a small amount 
of radioactive  material, creating a radiopeptide. When  injected into the patient’s 
bloodstream, the radiopeptide binds to the receptor of the tumor cell, delivering a high 
dose of radiation to the cancer. Various radiopeptides are used in PRRT, such as [111Indium-
DTPA]octreotide (111In-octreotide), [90Y-DOTA,Tyr3]octreotide (90Y-DOTATOC) and [177Lu-
DOTA,Tyr3]octreotate (177Lu-Octreotate or 177Lu-DOTATATE). In the early days, treatment 
with 111In-octreotide resulted in relief of symptoms in patients with metastasized NETs, 
but objective tumor response was rare (86,87). However, complete and partial response 
in 10-30% of NET patients is obtained after PRRT with 90Y-DOTATOC or 177Lu-Octreotate 
(88-92). The median time to progression is 29 months for 90Y-DOTATOC (91) and 33 
months for 177Lu-octreotate (93).
PRRT: INCLUSION CRITERIA, TREATMENT SCHEMES & 
ADMINISTERED ACTIVITIES 
The studies published in this thesis are part of the ongoing prospective study in 
patients with neuroendocrine tumors treated with 177Lu-octreotate at the Department 
of Radiology & Nuclear Medicine in Erasmus MC Rotterdam. General inclusion criteria 
were: patients with a somatostatin positive tumor and baseline tumor uptake on [111In-
DTPA]octreotide scintigraphy (OctreoScan®; Mallinckrodt, Petten, The Netherlands) with 
accumulation in the tumor at least as high as in normal liver tissue; no prior treatment 
with PRRT; baseline serum hemoglobin (Hb) ≥ 6 mmol/l; white blood cell (WBC) count 
≥ 2∙109/l; platelet (PLT) count ≥ 75∙109/l; serum creatinine ≤ 150 μmol/l or creatinine 
clearance ≥ 40 ml/min and Karnofsky performance status ≥ 50. 
[DOTA,Tyr3] octreotate was obtained from BioSynthema (St. Louis, MO). 177LuCl3 was 
supplied by IDB-Holland (Baarle-Nassau, The Netherlands) and 177Lu-DOTATATE was 
prepared locally (94). Granisetron 3 mg or ondansetron 8 mg was injected intravenously 
30 min before infusion of 177Lu-DOTATATE. Infusion of amino acids (2.5 % arginine and 
2.5 % lysine, 1 l) was started 30 min before administration of the radiopharmaceutical 
and lasted for 4 h. The radiopharmaceutical was coadministered for 30 min using 
a second pump system. In most patients cycle dosages of 3.7 GBq (100 mCi) and 7.4 
GBq (200 mCi) were injected over 30 min. The interval between treatments was 6 – 16 
weeks. The initial intended cumulative dose was 29.6 GBq (800 mCi). However, the dose 
was lowered or discontinued indefinitely if recurrent grade 3/4 hematological toxicity 
occurred or persistent low blood counts were observed. 
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COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) 
Over the last 20 years various adverse events grading systems have been developed 
(95). In 2003 the National Cancer Institute published version (v3.0) of the Common 
terminology criteria for adverse events (CTCAE) (96). CTCAE provides a grading scale, 
grades 1 through 5, with unique clinical descriptions of severity for each adverse 
event. Important clinical adverse events are grade 3 (severe), 4 (life-threatening) and 
5 (death). CTCAE was developed for uniform treatment-related toxicity in clinical 
(chemotherapeutic) trials, but has been generally adopted in the field of nuclear 
medicine for toxicity assessment. CTCAE version 3.0 provides also criteria concerning 
late- and acute-effects. The previously used “90-days rule” for acute effects is no longer 
applied and investigators are encouraged to report all observations by using individual 
Common terminology criteria (CTC) (95). In CTCAE version 4.0 bone marrow toxicity is 
further generalized by replacing absolute blood values with relative reduction from 
normal cellularity (97). Grade 4 toxicity is replaced with life-threatening consequences 
and aplastic persistence for > 2 weeks. Consequences of this generalization of (hema)
toxicity are the difficulties in comparing different studies. Therefore investigators should 
always clearly specify grade 3 and 4 hematoxicity, also additional toxicity parameters 
can be specified, e.g. duration of toxicity.
PRRT: TOXICITY
In general the side effects of PRRT with 177Lu-DOTATATE are mild, but possible adverse 
effects are: Nephrotoxicity (Chapter 2.1), (sub)acute hematotoxicity (Chapter 2.2), 
hematological malignancies (Chapter 2.3) and spleen volume decrease after PRRT 
(Chapter 2.4). Patients who are treated with 177Lu-DOTATATE may develop radiation-
induced hormone disturbances (98). In men 177Lu-octreotate therapy induces transient 
inhibitory effects on spermatogenesis (temporary infertility) and a gonadotropin 
decrease in postmenopausal women (98). In general these disturbances in endocrine 
function are temporary and not severe. 
A rare adverse effect after PRRT is carcinoid crisis. Carcinoid crisis is a life-threating 
state in patients with hormone producing neuroendocrine tumors (NETs) and is 
characterized by sudden blood pressure fluctuations, arrhythmias, and bronchospasms. 
The underlying mechanism is associated with a sudden release of serotonin and other 
vasoactive substances (99). Stress can trigger a carcinoid crisis, therefore one should 
be cautious when performing intervention procedures and therapies (100). Hormonal 
crises after 177Lu-octreotate occur infrequently. In one study, only 6 (1%) of 479 patients 
had such a crisis (101). The authors found that patients with VIPoma or bronchial 
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carcinoids are most at risk. Somatostatin analogues have been recommended for 
prophylactic administration before intervention procedures for functioning NETs (100). 
In our department, patients with excessive carcinoid syndrome and/or high hormone 
production were hospitalized before and after treatment with 177Lu-DOTATATE. Also iv 
somatostatin analogues were resumed directly after PRRT. 
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Dosimetry is used in the fi elds of health/medical physics and is concerned with the 
determination of radiation dose (or a related radiological quantity) that results from 
the interaction of ionizing radiation with matter. After the discovery of X-rays in 1895, 
quantifi cation of radiation evolved quickly since harmful eff ects were discovered after 
irradiation of the fi rst patients. In the early days, dosimetry was mainly used in external 
beam radiotherapy (EBRT) (1), but new applications for dosimetry were developed, 
like in radiation safety (2). In 1941, Saul Hertz gave the fi rst successful therapeutic 
treatment with a radioactive compound (radioiodine, 131I) to a patient with Graves 
disease (3). A decade later, Edith Quimby published the mathematical concept of 
internally administered radioactive isotopes (4). Whereas, Loevinger described the fi rst 
dose equations for internal dosimetry in 1955 (5) and a decade later the committee on 
Medical internal radiation dose (MIRD) was founded (6).
Figure 1: Diff erent fi elds of dosimetry
EBRT is an example of external exposure, which occurs when a radiation source is outside 
of the body in contrast to internal exposure. The latter can occur after administration 
of radioactive isotopes in patients and the nuclear substances inside the body emit 
radiation. Dosimetry planning for EBRT is relatively straightforward with a homogeneous 
irradiation fi eld, short exposure, and high-absorbed dose rate, in contrast to PRRT (table 
1). Most of the knowledge about radiation eff ects concerns EBRT and radiobiology, 
therefore, specifi c dosimetric aspects for PRRT need to be explored (7). 
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Table 1: Overview of physical, dosimetrical and radiobiological characteristics of external beam 
radiotherapy (EBRT) and peptide radionuclide receptor therapy (PRRT).
Characteristics EBRT Brachytherapy PRRT
- Physical
Type of Irradiation Homogeneous Homo- or 
heterogeneous
Heterogeneous and 
mixed
Exposure to radioactive source Short Short-long Protracted
Dose rate High Low-high Low
- Dosimetry Routinely used Routinely used Challenging
- Radiobiology
Absorbed dose and toxicities Established Established Unexplored
Response of irradiated tissues Known Known Different than EBRT?
Dose–effect correlation Known Known Limited data, 
see Strigari et al. (8)
In this subchapter a theoretical outline is given of dosimetry, imaging aspects and 
dosimetry of the critical organs in PRRT. In Chapter 2 we analyze the relationship 
between the absorbed dose and toxicity for the kidneys, bonemarrow and spleen.
Models
Linear Quadratic Model
Cell survival models were initially developed to compare different dose rates in EBRT 
and brachytherapy exposures, but their fundamental nature also applies to radionuclide 
therapy. The linear quadratic model (LQM) represents the surviving fraction (sf ) of cells 
after an absorbed dose D delivered instantaneously. The equation is:
   (1.1)
where α and β are tissue specific constants, representing the damage induced by 
irreparable (i.e. double DNA strand breaks) or reparable (single DNA strand breaks) 
events. In the model, irreparable events depend on the absorbed dose D and they have 
a probability proportional to D by a factor α. At low dose the combined irreparable 
event is induced by a single electron track. At higher doses two or more independent 
(separately reparable) ionizing events may be induced by several electron tracks. The 
DNA damage combination may become irreparable and generate cellular death when 
occurring within a short time interval and in close distance of the DNA filament. This 
probability is proportional to the product of D2 and β. The cell survival curve shows 
a bended shoulder on a logarithmic scale when this contribution dominates. Early 
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responding tissue like tumors show a less pronounced “shoulder” in their dose-response 
curve than late-responding tissue, like the kidneys.
When a dose D is delivered over a period of time (T), the DNA repair process (i.e. by repair 
enzymes) is initiated during the dose delivery and can then compete more effectively 
against radiation damage. An additional factor must therefore be introduced into the 
time-dependent LQ model equation:
    (1.2)
  with   (1.3)
where g(T) is a dimensionless function with a value between 0 and 1, which describes 
the probability of lethal combinations of reparable events over time (T). When time (T) 
of the prolonged dose delivery becomes large with consequently a lower dose rate, 
late-responding normal tissue is saved relatively to the tumor as the lower dose rate 
reduces the “shoulder” effect which is stronger in normal tissue than in tumor tissue. 
This relative sparing condition can be compared with fractionated EBRT. 
Biological effective dose (BED)
The linear quadratic model mathematically interprets this differential sparing and the 
BED concept is used to quantify the biological effects induced by different patterns 
of radiation delivery. BED allows for comparison of different irradiation conditions, 
producing the same endpoint of cell survival (sf ). The BED has physical dimensions of 
an absorbed dose and is defined as:
             ↔  (1.4)
This equation can be rewritten:
   
   (1.5)
Where, RE is the relative effectiveness and N is the number of given fractions. The ratio 
α/β with the dimension of dose gives an indication of the sensitivity of a tumour or 
normal tissue in response to changes in dose rate (fractionation). a/b indicates the dose 
where the linear contribution to cell kill is equal to the quadratic contribution. This ratio 
is in general higher for early responding tissue like tumours (5-25 Gy) than for late-
responding normal tissues (2-5 Gy), e.g. kidneys.
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BED values may be used to quantify the impact of a treatment on normal tissue and 
tumour. Biological eff ect (effi  cacy or toxicity) in PRRT can be predicted on the bases of 
BED by comparison with known EBRT BED values (9). Clinical use of BED in PRRT with 90Y 
has proven to be a reliable predictor for renal toxicity (see section Kidneys)
Tumor control probability (TCP)
The expected response rate to radiation treatment can be visualised with the tumour 
control probability (TCP) for effi  cacy and normal tissue complication probability (NTCP) 
for toxicity. TCP and NTCP curves are typically sigmoid in shape.
Diff erent dose response models have resulted in the same sigmoidal shaped curves 
(fi gure 2). One of these models is the logistic function: 
                    (1.6)
where P is the probability of a clinical eff ect, D is the radiation absorbed dose and D50 
is the radiation absorbed dose which leads to 50% cure/complication probability. The 
parameter k describes the slope of the dose-response curve (10). 
Figure 2: Relationship between tumor control (TCP) or normal tissue complication probability 
(NTCP) and radiation absorbed dose for representative tumor and normal tissues. A. shows 
representative TCP for Hodgkin’s lymphoma (11) ( ) and carcinoma of the nasopharynx (  for T1–2 
and  for T3–4) (12). B. shows representative NTCP for the three most radiosensitive critical organs 
for a myeloablative therapy: the lungs ( ), kidneys (), and liver ( ). Complication endpoints are 
pneumonitis, clinical nephritis, and liver failure. The liver and kidneys are about a factor of two 
more sensitive than the tumor. Also, the dose-dependent onset of eff ects is signifi cantly steeper 
for the normal tissues than for tumor. This is probably due to the greater conformity in dose-
response for normal tissues than for tumor. Adapted from Hartmann et al. (10).
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MIRD scheme
The medical internal radiation dosimetry (MIRD) scheme is the basis for absorbed dose 
calculations to internal organs, defined as the mean energy imparted to target tissue 
per unit tissue mass. In EBRT, dose calculations are relatively simple, since a calibrated 
external source (h) irradiates a target volume (k) within a selected time period. In PRRT, 
concentrations of radioactivity change over time in different organs (compartments), 
see figure 3. Therefore the intensity of irradiation to the source (k) by the radioactive 
sources (hn) changes over time, there is also irradiation from the source itself (hk). 
Figure 3: Graphical representation of the MIRD scheme. Sources (hn) irradiate target (k) including 
irradiation from the source itself (hk). 
The mean absorbed dose (D(rT, TD)), to target tissue (rT) can be calculated over a dose-
integration period (TD) from a uniformly distributed compound within a source tissue (rS):
 =
                  (1.7)
Where  is the time-integrated activity (no. of nuclear transformations) in  over 
 and  is the absorbed dose rate in  per nuclear transformation in . 
The pharmacokinetics (PK) compartment model
The pharmacokinetics (PK) compartment model describes the biodistribution of a drug 
using a series of coupled differential equations for uptake and clearance in organs, 
which physiologically interact with that drug. This PK compartment model can be solved 
analytically for 2 or 3 compartments, or otherwise numerically. (e.g. with the SAAMII 
software Simulation Analysis and Modeling; SAAM Institute, Seattle, Washington State). 
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Since the peptide is radiolabelled, it is possible to follow the radioactivity at different 
time points to determine its biodistribution (and clearance). These time dependent 
measurements, which follow the total injected activity (IA) over time, enable the 
development of a mathematical description for the molecule uptake and excretion 
patterns in blood and each organ.
Organs with physiological uptake (kidneys, liver and spleen) are modeled using 2 
compartments linked to the central (plasma) compartment, illustrated in figure 4. An 
additional extracellular fraction (ECF) single compartment was needed to fit the data. 
The urine data could be modeled by a single compartment linked to the kidney. 
Figure 4: Generalized compartment model for the biodistribution of 177Lu-Octreotate in humans. 
Abbreviations: Experimental input function; the time of drug administration (defined as T0); red 
dots, Sample time points for the indicated compartments (organs); ECF, Extracellular fraction; 
C1-9, Compartments (or organs) 1 to 9; k(i,j), Kinetic transfer components between the indicated 
compartments i and j (organs). 
The differential equations in the PK compartment model can be solved numerically. To 
do this, the amount of radioactivity administered to the central plasma compartment 
at time point 0 (T0) is normalized to 100%, and assuming that the radioactivity is 
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uniformly distributed in a plasma distribution volume which is assumed to be constant 
at 5 L. The radioactivity in plasma is then expressed as a percentage of the total IA. This 
normalization enables a direct coupling of the plasma time-activity curve with the time-
activity curves measured by planar imaging in the kidneys, spleen and liver, which are 
also normalized to the total IA. 
Compartmental models can be utilized for describing the kinetics of the radioactive 
compound in the source tissue. Each compartment can be mathematically written as 
a nondifferential equation and can be solved numerically (13).  In the model, the time-
integrated activity  is the area under de curve for each compartment (organ).
Radionuclide-specific S values are available from calculations using a generic anatomic 
model (14,15). This Reference man model has some discrepancies in the calculated 
quantities therefore ICRP adopted radionuclide S values at voxel level for SPECT or 
PET imaging, published in MIRD pamphlet no. 17 (16). A new reference man phantom 
has been defined by ICRP based on average patient imagery and several more realistic 
calculation models have evolved (17,18).
The speed of Monte Carlo calculations have made it as one of the feasible methods for 
calculation of the absorbed dose to solid organs and tumors (19-21). Patient specific 
S-values, based on CT/MRI images, have contributed to the accuracy of dose estimates 
(22-24). Standard S factors can yield mean absorbed doses for normal organs or tumors 
with a reasonable accuracy (26% for 9 cases studied) as compared with absorbed doses 
calculated with Monte Carlo, provided that they have been corrected for mass (25). 
However, Ljungberg et al. (26) demonstrated limited use of Monte Carlo simulation in 
post therapy 177Lu-SPECT images since minor improvement in accuracy was found in the 
dose calculation. This is mainly due to the particle range of 177Lu (2 mm) and the current 
spatial resolution of SPECT imaging (5 mm). 
Most dosimetry models are based on rigid stylized phantoms with a possibility for 
correcting the dose by the actual organ volumes, but do not allow correction for the 
actual patient geometry (27). The  Olinda/EXM code (15), considers only separate 
source organs and does not facilitate dose calculations for dispersed radioactivity by 
wide-spread receptor positive metastases. This technique has limitations for individual 
patient dosing, because it tends to overestimate organ doses and subsequently leads to 
conservative limits for the total cumulative dose of administered radioactivity. 
Dosimetry in PRRT
PRRT using 177Lu or 90Y radiolabelled somatostatin analogs show similarities to widely 
used 131I therapy (sodium-iodide Iodine-131) for the treatment of benign and malignant 
thyroid disorders (28). Table 1 shows the physical characteristics of 131I, 90Y and 177Lu. 
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Table 3: Physical Characteristics of therapy radionuclides 131I, 177Lu and 90Y (29).
Characteristic 131I 90Y 177Lu
Decay half-life (d) 8.021 d 2.671 d 6.647 d
Mean b-particle energy (keV/decay) 181.9 keV 932.9 keV 133.3 keV
Main g-rays energy (keV) and 
abundance (%/decay)
364 keV (81.7%/decay)
637 keV (7.2%/decay)
511 keV
(0.00032 %/decay)
113 keV (6.4%/decay)
208 keV (11.0%/decay)
Penetration depth (Rmax)
Mean range in tissue
3.4 mm
0.39 mm
11.3 mm
4.02 mm
1.8 mm
0.23 mm
Early therapeutic dose-escalating studies in patient’s demonstrated safe use of 90Y- and 
177Lu radiolabelled somatostatin analogues. The radiation toxicity dose estimates in 
these studies were predominately based on experience and knowledge obtained from 
external beam radiation. In external beam radiotherapy, recommended radiation toxicity 
threshold doses are based on empirical data. Over the years, the quality of dosimetry in 
external beam radiotherapy has improved significantly, and the combination of clinical 
experience and information on normal organ tolerance doses has resulted in consensus 
guidelines (30). In external beam radiotherapy, dosimetry-based treatment planning 
has largely reduced toxicity in normal organs (31). Dosimetry is currently not general 
practice in PRRT but is developing rapidly.
Biodistribution and dosimetry studies have shown that one of the critical organs in 
radionuclide therapies (with 177Lu and 90Y) is the bone marrow (see Chapter 2.2 & 2.3). 
Also a decline in renal function has been observed, particular for radionuclide therapy 
with 90Y labelled somatostatin analogues. Therefore, co-administration of amino acids is 
common during PRRT for minimal retention of the radiopeptide in the kidneys (32-34). 
More detailed information regarding renal toxicity after PRRT with 177Lu-DOTATATE can 
be found in chapter 2.1. 
90Y labelled somatostatin analogues
Imaging and quantification in patients administered with 90-Yttrium labelled peptides 
is not straightforward since only beta particles are emitted with a maximum energy 
(Emax) of 2.27 MeV. The physical half-life is 2.7 days with a tissue penetration depth (Rmax) 
of 12 mm. Four methods have been adopted for 90Y-dosimetry: surrogate SPECT or PET-, 
bremsstrahlung- and direct PET-imaging.
Surrogate  SPECT imaging
Surrogate imaging allows for quantitative analysis of 90Y-therapy, based on the 
hypothesis that pharmacokinetics and biodistribution are comparable. The receptor-
14802HBergsma_BW_DEF_15/8.indd   40 15-08-17   11:40
1.2 Dosimetry in PRRT
41 
specific uptake kinetics depends strongly on the amount of peptide used and the 
specific activity of the surrogate marker should therefore be adjusted to an equimolar 
to what is being used in the therapy setting (35). This reasoning is hardly fulfilled with 
most surrogate imaging settings and the resulted effects are not corrected.
In early studies, 111In-DTPA-octreotide was used for simulating therapy with 90Y-labeled 
compounds (36,37). However 111In-DTPA-octreotide is limited as a surrogate for 
90Y-DOTATOC because of the difference in biochemical structure (e.g. different chelator) 
(37).  Scintigraphic images derived from 111In-DOTATOC, 111In-DOTATATE and 111In-
Lanreotide reflect higher specific uptake in sst expressing tissue in comparison with 
111In-DTPA-octreotide (36-39). 
Cremonesi et al. (40) used 111In-DOTATOC for simulation of internal radiotherapy with 
90Y-DOTATOC. 111In-DOTATOC showed favorable pharmacokinetics (fast blood clearance 
and urinary excretion) and biodistribution, as well as high affinity to tumors expressing 
somatostatin receptors. Though the metal replacement can alter the binding affinity of 
the radioligand (41).
Surrogate PET imaging  
In diagnostic nuclear medicine, 68Ga-labelled peptides are important for diagnoses 
of somatostatin positive receptors (42). Widely used 68Gallium labeled somatostatin 
analogues are DOTA-TOC, DOTA-NOC and DOTA-TATE (43). The high quality PET images 
make it ideal for imaging, but less suitable for pre-therapeutic dosimetry. The washout 
trend on the time-activity curves cannot be derived due to the short physical half-life 
(68 minutes). Beauregard et al. (44) demonstrated a tumor sink effect in patients with 
highly varied burden of somatostatin receptor-positive neuroendocrine tumor on 
68Ga-DOTA-octreotate PET. Tumor sequestration of radiopharmaceuticals may lead to a 
decrease in uptake in healthy tissue, particularly the renal parenchyma. Besides, it is not 
clear whether the 68Gallium molecule might alter the compound as compared to the 90Y 
therapeutic agent.
Surrogate Positron Emission Tomography (PET) with 86Y-labelled compounds offers 
substantial advantages over 111In-labelled radiopeptides. The chemical structure of 
the compound is preserved and positron emitters allow the use of PET imaging which 
provides a higher quantitative accuracy and spatial resolution. Jamar et al. studied the 
pharmacokinetics and biodistribution of 86Y-DOTATOC in 24 patients (45). 
Förster et al. compared biodistribution and dosimetry in three patients injected with 
86Y-DOTATOC and 111In-DTPA-Otctreotide (46). The authors found that dosimetry based 
on 86Y-DOTATOC and 111In-DTPA-octreotide yields similar organ doses, whereas there 
are relevant differences in estimated tumor doses. They stated that dosimetry should 
be performed with the chemically identical tracer 86Y-DOTATOC. However, Barone et al. 
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observed an underestimation of the renal dose when using 111In-DTPA-Octreotide in 
comparison with 86Y-DOTATOC (47). Helisch et al. found an overestimation of doses to 
kidneys and spleen with 111In- DTPA-Octreotide in comparison with 86Y-DOTA-Phe1-Tyr3-
octreotide (48). These contradictory results could be related to the method of imaging 
for 111In-DTPA-Octreotide (SPECT vs. planar) and the use of amino acid infusion. 
Application of 86Y-labelled radioligands is limited, because it requires a PET facility and a 
high-energy cyclotron. Moreover, the short half-life of 86-Yttrium (14.3 h) does not allow 
acquisitions beyond 48–72 h after tracer administration and overall clearance kinetics 
can only be estimated by extrapolation (after 48 h). The decay characteristics of 86Y also 
involve a high number of prompt γ-rays responsible for overestimations of activity in 
the background and kidneys, when not properly accounted for. 
Bremstrahlung imaging
Direct imaging of 90Y can monitor distributions of 90Y in patients after therapy; therefore 
there has been a great interest in quantitative imaging of 90Y bremsstrahlung using 
SPECT. In the past, 90Y labeled Selective internal radiation (SIR) spheres have been imaged 
using SPECT (49), though the quality of the images was relatively poor. The continuous 
and broad energy distribution of bremsstrahlung photons requires modeling of image 
degrading factors for accurate quantitative imaging.
Minarik et al. (50) demonstrated the feasibility of 90Y bremsstrahlung quantitative SPECT 
by modeling the scatter (in a patient receiving 90Y-Ibritumomab tiuxetan (Zevalin)). In 
whole-body images, the accuracy of the organ activities was most of the time within 
15% (Minarik et al. 2009). In three patients, receiving 90Y labeled radio immunotherapy, 
absorbed doses were calculated based on WB scintigraphy. Differences between 
absorbed-dose estimates from pre-therapeutic 111In images were within 25%, except 
for the lungs. Their publications suggest that it is possible to quantify 90Y activity in ROIs 
with reasonable accuracy using this method. Fabbri et al. (51) demonstrated feasibility 
of SPECT/CT 90Y-bremsstrahlung imaging in a patient receiving 90Y-DOTATATE (figure 5).
Elschot et al. (52) compared quantitative PET and Bremsstrahlung SPECT for imaging the 
distribution of in vivo Yttrium-90 microsphere. The authors quantitatively demonstrated 
that the image quality of state-of-the-art PET is superior over Bremsstrahlung SPECT for 
the assessment of the 90Y microsphere distribution after radio-embolization. 
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Figure 5 - Coronal slices of fused SPECT-CT, showing uptake in the abdominal lesion (red arrow), 
the kidneys and the spleen. Images obtained 24 h after the injection of (A) OctreoScan® (185 
MBq), (B) 90Y-DOTATATE (1.7 GBq). Images adopted from Fabbri et al. (51).
Direct TOF and non-TOF PET-imaging
Yttrium-90 internal pair production can be imaged by positron emission tomography 
(PET)/CT with or without time-of-fl ight capability (53,54). Dosimetry in liver selective 
internal radiotherapy (SIRT) by direct 90Y time-of-fl ight (TOF) PET has proven feasible. 
LHommel et al. (55,56) demonstrated high-resolution absorbed dose distribution with a 
clear correlation with tumor response in one patient after administration of 90Y-labelled 
SIR-spheres. 3D time of fl ight PET acquisition was used for imaging. Werner et al. (57) 
reproduced these results with a non-TOF PET/CT in a patient after selective internal 
radiotherapy (SIRT).
Walrand et al. (58) evaluated whether 90Y TOF-PET was accurate enough for dosimetry 
in PRRT with 90Y. The authors used an anthropomorphic fantome with Activities 
corresponded to typical tissue uptake in a fi rst 90Y-DOTATOC therapy cycle. Although 90Y 
PET seems feasible in patients receiving radionuclide therapy, no clinical study has been 
published, so far. In a review article of Wallrand et al. (59) issues concerning 86Y positron 
emission tomography (PET), 90Y PET and 90Y bremsstrahlung imaging are discussed. The 
potential imaging capabilities with the radioisotopes 87Y and 88Y are also considered. 
Dosimetry with 90Y-labelled peptides is not straightforward, since 90Y decays with 
essentially no gamma photon emissions. Imaging over time can be done directly after 
therapy or pre-therapeutic with a surrogate radio peptide. Surrogate imaging results 
in good quantifi able images but pharmacokinetics and biodistribution could be 
diff erent from the therapeutic radioligand. On the other hand, direct imaging by PET or 
bremsstrahlung is time consuming with limited quantifi cation.
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177Lu labeled somatostatin analogues
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate is a low 
dose rate radiotherapy (as opposed to external beam radiation) developed for treatment 
of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that utilizes the carrier 
peptide, Octreotate. The radiolabelled peptide contains a DOTA-chelated radionuclide, 
Lutetium-177 (177Lu). Octreotate binds with high affinity to somatostatin receptors that 
are overexpressed on the cell surface of most neuroendocrine tumors. The targeting 
of radiolabelled somatostatin analogues to tumor cells is the basis of the therapeutic 
effect of these pharmaceuticals.
The radiation toxicity dose estimates used in PRRT are predominately based on the 
experience and knowledge obtained from external beam radiation. In external beam 
radiotherapy, the recommended radiation toxicity threshold doses are based on 
empirical data. Over the years, the quality of dosimetry in external beam radiotherapy 
has improved significantly, and the combination of clinical experience and information 
on normal organ tolerance doses has resulted in consensus guidelines (60). Although 
the recommendations by Emami (60) contain several limitations and uncertainties, they 
address a clinical need in external beam radiotherapy, and consequently the incidence 
of radiation toxicity to normal organs has been reduced by dosimetry-based treatment 
planning (31).
In addition to the large base of empirical knowledge that has been obtained from 
external beam radiation research, there is also more than 60 years experience in 
radionuclide therapy, in particular with 131I therapy (sodium-iodide Iodine-131) for 
the treatment of benign and malignant thyroid disorders (28). The most common 
radiation induced toxicity following 131I therapy is bone marrow suppression, mainly 
thrombocytopenia. Limiting the prescribed cumulative administered radioactivity to a 
radioactivity level where the bone marrow dose remains below 2 Gy has proven to be a 
successful guideline for preventing hematological side-effects (61,62). 
PRRT using 177Lu-Octreotate shows significant similarities to 131I therapy. The data in table 
3 show that the physical characteristics of 131I and 177Lu are similar, except for the high 
energy g (gamma)-rays of 131I, which cause a higher radiation dose to non-target regions 
(63). Biodistribution and radiation dosimetry studies have shown that the critical organ 
in both radionuclide therapies (131I and 177Lu-Octreotate) is the bone marrow. In both 
radionuclide therapies, the absorbed dose in the bone marrow can exceed the toxicity 
threshold dose established with external beam radiotherapy (see data in table 4). 177Lu-
Octreotate treatment results in radiation doses to other organs, such as kidney, spleen 
and pituitary that may be higher than the doses resulting from 131I therapy. However, 
based on clinical experience, the spleen and pituitary are not critical organs in terms of 
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radiation related damage from PRRT. The kidneys (and the bone marrow) are generally 
considered to be the critical organs for therapy with 177Lu-Octreotate. Therefore, it is 
common practice to co-administer amino acids to protect the kidneys (32,33,64,65).
Imaging
The residence time and localization of the Lutetium-177 can be estimated by scanning 
the patient at various times points post therapy. Siegel et al. described in MIRD pamphlet 
no. 16 (66), 2-dimensional quantitative planar imaging for calculation of the mean 
absorbed dose to target organs in patients. Errors of 30-100% have been reported when 
using this method of internal dose calculations (67). A recent MIRD pamphlet no. 23 (68), 
describes recommendations for patient-specific dosimetry with quantitative SPECT 
in internal radionuclide therapy. He et al. (69) compared different image acquisition 
methods with a phantom population and Monte Carlo simulations. Pure conventional 
planar images (CPlanar) performed worst with an mean error of 7-159% (± <108%) 
and pure quantitative SPECT (QSPECT) performed best with a mean error of < 9,9% (± 
<9,9%). The authors suggested hybrid CPlanar/QSPECT imaging (mean error <19.2% 
± <22.0%) as the method of choice for clinical practice, due to its simplified image 
acquisition protocol. Garkavij et al. compared the same methods in a clinical setting 
with 16 NET patients treated with 177Lu-Octreotate (70). Dosimetry based on planar 
images gave a higher absorbed dose to the kidneys in comparison with the two SPECT-
based methods. Sandström et al. investigated the reliability of individualized Planar/
SPECT-based dosimetry in 24 patients treated with 177Lu-Octreotate (71). Planar and 
SPECT dosimetry were comparable in the tumor free areas, but planar dosimetry highly 
overestimated the absorbed dose in the organs with tumors. Despite the disadvantages 
of planar image acquisition, it is a widely used and accepted technique in PRRT (72-74). 
A major cause for the difference between planar imaging and quantitative SPECT is due 
to the overlap of high activity areas, which gives an overestimation of the organ activity 
(figure 6). 
SPECT-derived images are limited in quantifying small volumes caused by the spatial 
resolution (5 mm). This partial volume effect underestimates the activity and absorbed 
dose within a volume of interest (VOI). 
Quantitative SPECT can be accurate up to 10% with optimized hybrid SPECT/CT systems 
using iterative reconstruction algorithms and corrections for image-degrading physical 
factors. However, a hybrid method (Planar and SPECT/CT) may be better in clinical 
practice for a good balance between clinical feasibility and accuracy of dosimetric 
results. 
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Figure 6 - Planar post therapy scan of a patient with a neuroendocrine tumor. A. anterior and 
B. posterior images. Red lines are the contour of the left kidney. Notice the overlap of the liver 
metastasis in the upper region of the kidney contour on the anterior image.
Garske et al. (Garske 2012) demonstrated signifi cant diff erences in eff ective half-life 
during fractionated 177Lu-octreotate therapies, especially in large tumor reductions 
during during treatment (75). The authors conclude that for most patients it is safe to 
estimate absorbed doses to kidney, liver and spleen from 24h activity concentration 
assuming an unchanged eff ective half-life during therapy. Patients with risk factors for 
kidney dysfunction or large changes in tumor size during therapy need to be monitored 
in more detail.
Planar dosimetry is accurate in patient populations to estimate stochastic risks, but 
inadequate for therapeutic applications, where toxicity and effi  cacy are the key issues 
(40). Therefore SPECT/CT should be used as a standard method for dosimetry in PRRT 
with 177Lu radiolabelled somatostatin analogues (68). In clinical practice, a hybrid 
method (Planar and SPECT/CT) may be the best solution. 
Bone Marrow
Radiation induced bone marrow toxicity results from damage of the hematopoietic 
tissue (the red marrow) where red blood cells, platelets and white blood cells are 
produced. The radiation dose to the red bone marrow contributes from b-ray irradiation 
of 131I or 177Lu in the blood circulating in the bone and from penetrating g-ray radiation 
from activity dispersed throughout the remainder of the body. This ‘blood dose’ bone 
marrow dosimetry model has been safely employed for decades with 131I therapy. It 
can also be used to determine the maximum dose that can be safely administered with 
177Lu-Octreotate. An overview of the radiation threshold doses to normal organs for 
external beam radiotherapy and 131I therapy is given in table 4.
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Table 4 Overview of radiation threshold doses to normal tissue for external beam 
radiotherapy and 131I therapy.
Organ Damage endpointsreported in literature
External beam 
radiotherapy  
threshold dose1 (Gy)
131I Therapy, 30 GBq2
(Gy)
Thyroid Ablation 80 Target
Bone marrow Hypoplasia 2 2~4
Kidneys Late nephritis 23 2~3
Urinary bladder Contracture 65 10~15
Liver Radiation Induced Liver Disease 30 1~2
Testes Temporary infertility 0.15 0.5~1
Interstitium (skin) Temporary baldness 3 1~2
Salivary glands Xerostomia 14 12~15
Pituitary Hypopituitarism 45 NR
Spleen Increased infection 40 NR
Pancreas Hyperglycemia NR 1.5
Adrenals Hypoadrenalism >60 1~2
1Data from Marks L et al. (31) and ICRP41 (76); 2Iodine-131 therapy with a cumulative injected radioactivity of 
30 GBq (ICRP 53 (77)); NR, Not reported.
Kidneys
Radiation induced kidney toxicity caused by PRRT is due to damage to the nephrons, 
the basic structural and functional units of the kidney. Nephrons consist of glomeruli 
and tubuli, which are responsible for filtration and reabsorption, respectively. 
The threshold dose for radiation damage to the kidneys by PRRT depends on the 
radionuclide that is used. To date the radionuclides used for PRRT with somatostatin 
analogues are Indium-111 (78,79), Yttrium-90 (90Y; (64,72,78,80-83) and Lutetium-177 
(177Lu; (38,72,84,85))
Tubular reabsorption of 90Y labeled peptides leads to a uniform radiation field to the 
kidney parenchyma that is comparable to that of external beam radiotherapy, despite 
the lower dose rate of PRRT (86). A correlation was found between the kidney radiation 
dose and chronic kidney toxicity after treatment with 90Y-Octreotide. The dose at which 
50% of the patients will encounter kidney toxicity was established to be ED50 = 35 Gy 
(87). This ED50 is 7 Gy higher than the 28 Gy established for external beam radiotherapy 
(88). Because the b-particles of 177Lu has a shorter range than those from 90Y, there is less 
damage to nearby non-target tissue (89,90). Moreover, PRRT using a radionuclide with 
much shorter-range emissions (111In Auger electrons) does not result in kidney damage 
despite higher cumulative doses to the kidney (78). Therefore, 23 Gy is considered to 
be a conservative value for the radiation toxicity threshold dose for PRRT using 177Lu-
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Octreotide. A summary of previously reported kidney and bone marrow dosimetry 
findings in studies using 177Lu-Octreotate are provided in Table 5.
Table 5: Overview of peer-reviewed publications on dosimetry for peptide receptor radionuclide 
therapy with 177Lu-DOTA0-Tyr3-Octreotate. 
Study Method N1 IA
2
(GBq)
Amino 
Acids
Kidney dose 
per IA  
(Gy/GBq)
Bone marrow 
dose per IA 
(Gy/GBq)
Kwekkeboom (33) Planar 5 1.85 Lys/Arg 0.88 ± 0.19 0.070 ± 0.009
Bodei (72) Planar 5 3.7 – 5.18 NR 0.9 ± 0.5 NR
Bodei (91) Planar 12 5.18 – 7.4 Lys/Arg 0.8 ± 0.4 NR
Forrer (92) Planar 15 7.47 ± 0.10 Lys/Arg NR 0.02-0.13
Wehrmann (73) Planar 69 3-7 Lys/Arg 0.9 ± 0.3 0.05 ± 0.02
Sandström (71) SPECT/CT 24 7.4 VAMIN-14 0.71 ± 0.24 NR
Sandström (93) SPECT/CT 200 7.4 Vamin 14 1.2 ± 0.6 NR
Garkavij (70) SPECT/CT 16 7.4 VAMIN-14 0.90 ± 0.21 0.07 ± 0.02
Swärd (74) Planar 26 8 NR 0.9 ± 0.4 NR
Claringbold (94) SPECT/CT 33 7.8 Synthamin 0.31 (0.14-0.46) NR
Svennson (95) Planar 51 3.5 – 8.2 Lys/Arg 0.8 ± 0.4 NR
This thesis
(Chapter 2.1) Planar 407 7.4 Lys/Arg 0.7 ± 0.2 NR
This thesis
(Chapter 2.2) Planar 24 7.4 Lys/Arg NR 0.067 ± 0.007 
N, Number of patients; IA, Administered radioactivity of 177Lu-DOTA0-Tyr3-Octreotate; NR, Not reported.
The dosimetry data analyzed in Chapter 2 is based on planar measurements for dosimetry 
calculations. Despite the disadvantages of the use of planar image acquisition, it is 
a widely used and accepted technique in PRRT (72-74). The use of planar data based 
on conjugate view methods is known to be less accurate for determining kidney and 
other normal organ radiation doses. Studies, which directly compare SPECT and planar 
imaging, show that the planar imaging method consistently overestimates organ 
dosimetry (70,71,94). This is primarily due to the occurrence of overlapping radioactivity 
that appears on planar images such as from the overprojection of the liver with tumor 
nodules into the right kidney region of interest, and also from intestinal radioactivity 
potentially overlapping the left kidney, see figure 6 (73,74). For this reason, in the study 
reported here, the organ uptake (abdominal region) was not differentiated into separate 
organs and instead was considered to be a single source region. One issue with this 
approach, however, is that dosimetry models, like the Olinda/EXM code (15), consider 
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separate source organs only and do not facilitate dose calculations for dispersed 
radioactivity by wide-spread receptor positive metastases. Most dosimetry models are 
based on rigid stylized phantoms with a possibility for correcting the dose by the actual 
organ volumes, but do not allow correction for the actual patient geometry (96). The 
technique has limitations for individual patient dosing, because it tends to overestimate 
organ doses and subsequently leads to conservative limits for the total cumulative dose 
of administered radioactivity. However, planar imaging based dosimetry with 111In-
Octreotide has been of value in determining threshold doses in population studies for 
90Y-Octreotide therapy (40).
Studies based on planar measurements for dosimetry calculations were performed 
by Bodei L et al. (72), Wehrmann C et al. (73), and Swärd C et al. (74). In each of these 
studies, patients were treated with cumulative doses of approximately 30 GBq (800 
mCi) 177Lu-Octreotate given in 4 separate administrations and their findings are in good 
agreement with the data presented in this report. Bodei and coworkers (72) suggest 
that for patients without risk factors such as hypertension and diabetes, the threshold 
for kidney damage is set at a biologically effective dose (BED) of 40 Gy, which would 
correspond to a MIRD based radiation dose by 177Lu of 36 Gy. In the report by Wehrmann 
no individual patient doses are given, but with a mean kidney dose per radioactivity of 
0.9 ± 0.3 Gy/GBq the cumulative dose to the kidneys will be 27 ± 9 Gy for a cumulative 
administered radioactivity of 29.6 GBq. There was no indication in their publication of 
any adjustment of the dosing scheme. In the study by Swärd C et al. (74), the patients 
were scheduled for 4 administrations of 8 GBq each, unless the total radiation dose to 
the kidneys was more than 27 Gy. Only 12 out of 26 patients were given the full therapy 
of 4 administrations. The mean radiation dose to the kidneys was determined to be 24 ± 
6 Gy, but no individual dosing schemes were provided. The reported patient-averaged 
dose per radioactivity is in the same order of magnitude as found by Wehrmann et al. 
(73) 0.9 ± 0.4 Gy/GBq. Therefore while these studies show general agreement on the 
radiation dose per unit of administered radioactivity to the kidneys, the lack of long-
term follow-up data prevents any conclusions about long-term renal toxicity.
Testes 
In men, PRRT with 177Lu-octreotate induces transient inhibitory effects on spermatogenesis 
(temporary infertility) (97). Also somatostatin scintigraphy, demonstrates uptake in the 
gonads region (Figure 7). Current radiation models of the testes are simple and cannot 
predict clinical toxicity (short and late effects). In analogy to the radiation model of the 
kidneys (89), heterogeneities in radioactivity distribution on a microscopic level might 
improve the current radiation model of the testes (98). 
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In order to create a new radiation model of the testis, selective binding of 177Lu-DOTATATE 
to the sst in the testes has to be demonstrated. Unger et al. (99) used polyclonal rabbit 
antisera on normal human testis tissue; the expression of ssts within the testis was very 
heterogenic. Sst type 2A was detected in the basal parts of the tubulus. Fombonne et 
al. (100) showed SST2A receptor expression in Leydig cells in situ from immature pigs 
using R57 antibody. Detailed cytological analysis demonstrated immunoreactivity 
to spermatogonia and Leydig Cells. However, both cell types immunostained 
heterogeneously, i.e. they showed varying intensity of labelling. 
We performed several experiments on frozen testes material from 3 patients who 
underwent orchiectomies. Staining with the antibody SSTR2a (Biotrend, Human) 
demonstrates minimal staining, which is in lines with results from Unger et al (99). 
We also performed a hematoxylin-eosin (HE) staining (fi gure 8A) and autoradiography 
on testes material with [111In]DOTATATE and [111In]DOTATATE + block (fi gure 8B,C).  
Figure 7. Whole body planar imaging of a male patient, which was performed in the anterior (A) 
and posterior (B) projections at 4 and 24 hours following the administration of 111In-Octreotide. 
Blue circle marks the bladder and red circle points out the gonads.
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Figure 8 Hematoxylin and eosin stain of normal testes (A). Autoradiography of testis tissue with 
1·10-8 M [111In]TATE (B) and with block (C). On a visual scale there seems to be no diff erence 
between fi gure B & C, therefore there seems to be no somatostatin receptor selective binding.
On a visual scale, phosphor autoradiography did not show any diff erence between Block 
+ [111In]DOTATATE (somatostatin receptors blocked) vs. [111In]DOTATATE (somatostatin 
receptors not blocked). Quantitative imaging demonstrated no diff erence in 
(radioactive) counts. Therefore, there seems to be no somatostatin receptor selective 
binding with [111In]DOTATATE autoradiography on testes tissue (n=3 patients). For this 
reason, no further enhancement of current dosimetric model for patients receiving 
177Lu-DOTATATE seems necessary.
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ABSTRACT 
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin 
analogues plays an increasing role in the treatment of patients with inoperable or 
metastasised gatroenteropancreatic neuroendocrine tumors (GEP-NETs). 90Y-DOTATOC 
and 177Lu- DOTATATE are the most used radiopeptides for PRRT with comparable tumor 
response rates (about 15–35%). The side effects of this therapy are few and mild. 
However, amino acids should be used for kidney protection, especially during infusion 
of 90Y-DOTATOC. Options to improve PRRT may include combinations of radioactive 
labeled somatostatin analogues and the use of radio- sensitizing drugs combined with 
PRRT. Other therapeutic applications of PRRT may include intra-arterial administration, 
neoadjuvant treatment and additional PRRT cycles in patients with progressive disease, 
who have benefited from initial therapy. Considering the mild side-effects, PRRT may 
well become the firstline therapy in patients with metastasized or inoperable GEP-NETs 
if more widespread use of PRRT can be accomplished. 
Keywords: 
Neuroendocrine tumors, Lutetium, Yttrium, Peptide receptor radionuclide therapy, 
PRRT, Somatostatin analogues
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INTRODUCTION 
In patients with inoperable metastasized gastroenteropancreatic neuroendocrine 
tumors (GEP-NETs), therapeutic options are limited. Treatment with somatostatin 
analogues such as octreotide and lanreotide reduces hormonal overproduction and can 
relieve symptoms in patients with GEP-NETs [1–3]. Furthermore, the long acting formula 
of the somatostatin Octreotide LAR significantly lengthens time to tumor progression in 
patients with metastatic midgut neuroendocrine tumors (NETs) [4]. 
The majority of GEP-NETs express somatostatin receptors, mainly somatostatin receptor 
subtype (1) 2 and 5 [5]. These can be visualized using radiolabelled somatostatin 
analogues. The first commercially available diagnostic somatostatin receptor analogues 
were [111Indium-DTPA0]octreotide (111In-octreotide or Octreoscan) [6] and 99mTechnetium-
depreotide (NEOSPECT or NEOTECT). Nowadays newer positron emission tomography 
(PET) radiopharmaceuticals have been developed, such as [68Ga-DOTA-Tyr3]octreotide 
[7] and [68Ga-DOTA-Tyr3]octreotate [8]. 
After the introduction of 111In-octreotide, the therapeutic application of high dose 
111In-octreotide showed promising results on symptomatology in patients with 
neuroendocrine tumors [9]. However, the reported number of objective responses was 
rather disappointing with a relatively low percentage of patients with tumor shrinkage. 
In subsequent studies, severe hematological toxicity (myelodysplastic syndrome (MDS) 
or leukemia) was observed in a few patients [10,11]. 
The use of beta-emitters, such as Yttrium-90 (90Y) and Lutetium-177 (177Lu) was made 
possible with the introduction of the chelator DOTA (1,4,7,10-tetraazcyclodecane-
1,4,7,10-tetraacetic acid). Newer, more efficient, radiolabelled somatostatin analogues 
were developed with high affinity to the somatostatin receptor, such as [90Y-DOTA0, Tyr3]
octreotide (90Y-DOTATOC) and [177Lu-DOTA0, Tyr3] octreotate (177Lu-DOTATATE). The main 
focus of this review is on this next generation of somatostatin analogues, labeled with 
177Lu and 90Y. 
Chelator and peptides 
The structure of somatostatin analogues that are used for diagnostic and therapeutic 
purposes consists of three parts: a radionuclide, a chelator and a cyclic octapeptide 
(Figure 1). 
DTPA (diethylene triamine penta-acetic acid) and DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,20- tetra-acetic acid) are commonly used as 
chelators for PRRT. The most widely used combinations of peptide-chelators are 
[DOTA0,Tyr3]octreotide (DOTATOC) and [DOTA0,Tyr3]octreotate (DOTATATE). Other 
complexes include [DOTA0-1-NaI3]octreotide (DOTANOC), 111In-DOTA-lanreotide 
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(Lanreotide) and DTPA-octreotide. Changes in radionuclide and chelator can 
considerably alter compound characteristics, e.g. biochemical stability, excretion 
and receptor affinity. Reubi et al [12] reported affinity profiles (Table 1) for different 
somatostatin analogues in cell lines transfected with somatostatin receptor subtypes 
(sst1-sst5). They concluded that small structural modifications, chelator substitution or 
metal replacement can considerably affect the binding affinity. 
Figure 1 - Structure of Somatostatin Analogue: Radionuclide, Chelator and Cyclic Octapeptide 
(adapted from Eberle et al. [63]). 
Table 1 - Affinity profile (Ic50) for human sst1-sst5 receptors of a series of somatostatin analogues. 
Adapted from Reubi et al [12]
Peptides Somatostatin receptor
  Subtype 1 Subtype 2 Subtype 3 Subtype 4 Subtype 5
Somatostatin-28 5.2 (0.3) 2.7 (0.3) 7.7 (0.9) 5.6 (0.4) 4.0 (0.3)
Octreotide > 10,000 2.0 (0.7) 187 (55) >1,000 22 (6)
DTPA-octreotide > 10,000 12 (4) 376 (84) >1,000 299 (50)
111In-DTPA-octreotide > 10,000 22 (3.6) 182 (13) >1,000 237 (52)
111In-DTPA-[Tyr3]octreotate > 10,000 1.3 (0.2) > 10,000 433 (16) >1,000
DOTA-[Tyr3]octreotide > 10,000 14 (2.6) 880 (324) >1,000 393 (84)
DOTA-[Tyr3]octreotate > 10,000 1.5 (0.4) >1,000 453 (176) 547 (160)
DOTA-lanreotide > 10,000 26 (3.4) 771 (229) > 10,000 73 (12)
90Y-DOTA-[Tyr3]octreotide > 10,000 11 (1.7) 389 (135) > 10,000 114 (29)
90Y-DOTA-[Tyr3]octreotate > 10,000 1.6 (0.4) >1,000 523 (239) 187 (50)
90Y-DOTA-lanreotide > 10,000 23 (5) 290 (105) > 10,000 16 (3.4)
90Y-DOTA-vapreotide > 10,000 12 (4) 102 (25) 778 (225) 20 (2.3)
68Ga-DOTA-[Tyr3]octreotide > 10,000 2.5 (0.5) 613 (140) >1,000 73 (21)
68Ga-DOTA-[Tyr3]octreotate > 10,000 0.2 (0.04) >1,000 300 (140) 377 (18)
All values are IC50 (Standard Error Mean) in nanometer.
No data are available for 177Lu labeled somatostatin analogs.
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Radionuclide characteristics 
Over the past two decades, different radionuclides have been used for PRRT. Indium-111 
(111In), with its auger electrons caused by gamma-emission, was used in early studies 
[10,11]. Besides encouraging results with regard to symptom relief, the reported 
number of objective responses was rather disappointing. Furthermore, 111In-coupled 
peptides are not ideal for PRRT due to the small particle range and therefore low tissue 
penetration. 
90Y has high tissue penetration (12 mm) due to beta particles with a maximum energy 
of 2.27 MeV. The half-life of 90Y 2.5 days is about the same in comparison with 111In (2.8 
days). Imaging is limited with 90Y because no direct gamma-radiation is emitted. Only 
indirect gamma-radiation by deceleration of a charged particle, Bremsstrahlung, can be 
used for imaging [13]. 177Lu with beta- and gamma-emission has a half-life of 6.7 days. 
The beta radiation of 177Lu with an energy of 0.5 MeV has a tissue penetration depth of 
2 mm. Gamma-rays at 208 and 113 keV, with yields of 10% and 6% respectively can be 
used for imaging purposes. In theory, the shorter beta-range of 177Lu provides better 
irradiation of small tumors, in contrast to the longer beta-range of 90Y which allows 
more uniform irradiation in large tumors with heterogeneous uptake [14]. De Jong et al 
[15] confirmed these findings in a preclinical study. 
90Y-labeled somatostatin analogues 
Early studies with 90Y labeled somatostatin analogues were done in Basel by Otte et 
al [16,17]. In their pilot study, 29 patients with mostly neuroendocrine tumors were 
treated with 90Y-DOTATOC in a mean cumulative administered activity of 6120 ± 1347 
MBq/m2 given in four or more single injections. Sixteen patients were diagnosed with 
inoperable or metastasized GEP-NETs. Disease stabilization (2) was reported in 14 (88%) 
GEP-NET patients and one (6%) patient had a partial remission (PR). One (6%) patient 
had progressive disease (3). 
Waldherr et al [18] reported overall tumor response rate (CR and PR) of 24% in 41 NET 
patients treated with four intravenous injections of a total of 6000 MBq/m2 90Y-DOTATOC. 
The median follow up was 15 months (range 1–36 months). 
In a multicenter dose escalating study [19], 58 GEP-NET patients received up to 14.8 
GBq/m2 of 90Y-DOTATOC in four cycles or up to 9.3 GBq/m2 in a single administration, 
without reaching the maximum tolerated single dose. The maximum cumulative 
radiation dose to the kidneys, estimated with planar scintigraphy, was limited to 27 Gy. 
Amino acids were given during infusion for renal protection. Three (5%) patients had 
dose-limiting toxicity: one liver toxicity, one thrombocytopaenia grade 4 (<25 Ÿ 109/l), 
and one MDS. Five (9%) out of 58 patients had PR, and seven (12%) patients had a minor 
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response (MR; 25–50% tumor volume reduction). The median time to progression was 
29 months. 
In a multicenter trial, 90 NET patients were treated with 90Y-DOTATOC in fixed doses 
of three times 4.4 GBq [20]. Four (4.4%) patients had PD, whereas 63 (70%) out of 90 
patients had SD. All patients had proven progression at baseline. Reversible renal 
toxicity (according to Common Toxicity Criteria (CTC) v2.0), grade 3 and 4, in three 
(3.3%) patients was reported, despite coadministration of amino acids. The median 
progression-free survival (PFS) was 16 months and the median overall survival (OS) was 
27 months. 
In the European Mauritius trial [21], 154 patients with different tumors were treated with 
[90Y- DOTA]lanreotide (90Y-DOTALAN) with cumulative doses up to 8.6 GBq. Within the 
GEP-NETs subgroup (39 patients), none showed PR and eight (20%) out of 39 patients 
demonstrated MR. 
In a Danish cohort [22], 69 patients with mainly GEP-NETs were treated with 90Y-DOTATOC 
and/or 177Lu-DOTATOC. In one group (of 53 patients), 90Y-DOTATOC was given in two 
cycles with cumulative doses of 9.62–15.54 GBq. Two (4%) patients had complete 
remission (CR) and PR was reported in ten (19%) patients. 
Cwikla et al [23] described the results of treatment with 90Y-DOTATATE in 60 GEP-NET 
patients. The cumulative dose was 11.2 GBq given in four therapy cycles. Three (5%) 
patients died after the second cycle due to extensive progressive disease. PR was 
reported in 13 (22%) out of 60 patients. The median PFS was 17 months and median 
OS was 22 months (with exclusion of the three deceased patients). Twelve months after 
the completion of the therapy, three (7%) out of 43 patients had grade 2 and two (5%) 
patients had grade 3 World Health Organization (WHO) renal toxicity. 
Imhof et al [24] published the effects of treatment with 90Y-DOTATOC in a large group 
of 1109 patients with NETs. Results in a smaller number of patients were also reported 
earlier [17,18,22,25]. After the first treatment cycle, response was evaluated and 
defined as clinical, biochemical or morphologic disease control. Morphologic response 
was assessed by computed tomography (CT), magnetic resonance imaging (MRI), or 
ultrasound. Tumor response was defined as any measurable decrease in the sum of the 
longest diameters of all pretherapeutically detected tumor lesions. Additional treatment 
cycles were given if no stop criteria were met: tumor progression during 90Y-DOTATOC 
treatment or severe toxicity (grade 3–4 hematological toxicity and/or grade 4–5 renal 
toxicity according to CTC v3.0). Of 1109 patients, 378 (34%) had a morphologic response. 
Fifty-eight (5%) of these patients had SD. However response evaluation was not based 
on Response Evaluation Criteria In Solid Tumors (RECIST), Southwest Oncology Group 
(SWOG) or WHO criteria. The median survival from diagnosis was 95 months. No data on 
median PFS was available. Two (0.2%) patients developed myeloproliferative diseases. 
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One patient developed MDS after two cycles; one patient developed acute myeloic 
leukemia after four cycles. Despite infusion of amino acids for renal protection, 102 
(9%) patients had severe permanent renal toxicity. Sixty-seven (6%) patients developed 
grade 3 (GFR 15–29 ml/min/1.73 m2) and 35 (3%) grade 4 (GFR < 15 ml/min/1.73 m2) 
renal toxicity. This relatively high incidence could be related to relatively high activities 
administered per cycle and to the fact that patients with pre-existing reduced kidney 
function were not excluded from treatment. The possible lack of use of amino acids in 
the first years of this study [17,18] must also be taken into account. 
Table 2 summarizes the reported tumor outcome in different clinical trials using 90Y 
labeled somatostatin analogues. Differences in outcome, despite using the same 
compound (90Y-DOTATOC). This may be due to several factors. An important factor is 
the variety in administered doses (fixed or dose-escalating) and the number of therapy 
cycles. Furthermore, patient and tumor characteristics also differ between the studies 
mentioned, possibly contributing to the differences in radiological response. 
177Lu-labeled somatostatin analogues 
De Jong et al [26] compared different radiolabelled somatostatin analogues in a 
preclinical setting. 111In-octreotide, 90Y-DOTATOC and 177Lu-DOTATATE were injected 
in rats bearing Somatostatin receptor subtype 2 (sst2) tumors. 
177Lu-DOTATATE 
demonstrated the highest tumor uptake together with excellent tumor-to-kidney ratios. 
Forrer et al [27] injected 222 MBq 111In-DOTATOC and 111In-DOTATATE within two weeks 
in five patients with metastatic neuroendocrine tumors. They examined whether one 
of the 111In labeled peptides had a more favorable biodistribution and used 111In as a 
surrogate for 90Y and 177Lu. The mean absorbed dose was calculated for tumors, kidney, 
liver, spleen and bone marrow. In all cases 111In-DOTATATE showed a higher percentage 
of injected activity (%IA) in kidney and liver. 111In- DOTATOC showed a higher tumor-to-
kidney absorbed dose ratio in seven (78%) out of nine evaluated tumors. They concluded 
that the two peptides appear to be nearly equivalent for PRRT in neuroendocrine 
tumors, with minor advantages for 111In-DOTATOC. 
In an earlier study, Esser et al [28] compared 177Lu-DOTATOC with 177Lu-DOTATATE in 
seven patients. In the same patients 3.7 GBq of each compound was administered in 
separate therapy sessions (Figure 2). The residence times in the spleen and the kidneys 
were significantly longer after 177Lu- DOTATATE injection. Also tumor uptake over time 
was longer after 177Lu-DOTATATE, which resulted in a higher tumor dose. They concluded 
that 177Lu-DOTATATE is the radiolabelled Somatostatin analogue of choice for PRRT. 
Kwekkeboom et al [29] reported the first clinical results of 177Lu-DOTATATE (cumulative 
dose 22.2– 29.6 GBq) in 34 GEP-NET patients. Three months after the final administration, 
CR was found in one (3%) patient, partial remission in 12 (35%), stable disease in 14 
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(41%) and progressive disease in seven (21%) patients. Teunissen et al [30] evaluated the 
Quality of Life (QoL) in 50 Dutch patients before therapy and at follow-up visit six-weeks 
after the last cycle. A signifi cant improvement in the global health status/QoL scale was 
observed after therapy with 177Lu-DOTATATE. In the study that followed, Khan et al [31] 
concluded that 177Lu-DOTATATE therapy not only can reduce tumor size and can prolong 
overall survival but also led to an improvement in symptoms. Two hundred and sixty-
fi ve (94%) out of 282 Dutch patients completed the Quality of Life (QoL) questionnaire 
at fi xed times points: six weeks, three months and six months after therapy with 177Lu-
DOTATATE. In 40–70% of the patients, symptoms improved after 177Lu-DOTATATE therapy 
and no signifi cant decrease in QoL was observed in patients who had no symptoms 
before therapy. 
Figure 2 - Planar anterior scans of a patient with a GEP-NET after 177Lu-DOTATOC (left) and 177Lu-
DOTATATE (right) injection. A longer mean residence time is observed on the 177Lu-DOTATATE scan 
(right) in comparison with 177Lu-DOTATOC (left). (Adapted from Esser et al.[28] ).
Analysis of a large group of a total of 310 GEP-NET patients was published in 2008 [32]. 
Patients were treated with 177Lu-DOTATATE up to 27.8–29.6 GBq, usually in four treatment 
cycles. Complete and partial tumor remissions (CR and PR) occurred in fi ve (2%) and 86 
(28%) of 310 GEP-NET patients, respectively. A reduced tumour uptake after the second, 
third or fourth therapy in comparison with fi rst post-therapy scan was frequently seen in 
patients with PR during follow-up (Figure 3). The median PFS was 33 months. The most 
important factor predicting increased survival was treatment outcome. Patients with 
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PD had a signifi cantly shorter survival in comparison with SD, CR, PR and MR. Compared 
with historical controls, there was a survival benefi t of 40–72 months. 
In a recent dose escalating study with 177Lu-DOTATATE, Bodei et al [33] treated 51 patients 
with sst2 receptor positive tumors. Forty-two (82%) patients were diagnosed with GEP-
NETs. One patient (2%) had CR, 12 (29%) patients showed PR after the last administration 
of 177Lu-DOTATATE. Three year overall survival was 68%. The median time to progression 
was 36 months, which is in accordance with results of the Kwekkeboom et al [32]. 
Figure 3 - A. Posterior and anterior post-therapy scans after each cycle of PRRT with 7400 MBq 
177Lu-DOTATATE in a patient with neuroendocrine tumor (primary in rectum) with liver metastasis 
who eventually had partial remission (PR) as tumor outcome. Note the decrease of uptake in the 
lesion of liver segment 8 compared to physiological liver uptake. 
B. CT of abdomen of the same patient before PRRT (left panel) and 3 months after PRRT (right 
panel). (Adapted from Teunissen et al. [64])
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Side effects 
The kidneys are the dose-limiting organs for PRRT, when 90Y labeled somatostatin 
analogues are used. Valkema et al [34] compared the decline in creatinine clearance 
after treatment with 90Y- DOTATOC or 177Lu-DOTATATE. A median decline in creatinine 
of 7.3% per year was observed in 28 patients treated with 90Y-DOTATOC with a median 
follow-up of 2.9 years [35]. The median decline in creatinine was 3.8% per year in 37 
patients treated with 177Lu-DOTATATE (cumulative administered activity of 27.8–29.6 
GBq) [29]. Two (7%) out of 28 patients treated with 90Y-DOTATOC developed grade 3 
renal toxicity. All patients treated with 90Y-DOTATOC received concomitant amino acids 
for kidney protection, since high amounts of lysine lead to a greater reduction in renal 
uptake of radiopeptides [36]. The mean cumulative renal dose was higher in patients 
treated with 90Y-DOTATOC than in patients treated with 177Lu-DOTATATE (27 vs. 20 Gy). 
Age, hypertension and diabetes were probable risk factors contributing to a further 
decline of creatinine clearance after PRRT. Bodei et al [37] reported age, hypertension, 
diabetes and renal morphological abnormalities as contributing risk factors to a further 
decline of creatinine clearance. In the study of Bodei et al [37], who treated patient with 
90Y-DOTATOC, WHO grade 1–3 creatinine toxicity was reported in nine (3%) out of 23 
patients. These patients were selected for further dosimetric studies out of a group 
of 211 patients. One of these nine patients developed a grade 3 (3–6 Upper Limit of 
Normal, ULN) renal toxicity. Patients were followed up for renal toxicity by measuring 
creatinine and creatinine clearance according to the Cockcroft–Gault formula. 
In the study of Valkema et al [19], 58 patients were treated with 90Y-DOTATOC with 
cumulative doses of 1.7 GBq up to 32.8 GBq. Two (4%) patients had dose-limiting toxicity 
unrelated to renal function: one patient had transient grade 3 liver toxicity and one 
patient had grade 4 thrombocytopenia. One (2%) patient developed MDS, two years 
after the start of PRRT. Nine (16%) patients had a more than 15% per year decline in 
creatinine clearance with end-stage renal disease in one patient. 
Side effects of 177Lu-DOTATATE were analyzed in 504 patients with GEP-NETs [32]. 
Subacute hematological toxicity (WHO grade 3 or 4) occurred four–eight weeks after 
at least one of several treatments in 48 (9.5%) patients. Factors associated with a higher 
frequency of hematological toxicity grade 3 or 4 were: age over 70 years, previous 
chemotherapy, creatinine clearance (calculated with Cockcroft–Gault formula) 60 ml/
min, and the presence of bone metastasis. Serious delayed toxicities were observed in 
nine (2%) out of 504 patients. Two (0.4%) patients developed renal insufficiency, which 
was probably unrelated to treatment with 177Lu-DOTATATE in both patients. Three (0.6%) 
patients had serious liver toxicity, two (0.4%) of whom were probably related to the 
treatment. MDS was found in four (0.8%) patients, which was potentially treatment 
related in three (0.6%) patients. In six patients with a hormonally highly active NET 
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(mostly VIPomas), a hormone-related crisis occurred after administration due to massive 
release of bioactive substances [38]. 
Bodei et al [33] reported in their dose escalating study with 177Lu-DOTATE (Cumulative 
activities 3.7–29.2 GBq) of 51 patients, only one (2%) patient with both grade 3 
leukopenia and thrombocytopenia. 
Retreatment 
Van Essen et al [39] reported successful retreatment with 177Lu-DOTATATE in 33 NET 
patients. All patients had benefit from prior therapy with 18.5–29.6 GBq of 177Lu-
DOTATATE and later again experienced progressive disease, documented by CT or 
somatostatin receptor scintigraphy (SRS). Two additional cycles of 7.4 GBq 177Lu-
DOTATATE were given. Tumor response was evaluated using SWOG criteria. Two (6%) 
patients had PR, six (18%) patients responded with MR, SD was reported in ten (30%) 
patients and 15 (45%) patients had PD. No kidney failure or MDS was observed during a 
median follow- up of 16 months. 
Forrer et al [36] also retreated 27 patients with 177Lu-DOTATATE who had initially been 
treated with 90Y-DOTATOC. The mean time between the initial treatment and retreatment 
was 15.4 months. All patients were injected with a single dose of 7.400 MBq 177Lu-
DOTATATE. In two (7%) patients PR was found, in five (19%) minor response, in 12 (44%) 
patients SD and PD in eight (30%) patients. 177Lu- DOTATATE therapy was well tolerated 
and no severe toxicities (grade 3–4) occurred. 
From these studies it can be concluded that patients with good response after initial 
therapy with PRRT are eligible for retreatment, but tumor response rates of retreatment 
are less favorable than for the initial treatment. 
Dosimetry 
In the first PRRT biodistribution and therapy studies, it was found that the kidneys and 
bone marrow are the critical organs for PRRT. The current role of dosimetry is that of a 
guide with respect to safety, especially to prevent kidney damage. 
In a recent 177Lu-DOTATATE dose escalating study of Bodei et al [33], evaluation of 
pharmakinetics, activity biodistribution and absorbed dose to normal organs and 
tumors was performed. Fifty-one patients with metastatic sst2-positive tumors (mainly 
NETs) were divided into two groups. Group 1 received escalating activities of 3.7–5.18 
GBq/cycle and group 2 received escalating activities of 5.18– 7.4 GBq/cycle. No major 
acute or delayed renal or hematological toxicity occurred. Cumulative renal absorbed 
doses were 8–37 Gy. A median decrease of creatinine clearance of 27.6% after two years 
was observed. 
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Cumulative bone marrow doses were <1.5 Gy. Blood cell counts showed a progressive 
mild drop during cycles and recovered during follow-up (median 30 months). The 
authors concluded that the maximum tolerated dose/cycle of 177Lu-DOTATATE was not 
reached and therefore 7.4 GBq, as a maximum activity per cycle, can be used safely. 
Sward et al [40] analyzed the clinical impact of dosimetry by using the absorbed dose to 
the kidneys as a limiting factor in treatments with 177Lu-DOTATATE. Twenty-six patients 
with GEP-NETs were treated with 8 GBq/cycle in up to five cycles with a dose limit of 27 Gy 
to the kidneys. Ten (39%) out of 26 patients did not receive the planned four treatments 
due to dosimetric calculations to prevent overtreatment. Four patients had the potential 
to receive additional treatment without exceeding the dose limit. Three (12%) patients 
experienced CTC grade 3 hematologic with low platelet counts. A significant difference 
in glomerular filtration rate (GFR) was observed before treatment (80 ml/ 1.73 m2/min) 
in comparison with mean GFR at follow-up (70 ml/1.73 m2/min). The authors conclude 
that by using the absorbed dose to the kidneys as a limiting factor, treatment with 177Lu-
DOTATATE can be individualized. Overtreatment can be avoided and patients with the 
potential to receive additional treatment can be identified. 
Dosimetry is currently used as a tool for risk assessment in critical organs. Dosimetric 
analysis can help maximize full potential of PRRT in regards of maximum activity 
per treatment cycle. In the future, individual dosimetry could be used for treatment 
planning of PRRT on a patient level. 
Options to improve PRRT 
Combination of compounds 
A preclinical study by de Jong et al [15] compared the antitumoral effects of the 
combination of 177Lu- and 90Y-labelled somatostatin analogues with either 90Y- or 177Lu-
analogue alone in animals bearing tumors of various sizes. The combination of both 
compounds was best for tumor control of both large and small tumors and resulted 
in the longest survival of the animals. The tumor in this rat model was rapidly growing 
and this may led to necrosis in parts of the tumor, therefore causing a heterogeneous 
expression of the somatostatin receptor. In contrast, neuroendocrine tumors in humans 
have a homogeneous receptor distribution and grow slowly. Extrapolation of preclinical 
results to neuroendocrine tumors in humans is limited, as has been reviewed by de Jong 
and Maina [41]. 
In a clinical setting, Frilling et al [42] treated 20 patients suffering from metastatic non-
resectable NETs. All patients received 90Y-DOTATOC as an initial treatment and additional 
sessions with 177Lu- DOTATATE took place in six individuals. They concluded that it is safe 
to administer 90Y-DOTATOC and additional 177Lu-DOTATATE within a reasonable time in 
patients with NETs. 
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Villard et al [43] compared the efficacy of 90Y-DOTATOC with a combination of 90Y-DOTATOC 
and 177Lu-DOTATATE in 486 patients with NETs. Patients receiving 90Y-DOTATOC plus 
177Lu-DOTATATE had a significantly longer survival than patients receiving 90Y-DOTATOC 
alone, 5.5 and 4.0 years respectively. This is a good result although a large discrepancy 
between the two treatment arms was observed. In this retrospective study 1396 patients 
were enrolled initially, but only patients who received more than two treatment cycles 
were included in the analysis. In order to be a candidate for a next treatment cycle, a 
patient had to benefit (clinically, biochemically or on tomographic imaging) from the 
previous treatment cycles. Thirty-eight (13%) out of 287 patients in the combination 
arm were not analyzed because they received two or less treatment cycles. On the other 
hand, 872 (71%) out of 1109 patients in the 90Y-DOTATOC arm were not analyzed. A 
higher percentage of patients in 90Y- DOTATOC group were not analyzed, which could 
imply that patients were in a poorer clinical condition than those treated with the 
combination of radiopharmaceuticals. This selection bias could influence trial outcome 
dramatically. 
Kunikowska et al [44] published results of a retrospective, non-randomized study 
in 50 patients (25 per arm) with NETs. Candidates were treated with a combination 
of 90Y-DOTATOC and 177Lu-DOTATATE or with 90Y-DOTATOC as a monotherapy. The 
investigators found that the median PFS was not significantly different between the 
groups, but that overall survival was longer in patients who were treated with the 
combination of radiopharmaceuticals. However, the median concentration of the 
serum tumour marker chromogranin A (CgA) was 179 microgram per liter in patients 
treated with the combination of radiopharmaceuticals, whereas it was 423 microgram 
per liter in the patients treated with 90Y-DOTATOC only, suggesting a higher tumor load. 
This selection bias could have influenced outcome of this study. 
Seregni et al [45] described a study protocol using a dual treatment with 90Y-DOTATOC 
and 177Lu- DOTATATE. Patients with NETs were treated with an intended dose of 5.6 GBq 
177Lu-DOTATATE alternating with 2.6 GBq 90Y-DOTATOC with a total of four administrations. 
Nine (69%) out of 13 patients had progressive disease before treatment. Tumor response 
was PR in eight (62%) out of 13 patients with GEP-NETs. However, two patients who 
had a deterioration of their health condition during treatment were excluded from the 
analysis, thus resulting in a more favorable treatment outcome. 
Despite these promising results from the studies mentioned above, doubts remain 
about the selection bias [46]. A proper randomized trial with long-term follow-up is 
necessary for final confirmation regarding PRRT with combined compounds. 
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Neo-adjuvant use of PRRT 
In a case report, Kaemmerer et al [47] described the neoadjuvant use of 90Y-DOTATATE in 
a patient with an initially inoperable malignant neuroendocrine tumor of the pancreas. 
In a Dutch cohort [32], four patients had inoperable pancreatic NETs that had not 
metastasized. Tumor shrinkage subsequent to treatment with 177Lu-DOTATATE made 
these patients candidates for surgery (Figure 4). 
Sowa-staszczak et al [48] treated 47 inoperable NET patients with 90Y-DOTATOC. Six 
patients were selected for neoadjuvant treatment. Stabilization of the disease was 
observed in four (66%) patients and partial responses in two (33%) patients. Tumor 
response was evaluated by RECIST criteria. In two patients, reduction of the tumor size 
enabled surgical intervention. 
Barber et al [49] treated five inoperable pancreatic and duodenal NET patients without 
distant metastatic disease with 177Lu-DOTATATE and concurrent Fluorouracil (5-FU) 
chemotherapy. Patients were followed up three months post-treatment with SRS, 
radiology, biochemical markers and clinical assessment. All five patients had an on-
going treatment response beyond three months. One (20%) patient with localized 
pancreatic NET encasing the portal vein before PRRT was reconsidered for curative 
surgery. A complete resection was performed and histopathological evaluation 
confirmed surgical margins free of tumor. 
In conclusion, PRRT can be effective in patients with inoperable GEP-NETs without 
other sites of unresectable metastatic disease. The neoadjuvant use of PRRT, though 
applicable in select cases only, may potentially cure such patients. 
Intra-arterial administration 
Selective hepatic intra-arterial injection of 90Y-DOTA-lanreotide (DOTALAN) was safely 
used as a palliative therapy in 23 patients with large volume liver metastasis from 
NETs [50]. Selective hepatic intra-arterial injection of 90Y-DOTALAN (36 treatments; 
median activity per dose, 1 GBq) was administered with or without embolization. 
Objective tumor response was classified according to WHO response criteria. PR after 
the treatment was accomplished in three (16%) out of 19 patients and stable disease 
was achieved in 12 (63%) patients. The authors concluded that hepatic intra-arterial 
injection of 90Y-DOTALAN is a safe and effective palliative treatment. 
Kratochwil et al [51] investigated the effectiveness of infusion into the hepatic artery 
of 90Y- DOTATOC and/or 177Lu-DOTATOC in 15 patients with liver metastases arising 
from GEP-NETs. Response was assessed using 68Ga-DOTATOC PET, multiphase contrast 
enhanced CT, MRI and chromogranin A. CR was achieved in one (7%) patient and PR was 
observed in eight (53%) patients, six (40%) patients were classified as SD. 
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Figure 4 - Initially inoperable NET of the pancreas. CT of abdomen before (A) and 3 months after 
(B) PRRT in 4 cycles with cumulative 29.6 GBq of 177Lu-DOTATATE. This patient had eventually partial 
remission (PR) as tumor outcome. A successful Whipple procedure plus reconstruction of the 
portal vein was performed 7 months after the last treatment. Resection edges and lymphnodes 
were free of tumor. 
Limouris et al [52] evaluated the effectiveness of 111In-octreotide after selective 
catheterization of the hepatic artery in 16 GEPNET patients with liver metastasis. These 
patients received a mean cumulative dose of 58 GBq 111In-octreotide in a mean number 
of 11 treatments. Tumor response was CR in one (6%) patient and PR in eight (50%) 
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patients. Median survival time was 32 months for the patients with CR, PR or SD as a 
tumor response. Minimal hematological toxicity was observed in this study. WHO 
toxicity grade 1 anemia occurred in five (31%) patients and grade 1 leucocytopenia and 
thrombocytopenia in three (20%) patients. 
The results of intra-arterial administration of PRRT is promising, though only GEPNET 
patients with a predominant tumor load in the liver can benefit. Furthermore intra-
arterial administration makes PRRT more complex with additional risks (e.g. infection, 
bleeding). 
Radiosensitising drugs and PRRT 
A way to improve PRRT may be to combine the treatment with radiosensitizing 
chemotherapeutical agents (Cisplatin, 5-FU, capecitabine, etc.). Intravenous 5-FU was 
used in different trials to investigate the effects of (fractionated) external beam radiation 
on various tumor types. On a biochemical level, the enzyme thymidine phosphorylase 
(TP) converts the inactive form (capecitabine) into its active form (5-FU). Many tumors 
have a higher amount of TP and this results in an increased concentration of the active 
form in such tumors than in normal tissue. In addition, irradiation induces upregulation 
of TP in the tumor cell [53]. With the combination of external beam radiotherapy and 
capecitabine, an increased efficacy in terms of tumour growth control was reported, 
when compared to external beam radiotherapy as single treatment modality for a 
variety of tumors [54]. These results led to the hypothesis that PRRT in combination with 
capecitabine could be more effective than PRRT without capecitabine. 
Van Essen et al [55] reported the safe use of 177u-DOTATATE and capecitabine in seven 
patients with GEP-NETs. A clinical randomized controlled trial was started in our 
institution in 2008 to compare this combination with 177Lu-DOTATATE as a single agent 
with regard to anti-tumor effects and side effects. 
In a recent non-randomized study [56], 33 GEP-NET patients were treated with 177Lu-
DOTATATE in combination with capecitabine. The cumulative intended administered 
activity was 31.2 GBq with 14 days of 1.650 mg/m2 capecitabine per day per treatment 
cycle. Three patients discontinued capecitabine use due to transient angina. Objective 
response rates (ORR) were: eight (24%) out of 33 patients had PR, and 23 (70%) out of 
33 had SD according to the revised RECIST (version 1.1) criteria. The authors defined 
an increase of >30% in target lesions as PD, but in the revised RECIST guideline PD is 
defined as an increase of >20% in target lesions. This modified RECIST criteria could 
have influenced the outcome of PD in a positive way. A proper randomized control 
trial comparing treatment with 177Lu-DOTATATE with and without capecitabine will 
demonstrate if capecitabine has an additive effect in NET patients treated with PRRT. 
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Targeted alpha-particle therapy 
Alpha particles have a short path length and are potentially ideal to treat small 
tumor-volumes effectively. Several oncological studies with alpha-particle-emitting 
radionuclides have been reported, including the treatment of myeloid leukemia with 
an anti-CD33 monoclonal antibody labeled with 213Bismuth [57], the therapy of patients 
with bone metastases from hormone- refractory prostate cancer with 223Radium [58] 
and the loco-regional targeted radiotherapy with 211Astatine-labelled antitenascin 
monoclonal antibody in patients with recurrent malignant brain tumors [59]. 
Only limited research has been done on somatostatin analogues labeled with alpha-
emitters. Nayak et al demonstrated in two preclinical studies [60,61] the advantages 
of 213Bismuth-[DOTA0-Tyr3]-octreotide (213Bi-DOTATATE) over 177Lu-DOTATATE in 
somatostatin receptor-positive cell line (Capan-2). 
In a clinical study, Kratochwil et al [62] reported preliminary data on the therapeutic 
application of the intra-arterial administration of alpha-emitter with 213Bi-DOTATATE. Ten 
patients with neuroendocrine liver metastases were injected intra-arterially with 213Bi-
DOTATATE. No acute kidney, endocrine or hematologic toxicity (>grade 1) was observed 
during the first dose-escalating steps (2.5 GBq cumulative activity, 1.5 GBq per cycle). 
Despite the conceptual appeal and the theoretical advantages, the translation of 
targeted alpha particle therapy into the clinical domain has been slow, in part because 
of limited radionuclide availability and the lack of alpha emitters with physical half-lives 
that can be implemented in the daily clinical practice. 
SUMMARY 
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues 
plays an increasing role in the treatment of patients with inoperable or metastasised 
gatroenteropancreatic neuroendocrine tumors (GEP-NETs). 90Y-DOTATOC and 177Lu-
DOTATATE are the most used radio- peptides for PRRT with comparable tumor response 
rates (about 15–35%). The side effects of this therapy are few and mild. However, amino 
acids should be used for kidney protection, especially during infusion of 90Y-DOTATOC. 
PRRT based on dosimetry could monitor and even prevent damage to normal organs on 
an individual level, especially when different ‘cocktails’ of radiopeptides are used. 
Options to improve PRRT may include combinations of radioactive labeled somatostatin 
analogues and the use of radiosensitising drugs combined with PRRT. Other therapeutic 
applications of PRRT are neo-adjuvant treatment and additional therapy cycles in patients 
with progressive disease, after benefit from initial therapy. Intra-arterial administration 
could enhance tumor response rates with current radioactive compounds and can 
locally administer radiopeptides labeled with alpha-emitters. 
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If more widespread use of PRRT can be accomplished, PRRT may well become the 
therapy of first choice in patients with metastasized or inoperable GEP-NETs. 
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ABSTRACT 
After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular 
in PRRT with 90Y-labelled somatostatin analogues. Risk factors have been identified for 
increased probability of developing renal toxicity after PRRT, including hypertension, 
diabetes and age. We investigated the renal function over time, the incidence of 
nephrotoxicity and associated risk factors in patients treated with PRRT with [177Lu-
DOTA0,Tyr3]-Octreotate (177Lu-Octreotate). Also, radiation dose to the kidneys was 
evaluated and compared with the accepted dose limits in external beam radiotherapy 
and PRRT with 90Y-radiolabelled somatostatin analogues. 
Methods:
The annual decrease in creatinine clearance (CLR) was determined in 209 Dutch patients 
and the incidence of grade 3 or 4 renal toxicity (according to CTCAE v4.03) was evaluated 
in 323 patients. Risk factors were analyzed using a nonlinear mixed effects regression 
model. Also, radiation doses to the kidneys were calculated and their association with 
high annual decrease in renal function were analyzed. 
Results:
Of the 323 patients, 3 (1 %) developed (subacute) renal toxicity grade 2 (increase in serum 
creatinine >1.5 – 3.0 times baseline or upper limit of normal). No subacute grade 3 or 4 
nephrotoxicity was observed. The estimated average baseline CLR (± SD) was 108 ± 5 
ml/min and the estimated average annual decrease in CLR (± SD) was 3.4 ± 0.4 %. None 
of the risk factors (hypertension, diabetes, high cumulative injected activity, radiation 
dose to the kidneys and CTCAE grade) at baseline had a significant effect on renal 
function over time. The mean absorbed kidney dose in 228 patients was 20.1 ± 4.9 Gy. 
Conclusion:
Nephrotoxicity in patients treated with 177Lu- octreotate was low. No (sub)acute grade 
3 or 4 renal toxicity occurred and none of the patients had an annual decrease in renal 
function of >20 %. No risk factors for renal toxicity could be identified. Our data support 
the idea that the radiation dose threshold, adopted from external beam radiotherapy 
and PRRT with 90Y-labelled somatostatin analogues, does not seem valid for PRRT with 
177Lu-octreotate. 
Keywords: 
PRRT, 177Lu-Octreotate, Kidneys, Renal function, Toxicity, Dosimetry, Nephrotoxicity
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INTRODUCTION 
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues 
is increasingly being used in patients with neuroendocrine tumors. Frequently used 
somatostatin analogues are [90Y-DOTA0,Tyr3]- octreotide (90Y-DOTATOC) and [177Lu-
DOTA0,Tyr3]- octreotate (177Lu-Octreotate). Although the side effects of this therapy 
are mild, renal toxicity has been observed, particularly in PRRT with 90Y-DOTATOC with 
an average annual decrease in creatinine clearance (CLR) of 7 % in contrast to 3 % for 
177Lu-Octreotate [1–4]. Also several risk factors have been identified for developing renal 
toxicity after PRRT: poor renal function, hypertension, and diabetes at baseline [2,5]. 
In the kidneys, radiolabelled somatostatin analogues are reabsorbed in the renal 
proximal tubules [6]. A decrease in renal uptake can be achieved by coinfusion of amino 
acids during PRRT [7,8]. Despite this renoprotection, there is still a significant radiation 
dose to the kidneys. In the past, the threshold dose for late-stage kidney radiation 
damage was set at 23 Gy, which was the dose adopted from external beam radiation 
therapy (EBRT) [9]. According to new consensus guidelines, the limit for fractionated 
EBRT is set at 18 Gy that results in late radiation damage to the kidneys in 5 % of a 
treated population [10]. However, doses higher than 23 Gy are safely given to patients 
receiving PRRT with (mainly) 90Y-based somatostatin analogues [2,11]. Here we present 
our dosimetric results and long-term follow-up of a large number of patients treated 
with 177Lu-Octreotate. We also analyzed the association between known risk factors that 
have been indicated for PRRT with 90Y-based somatostatin analogues [2,5] and change 
in renal function, including hypertension, diabetes, cumulative injected activity, age, 
previous therapies and poor renal function at baseline. In addition, radiation doses to 
the kidneys were calculated and analyzed. 
MATERIALS AND METHODS 
Patients 
A total of 615 patients, who were treated from January 2000 to December 2007 were 
studied. Inclusion criteria for the study were: patients with somatostatin positive tumors 
and baseline tumor uptake on [111In-DTPA0]Octreotide scintigraphy (Octreoscan®; 
Mallinckrodt, Petten, The Netherlands) with accumulation in the tumor at least as high 
as in normal liver tissue; no prior treatment with PRRT; baseline serum hemoglobin (Hb) 
≥6 mmol/l; white blood cells ≥2 109/l; platelets ≥75 109/l; Karnofsky performance status 
≥50; serum creatinine ≤150 μmol/l; and 24-h CLR ≥40 ml/min. Of the 615 patients, 323 
Dutch patients were selected for this long- term evaluation, because loss to follow-up is 
limited in these patients. 
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This study was part of an ongoing prospective study in patients with neuroendocrine 
tumors treated with 177Lu- Octreotate at the Department of Nuclear Medicine, Erasmus 
University Medical Center Rotterdam. The hospital’s medical ethics committee approved 
the study. All patients gave written informed consent for participation in the study. 
Treatment 
[DOTA0,Tyr3]Octreotate was obtained from BioSynthema (St. Louis, MO). 177LuCl3 was 
supplied by IDB-Holland (Baarle-Nassau, The Netherlands) and 177Lu-Octreotate was 
locally prepared [12]. 
Granisetron 3 mg or ondansetron 8 mg was injected intravenously 30 min before 
infusion of 177Lu-Octreotate. Infusion of amino acids (2.5 % arginine and 2.5 % lysine, 1 l) 
was started 30 min before administration of the radiopharmaceutical and lasted for 4 h. 
The radiopharmaceutical was coadministered for 30 min using a second pump system. 
The interval between treatments was 6 – 16 weeks. The intended cumulative activity 
was 29.6 GBq (800 mCi). Median cumulative activity was 29.6 GBq (range 7.4 – 29.6 GBq) 
and the median number of therapy cycles was four (range one to eight). However, the 
total administered activity was lowered if the calculated kidney dose was higher than 
23 Gy. Other reasons for dose reduction or cessation of further therapy were recurrent 
grade 3 or 4 hematological toxicity and persistently low blood cell counts. 
Toxicity, risk factor assessment and follow-up 
Hematology, liver and renal function tests were performed during the 6 weeks before 
the first therapy, 4 and 6 weeks after each therapy, and at follow-up visits. Acute and 
long-term renal toxicity assessment was done according to Common Terminology 
Criteria for Adverse Events (CTCAE v4.0) [13]. 
Hypertension was defined as the use of antihypertensive drugs (thiazide diuretics, 
beta blockers, ACE inhibitors, angiotensin II receptor antagonists and calcium channel 
blockers). Diabetes mellitus was defined as an HbA1c of ≥6.0 % and/or the use of 
antidiabetic medication (insulin and insulin sensitizers). CLR in milliliters per minute 
was used as an estimate of glomerular filtration rate (GFR). Four serum-based methods 
were used to determine baseline 24-h urine CLR, and the results compared (see 
Supplementary material). The Cockcroft-Gault (CG) formula had the highest Spearman’s 
rank correlation coefficient. Therefore, changes in renal function during follow-up were 
assessed in terms of CLR determined using the CG formula: 
  
 (2.1)
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Statistical analysis 
SPSS (SPSS 19; IBM, Armonk, NY) and R (R 3.2.2; R Foundation for Statistical Computing, 
Vienna, Austria) soft- ware was used for statistical analysis. The Shapiro-Wilk test was 
used to assess the normality of the response. The primary outcome was CLR predicted 
by a nonlinear mixed effects regression model with independent factors (hypertension, 
diabetes, cumulative injected activity, radiation dose to the kidneys, age and CTCAE 
at baseline). Various functional model forms (linear, nonlinear, polynomial and spline) 
were fitted to the CLR data (see Supplementary material). The nonlinear model with the 
monoexponential function performed best:
                (2.2)
where b0
 is the estimated average CLR at time 0 when all other covariates are zero, and 
b1
 is the estimated average change in CLR in percent/time. Time is expressed in weeks 
and factor1 and factor2 are constants, given specific values of the covariates included in 
the mixed model. The combined term  represents the estimated average 
CLR at time = 0 for a specific covariate pattern, whereas  is the estimated 
average percentage decrease/increase in CLR per week. Random effects were included 
on both the intercept and slope parameters, and a diagonal covariance matrix was 
assumed. 
Dosimetry 
Uptake of radioactivity in the kidneys was determined by planar imaging at 1, 3–4 and 
7 days after administration of 177Lu-Octreotate. Extensive information regarding the 
dosimetric method is provide in an earlier paper [12]. Dosimetry values were computed 
with S-factors for 177Lu derived from the Radiation Dose Assessment Resource 
(RADAR) website [14, 15]. The general scheme for calculating radiation dosimetry with 
radionuclides has been defined by the MIRD scheme dosimetry formula [16]: 
 (2.3)
  (2.4)
The dose to the target organ (Dkidneys) is calculated as the product of the number of decays 
in a source organ (Ãs) and the S-value, which expresses the dose rate per radioactivity 
for a source (rs) to target (rt) combination. With moderately weak β-particle-emitting 
radionuclides such as 177Lu, only the self-dose needs to be considered (rs = rt). The 
radioactivity uptake and clearance kinetics of 177Lu-Octreotate A (t) in the kidneys is 
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needed for calculation of the radiation dose to the kidneys, together with the S-value 
for the kidney self-dose. The 177Lu S-values were taken from the RADAR website [15]: 
for adult male kidneys (with a mass of 299 g) the S-value is 0.289 mGy/ MBq.h and 
for a adult female kidneys (with a mass of 275 g) the S-value is 0.314 mGy/MBq.h. In a 
subgroup of patients, the kidney volume was determined based on baseline CT images, 
since complete kidney imaging was not always avail- able. A correction factor and 
adjusted dose were calculated in these patients, using OsiriX 5.9 (Pixmeo Sàrl, Bernex, 
Switzerland). A polygonal region of interest was (semi)automatically drawn on each CT 
slice and the slices were summed for calculation of the total kidney volume. 
RESULTS 
In 554 patients the inclusion criteria were met. In-depth evaluation was done in 322 
Dutch patients (excluding one patient with no baseline CLR). Patient characteristics are 
summarized in Table 1. A Spearman’s correlation coefficient of 0.76 was found between 
baseline 24-h urine and serum-based CLR (Figure 1). 
Figure 1 - Baseline 24-h urine creatinine clearance (CLR) versus serum-based CLR according to the 
Cockcroft-Gault formula in 281 of 323 patients. The solid line is the linear regression line with a 
slope of 1 with 95 % confidence intervals (dotted lines).
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Table 1 - Baseline characteristics of 323 Dutch patients 
Characteristic no. 
Gender 
  Male 158 (49 %) 
  Female 165 (51 %) 
Age (years) 
  ≥70 63 (20 %) 
  <70 260 (80 %) 
Karnofsky performance status 
  ≤70 46 (14 %) 
  >70 277 (86 %) 
Diabetes 
  Yes 104 (32 %) 
  No 219 (68 %) 
Hypertension 
  Yes 77 (24 %) 
  No 246 (76 %) 
Solitary kidney 
  Yes 10 (3 %) 
  No 313 (97 %) 
Previous therapy 
  Radiotherapy (external)
    Yes 32 (10 %) 
    No 291 (90 %) 
  Chemotherapy 39 (12 %) 
    Cisplatin 5 (13 %) 
    Other 34 (87 %) 
Tumour type 
  Neuroendocrine tumour 281 (87 %) 
  Other 42 (13 %) 
Dosimetry 
  Dosimetric data available 228 (71 %) 
  Limit 23 Gy to the kidneys 
    Yes 55 (24 %) 
    No 173 (76 %) 
  Volume of kidneys available 
    Yes 119 (52 %) 
    No 109 (48 %) 
Cumulative activity (GBq) 
  Up to 22.2 106 (33 %) 
  Up to 29.6 Kidneys 217 (66 %) 
Baseline creatinine clearance 
  <60 ml/min/1.73 m2 37 (11 %) 
  ≥60 ml/min/1.73 m2 286 (89 %) 
Baseline Cockcroft-Gault 
creatinine clearance (ml/ min), median (range) 95 (34 – 245) 
Follow-up (months), median (range) 25 (0 – 142) 
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Kidney toxicity 
Of the 323 patients, 14 (4 %) had a (sub)acute toxicity grade 1 (creatinine increase >26.5 
μmol/l). Three patients (1 %) developed (subacute) toxicity grade 2 (creatinine increase 
>1.5 – 3.0 × baseline or upper limit of normal). These were judged not related to therapy: 
one patient had received prolonged antibiotics due to an infection and developed 
temporary renal insufficiency, one patient was dehydrated because of diarrhea, and 
one patient showed progression of disease with hypoalbuminaemia and forward heart 
failure resulting in death 2 weeks after the first treatment. No grade 3 or 4 (sub)acute 
nephrotoxicity was observed. 
Figure 2 - Distribution of creatinine clearance in 323 patients according to Common Terminology 
Criteria for Adverse Events (CTCAE) classifica- tion at baseline, and at 1, 2 and 3 years after 
inclusion. Number (N) of patients with serum creatinine available / total number of patients in 
follow-up. No CTCAE grade 4 was observed.
Table 2 - Cumulative numbers of 323 Dutch patients lost to follow- up 1, 2 and 3 years after the 
last PRRT with 177Lu-Octreotate.
Reason lost to follow-up after 1 year after 2 years after 3 years
Progressive Disease 43 47 56
Death 8 9 12
Follow-up elsewhere (patient request) 18 23 32
Complications (e.g. bleeding, infection, ileus, dyspnea) 11 13 19
Bone marrow depression 4 7 9
Liver failure 2 2 2
Other therapy 23 28 40
Octreoscan negative lesions during follow-up 2 2 3
Retreatment with 177Lu-DOTATATE 3 37 51
Kidney failure (see text) 0 0 1
Total number of patients 114 168 225
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Follow-up data for 1, 2 and 3 years after the last therapy were available in 209, 155 
and 98 patients, respectively. Grade 3 kidney toxicity was observed in 5 out of the 323 
patients during this follow-up. Toxicity was not related to PRRT since all five patients 
had a baseline CLR of <60 ml/min (i.e. grade 2), making them more prone to more 
severe renal function impairment. However, the annual decrease in CLR was <12 %. The 
distribution of CLR at baseline and during follow-up (1, 2 and 3 years after inclusion) is 
shown in Figure 2. Reasons for loss to follow-up after 1, 2 and 3 years are summarized in 
Table 2. One patient was lost to follow-up after 2 years, due to kidney failure resulting in 
dialysis based on preexisting kidney disease. 
Long-term change in renal function 
Follow-up of more than 1 year was available in 209 of the 323 patients. One patient with 
an incomplete set of risk factors was excluded; thus the analysis included 208 patients. 
The estimated average annual decrease in CLR (± SD) was 3.4 ± 0.4 %, and the estimated 
average baseline CLR (b0) was 108 ± 5 ml/min (Figure 3). The time course of CLR and 
the fitted nonlinear model in an example patient are shown in Figure 4. In 203 out of 
208 patients, the annual decrease in renal function was <10 %. Five patients had an 
annual decrease in CLR of ≥10 %, and two patients had an annual decrease of ≥15 % 
(Figure 5). In 29 (14 %) of 208 patients, a positive annual change in CLR (improvement in 
renal function) was observed. No patient showed an annual decrease in renal function 
of ≥20 %. 
Risk factor assessment 
Age and baseline CTCAE had significant effects on the baseline CLR (both p < 0.0001). 
With all other factors held con- stant, the estimated average baseline CLR showed a 
significant decrease in patients older than 70 years or with baseline CTCAE grade 2. 
None of the risk factors considered for inclusion in the model (hypertension, diabetes, 
age >70 years, cumulative injected activity >22.2 GBq, high radiation dose to the kidneys 
and CTCAE grade at baseline) had a significant effect on the estimated rate of change in 
CLR over time, and were thus not included in the final model. 
Dosimetry 
Dosimetric data for kidney dose calculations was available in 407 of the 554 on-protocol 
patients. In 147 patients no radiation dose to the kidneys could be calculated due 
to incomplete dosimetric data and/or over-projection of tumour nodules on planar 
images of the kidney region of interest. Clearance of radioactivity from the kidneys 
proceeded with a median effective half-life of 58 h (range: 27 – 135 h) in 407 patients.
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Figure 3 - Nonlinear model of creatinine clearance (CLR) over time based on 208 patients. Solid 
line is the exponential function with 95 % confidence interval (dashed lines). The estimated 
average baseline CLR (± SD) is 108 ± 5 ml/min and the estimated average annual change in CLR 
(± SD) is 3.4 ± 0.4 % 
Figure 4 - Time-course of creatinine clearance (CLR) and fitted monoexponential decay (solid line) 
in a 71-year-old patient with a neuroendocrine tumor, hypertension and diabetes, who received 4 
× 7.4 GBq 177Lu-Octreotate. The estimated decrease in CLR is 11.4 % per year 
Figure 5 – Distribution of the change in creatinine clearance per year in 208 patients with long-
term follow-up. Note the log scale on the y-axis. Coloured bars represent annual loss of renal 
function < 10% (blue), 10-15% (yellow) and >15% (orange).
14802HBergsma_BW_DEF_15/8.indd   94 15-08-17   11:40
2.1 Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate 
95 
Figure 6 - Distribution in 1-Gy increments of the radiation dose to the kidneys for 407 patients 
and in 228 patients with quantifiable kidney uptake: a actual distribution in 407 patients; b 
hypothetical distribution for 4 × 7.4 GBq of 177Lu-Octreotate; c actual distribution in 228 Dutch 
patients. Gaussian fits (dashed lines) are overlain on the histograms. The green arrow indicates the 
kidney threshold dose (18 Gy) according to current EBRT guidelines [10]. The orange arrow (24 Gy) 
and red arrow (28 Gy) correspond to the PRRT dose limits for kidney damage according to Wessels 
et al. [11] and Bodei et al. [2], respectively, for therapies given in four cycles.
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The mean radiation dose to the kidneys was 19.3 ± 5.0 Gy (Figure 6a). The mean kidney 
absorbed dose for a hypothetical dose distribution of 4 × 7.4 GBq of 177Lu-Octreotate was 
19.8 ± 5.8 Gy (Figure 6b). The mean calculated radiation dose to the kidneys in 228 of the 
323 Dutch patients in whom it could be calculated was 20.1 ± 4.9 Gy (Figure 6c), and 11 
(5 %) of these 228 patients had a calculated kidney absorbed dose of more than 28 Gy. 
The total administered injected activity was reduced in 55 of the 228 patients because 
the calculated kidney dose was more than 23 Gy. The average measured kidney volume 
(with corresponding mass) in 119 (49 %) of the 228 patients in whom it could be measured 
was a factor of 0.95 (range 0.49 – 1.71) less than the fixed phantom-based kidney mass. 
DISCUSSION 
After PRRT with 177Lu-Octreotate, the average annual decrease in CLR was 3 % and no 
patient showed a decrease of more than 20 %, which is in line with the results of other 
studies with 177Lu-Octreotate [2, 5, 17, 18]. Of the patients treated with 177Lu-Octreotate, 
14 % showed an annual improvement in CLR. Tumor response and improvement in 
clinical condition could explain the increase in CLR in these patients, since a rapid weight 
gain with stable serum creatinine values results in a higher CLR. Therefore, we suspect 
that the improvement in CLR did not reflect a true improvement in renal function. 
In practice, an annual decrease of 3 % means a CLR of 91 ml/min after 3 years in a 
patient with normal renal function at baseline (Table 3). Five of our patients had an 
annual decrease in renal function of more than 10 %, translating to a CLR after 3 years 
of 74 ml/min in an individual with normal renal function at the start. Since the overall 
survival following PRRT with 177Lu-octreotate is 3 to 4 years [19], it is unlikely that the 
kidneys are the long-term limiting factor. A decrease in renal function to CTCAE grade 
2 or higher occurs after 7 years in a patient with normal renal function at the start and 
an annual decrease of 10 % (Table 3). In our study, only 1 % of the patients developed 
therapy-unrelated severe (grade 3) renal toxicity after 1 year. Furthermore, the CTCAE 
distribution of CLR over time did not change, confirming the low nephrotoxicity of PRRT 
with 177Lu-Octreotate. 
Several risk factors for kidney toxicity after PRRT with mainly 90Y-labelled somatostatin 
analogues have been identified, including age (>60 years), diabetes, hypertension, 
previous chemotherapy and poor baseline renal function [1, 2, 4]. In a recent study 
[5], renal function was analyzed in 807 patients treated with 177Lu-Octreotate and/
or 90Y-Octreotide. Hypertension was identified as a main risk factor for (persistent) 
nephrotoxicity. However, nephrotoxicity was defined as a categorical outcome 
according to CTCAE, neglecting the change in renal function over time. This can lead 
to a simplified representation of kidney toxicity after PRRT and false identification of 
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risk factors. Valkema et al. analyzed renal function in 37 patients treated with 177Lu-
Octreotate by taking the subject-specific annual decrease in CLR extracted from fitted 
monoexponential curves [1]. Hypertension was also found to be a possible factor 
contributing to the rate of decrease in CLR after PRRT. Although the authors did take 
into account the change in renal function over time, they were unable to determine 
the impact of covariates on the change over time but only on summary measurements 
obtained from individually fitted curves. 
Table 3 - Creatinine clearance in hypothetical patients with a baseline renal function of 100 ml/
min and annual decreases of 3 %, 10 % and 20 %.
  Creatinine clearance in ml/min 
Year 3% annual decrease 10% annual decrease 20% annual decrease
0 100 100 100
3 91 74 55
5 86 61 37
7 81 50 25
*red highlighted number are Creatinine clearance of CTCAE grade 2 or higher
Given the repeated measurement structure of the data and the need to assess the effect 
of risk factors on both baseline CLR and change in CLR over time, a more advanced 
approach is required. We therefore used a mixed effects regression model. Mixed effects 
models are the standard modeling framework for the analysis of longitudinal data. These 
models explicitly account for differences in correlation structure of the data within/
between patients and deal well with unbalanced data (varying times of measurement 
in each subject and un- equal numbers of follow-up measurements among subjects). 
In our present analysis, age >70 years and baseline CTCAE grade influenced the 
nonlinear model. However, the two risk factors only changed the estimated average 
baseline CLR component in our model, meaning that patients older than 70 years and/
or patients with baseline CTCAE grade 2 had a lower estimated average CLR at baseline. 
None of the evaluated risk factors modified the percentage CLR change component 
significantly, implying that the percentage change in CLR over time in patients with risk 
factors was not different from that in patients without risk factors. 
An explanation for our results could be that the frequency of nephrotoxicity after 
PRRT with 177Lu-Octreotate is low and a higher number of patients would be required 
to show statistical significance of the risk factors. For the same reason, we were not 
able to compare patient’s with/without a solitary kidney and with/without alkylating 
chemotherapy (e.g. cisplatin). The relatively low numbers of patients resulted in low 
statistical power for testing these risk factors. 
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GFR measurement with inulin is the gold standard for measuring renal function, but 
practical implementation is difficult [20]. Other radionuclide-based filtration markers 
such as 99mTc-MAG3 (mercaptoacetyltriglycine) are used for accurate assessment of 
renal function in clinical practice [21]. However, these methods are expensive and 
time-consuming in the follow-up of large patient groups. We used CLR as an indirect 
marker for estimating GFR since serum creatinine is widely available. Also most of our 
patients had normal baseline renal function, making CLR a reasonable estimator for 
GFR. However, different formulas for calculation of renal function are available: the 
(body surface area-corrected) CG formula and the (abbreviated) modification of diet 
in renal disease (MDRD) equations. The CG formula estimates CLR [22], whereas the 
MDRD equations estimate GFR [23]. All formulas have different performance in various 
subgroups of patients depending on age, sex, weight and range of renal function 
[24]. Therefore, we calculated Spearman’s rank correlation co- efficients for different 
equations versus 24-h urine CLR in our patient group. The CG formula had the best 
correlation (Figure 1). Our results are in line with those of other studies indicating that 
CG is more precise than MDRD [24], meaning that individual changes in renal function 
over time are more reliable. 
Radiation toxicity dose effect models used in PRRT are pre- dominantly based on the 
experience and knowledge obtained from EBRT. In the past, the threshold dose for late-
stage kidney radiation damage for EBRT was set at 23 Gy [9]. However, the tolerable 
dose in current guidelines for radiotherapy-associated kidney injury are lower at 18 Gy 
[10]. Kidney radiation doses of 18 Gy given in a fractionation scheme of 2 Gy per fraction 
are considered to result in a 5 % probability of developing radiation nephropathy during 
the 5 years after EBRT. 
For PRRT with 90Y-DOTATOC, a correlation was found between the kidney absorbed dose 
and chronic kidney toxicity. The dose at which 5 % of patients will show kidney toxicity 
has been estimated at 24 Gy for 90Y-DOTATOC [11]. Another study has confirmed this 
dose limit in 22 of 50 patients treated with 90Y-DOTANOC [25]. The absorbed dose limit 
after 90Y irradiation and that for fractionated EBRT can be compared using the concept 
of the biologically effective dose (BED). BED is a measure of the true biological dose 
delivered at a particular dose rate and fractionation pattern, tissue-specific for a relevant 
biological end-point (in this case late-stage renal disease). It takes the protracted nature 
of the absorbed dose delivery by radionuclides into account by adjusting the kidney’s 
radiation sensitivity for the repair of sublethal radiation damage during the absorbed 
dose buildup according to the linear quadratic (LQ) model. The BED concept is thought 
to explain the 6-Gy higher dose limit than the 18 Gy accepted for EBRT [10]. Bodei et al. 
proposed a BED limit of 40 Gy to the kidneys in patients without risk factors and a BED 
of 28 Gy in patients with risk factors, corresponding to absorbed doses of 28 and 24 Gy, 
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respectively (both given in four fractions) [2]. A summary of previously reported kidney 
dosimetry findings in studies using 177Lu- Octreotate is provided in Table 4. 
Table 4 - Reported data on kidney dosimetry for PRRT with 177Lu-Octreotate 
Reference Method No. of patients
Administered 
Activity  
(GBq)
Amino acids
Dose to kidneys 
Per activity 
administered 
(Gy/GBq)
For 4×7.4 
GBq 
(Gy)
[12] Planar 5 1.85 Lys/Arg 0.9 ± 0.2 26.6 ± 5.3
[2] Planar 5 3.7 – 5.18 NR 0.9 ± 0.5 26.6 ± 13.3
[32] Planar 69 3 – 7 Lys/Arg 0.9 ± 0.3 26.6 ± 8.0
[33] SPECT/CT 24 7.4 VAMIN-14 0.7 ± 0.3 20.7 ± 6.2
[34] SPECT/CT 16 7.4 VAMIN-14 0.9 ± 0.3 26.6 ± 8.0
[35] Planar 26 8 NR 0.9 ± 0.4 26.6 ± 10.6
[36] SPECT/CT 33 7.8 Synthamin 0.3 (0.1-0.5) 9.2 (4.1-13.6)
[18] Planar 12 5.18 – 7.4 Lys/Arg 0.8 ± 0.4 23.7 ± 9.5
[37] SPECT/CT 200 7.4 VAMIN-14 1.2 ± 0.6 36.3 ± 16.0
[28] Planar 51 3.5 – 8.2 Lys/Arg 0.8 ± 0.4 23.7 ± 9.5
This study Planer 407 7.4 Lys/Arg 0.7 ± 0.2 19.8 ± 5.8
Values are means ± SD, or median (range)
Lys/Arg Lysine 2.5 % and arginine 2.5 %, Lys Lysine 2.5 %
In this study, we did not find a significant difference in the effect of kidney dose on renal 
function. Most patients received a kidney dose of less than 28 Gy (Figure 6c). However, 
in a small number of patients the kidney dose exceeded this limit. In our long-term 
follow-up group, 11 patients received a kidney dose that exceeded 28 Gy. None of these 
patients developed grade 3 or 4 nephrotoxicity and/or had an annual decrease in CLR 
of more than 10 %. Therefore, the 28 Gy dose limit seems to be a conservative value 
for PRRT with 177Lu-Octreotate. Another argument for a higher dose limit is that 177Lu 
has shorter-range β-particles than 90Y. This results in less damage to nearby non-target 
tissue and (theoretically) in fewer cases of nephrotoxicity at a fixed kidney dose [26–28]. 
In PRRT studies, the LQ model concept of BED was first introduced with dosimetric data 
from 18 patients who received 90Y-DOTATOC [29]. A stronger correlation was observed 
with the decrease in CLR when applying this model, compared with using absorbed 
renal dose alone. Also, a comparison between the relatively high dose-rate of EBRT and 
low dose-rate irradiation of radionuclide therapy is possible using BED. The LQ model 
can be used to analyze the effects of dose rate, number of therapy cycles in EBRT/
PRRT and the type of radionuclide in PRRT. The LQ model-based BED for PRRT has been 
adopted by the Committee on Medical Internal Radiation Dose (MIRD) for late kidney 
damage [11]. In PRRT little scientific evidence is available for the choice of α/β ratio and 
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repair T1/2, which represents the damage and repair half-life in the BED model, however 
the two variables have an important effect on the dosimetric outcome [30, 31]. Also, 
since no severe renal toxicity was observed in the present study with an intended dose 
scheme of 4 × 7.4 GBq, reporting the BED did not seem appropriate. Moreover, in the 
present study the factor relating absorbed dose and BED was low: median 1.09 (range 
1.02 – 1.21). 
Our results demonstrate that the kidneys are not the dose- limiting organ in patients 
treated with 177Lu-Octreotate. Therefore, in clinical practice, kidney dosimetry does not 
currently have a prominent place in PRRT with 4 × 7.4 GBq 177Lu-Octreotate. However, 
(serum-based) assessment of renal function during and after PRRT is mandatory since 
renal toxicity unrelated to PRRT could occur. Also measurement of renal function 
at baseline is required since low GFR is a risk factor for development of (sub)acute 
haematotoxicity after PRRT. 
CONCLUSION 
The number of patients with nephrotoxicity after PRRT with 177Lu-Octreotate is low. No 
patient showed (sub)acute grade 3 or 4 nephrotoxicity or an annual decrease in renal 
function of >20 %. No risk factors (e.g. hypertension, diabetes) leading to an additional 
annual decrease in renal function could be identified. Our study showed that the 
maximum radiation dose to the kidney adopted from EBRT and PRRT with 90Y-labelled 
analogues does not seem to apply to PRRT with 177Lu-Octreotate.
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SUPPLEMENTAL DATA
Follow-up and data analyses
Creatinine clearance (CLR) was used as an estimate of the glomerular filtration rate 
(GFR).  Baseline 24hr urine creatinine was collected and compared with different serum 
based creatinine clearance methods (Supplemental figure 1 and 2). We estimated the 
serum CLR with four formulas (see below) in comparison to 24-h urine CLR at baseline. 
24hr urine collection: 
   
  (2.5)
Cockcroft-Gault (C-G):
              
  (2.6)
Cockcroft-Gault (C-G) correct for body surface area (BSA):
 (2.7)
Body surface area (BSA)according to Du Bois and Du Bois:
(2.8)
Modification of Diet in Renal Disease (MDRD):
(2.9)
or
 (2.10)
Extended Modification of Diet in Renal Disease (extMDRD):
(2.11)
or
(2.12)
where BUN is the blood urea nitrogen in mmol/l and Alb is the albumin in g/l.
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The difference between estimated and measured CLR from 24h-urine was the smallest in 
the C-G formula (Supplemental figure 1). Also the spearman rank correlation coefficient 
was the best in the latter (Supplemental figure 2).
Dosimetry
All patients underwent planar imaging to determine kidney dosimetry. Dosimetry was 
performed minimally after the first treatment to determine if the 4th treatment with 
7.4 GBq of 177Lu-Octreotate would result in a kidney radiation dose that would not 
exceed the 23 Gy threshold limit. 407 of the 554 on-protocol patients had quantifiable 
kidney uptake, which enabled kidney dosimetry. The lack of accurate dosimetry data for 
the remaining patients is largely due to overlapping radioactivity from tumours in the 
abdominal region obscuring organ delineation. 
The 177Lu S-values were taken from the Radiation Dose Assessment Resource (RADAR) 
website [15]: for a male adult (with 300g kidneys) the S-value is 0.289 mGy/MBq.h and 
for a female adult (with 275 g kidneys) the S-value is 0.314 mGy/MBq.h. These can be 
adjusted with the actual patient’s kidney volume, derived from CT imaging [38]. A 
correction factor and adjusted dose was calculated in patients with CT scan available 
before the first treatment, using OsiriX 5.9 (Pixmeo SARL, Bernex – Swiss). A polygon 
region of interest (ROI) was (semi)automatic drawn on each CT slice and each slice was 
summed up for calculation of the total kidney volume.
Imaging
Planar spot images of the upper abdomen, chest, and the head and neck region were 
obtained with a double head camera (Picker Prism 2000) at regular intervals. For the first 
administration in Group-1, the imaging time points were 4 h, and 1, 3, 10 and 17 days 
after administration. After the second administration in Group-1 (with amino acid co-
infusion) and in all other groups, the imaging time points were 1, 3 or 4 and 7 or 10 days 
after administration. Counts from both gamma-peaks (208 and 113 keV) were collected 
in separate windows (width 20%). Acquisition time was 15 min/view at maximum. 
A standard with a known aliquot of the infused radioactivity was also counted for 
dosimetry calibration.
Regions of Interest 
For biodistribution studies the percentage of infused radioactivity (%IA) accumulated in 
each organ was measured by manually contouring and selecting the regions of interest 
(ROIs) for the whole body, bone marrow, kidney, liver, spleen, total abdomen, thyroid, 
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gonads, pituitary, adrenals and pancreas. The geometric means of the regions were 
computed and these values were used to calculate the %IA based on a comparison to 
an aliquot of the administered dose [3, 4].
Dosimetry Calculations 
Dosimetry values were computed with a MIRDOSE software package, version 3.0, and 
using S-factors for 177Lu [5]. The general scheme for calculating radiation dosimetry with 
radionuclides has been defined by the MIRD scheme dosimetry formula [16]. 
  (2.3)
    (2.4)
The dose to the target organ (D; kidney or bone marrow) is calculated by the product 
of the number of decays in a source organ (Ã
s
) and the S-value, which expresses the 
dose rate per radioactivity for a source (rs) to target (rt) combination. With moderately 
weak beta-particle emitting radionuclides like 177Lu, only the self-dose needs to be 
considered (r
s
=r
t
). The radioactivity uptake and clearance kinetics of 177Lu-DOTA0-Tyr3-
Octreotate A
s
(t) in the kidneys is needed for calculation of the radiation dose to the 
kidneys, together with the S-value for the kidney self-dose. The 177Lu S-values were 
taken from the Radiation Dose Assessment Resource (RADAR) website [15]: for a male 
adult (with 300g kidneys) the S-value is 0.289 mGy/MBq.h and for a female adult (with 
275 g kidneys) the S-value is 0.314 mGy/MBq.h. These can be adjusted with the actual 
patient’s kidney volume, derived from CT imaging [38], this was not done in a select 
number of patients. 
Results
Statistical analysis
Baseline 24hr urine CLR was compared with 4 serum based CLR methods (Appendix A). 
The Cockcroft-Gault (CG) formula had the highest Spearman rank correlation coefficient 
(see figure 7 & 8).
Dosimetry
In 228 out of 323 Dutch patients the radiation dose to the kidneys (and SD) was 20.1 ± 4.9 
Gy (figure 6C), calculated with standard kidney mass. In 119 out of 323 Dutch patients 
the radiation dose to the kidneys was 19.9 ± 5.4 Gy with standard kidney volume and 
16.9 ± 5.2 Gy with individual CT-based kidney volume.
14802HBergsma_BW_DEF_15/8.indd   103 15-08-17   11:40
Chapter 2: Toxicity after PRRT
104 
Supplemental figure 1 – The difference between estimated and measured CLR from 24h-urine 
for Cockcroft (A), Cockcroft-Gault (C-G) correct for body surface area (BSA) (B), Modification of Diet 
in Renal Disease (MDRD) and Extended Modification of Diet in Renal Disease (extMDRD).
Supplemental figure 2 – Absolute estimated and measured CLR from 24h-urine for Cockcroft (A), 
Cockcroft-Gault (C-G) correct for body surface area (BSA) (B), Modification of Diet in Renal Disease 
(MDRD) and Extended Modification of Diet in Renal Disease (extMDRD). Also Spearman’s rank 
correlation coefficient (Rspearman) is given per graph.
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Supplemental figure 3 - Evolution of renal function (Cockcroft-Gault) over time overlaid on the 
same plot in 209 Dutch patients.
Supplemental figure 4 - Smooth average longitudinal renal function (Cockcroft-Gault) for 209 
Dutch patients is indicated by blue line. Dots are single measurement of Creatinine clearance 
(CLR).
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Supplemental figure 5 - Smooth average longitudinal profile of all patients indicated by blue 
line (loess plus confidence band): 
Supplemental Table 1 – Comparison of different models
Model AICc BIC df
Linear 18983.36 19012.45 5
Polynomial 18974.54 19015.76 7
Spline 18960.14 19018.28 10
Nonlinear with plateau 19606.72 19641.63 6
Nonlinear without plateau 19000.84 19029.94 5
Subset Analysis: Model AICc BIC df
Nonlinear without plateau 15281.36 15337.47 10
 - including Kdose 15281.93 15343.64 11
 -including BED 15282.3 15344.01 11
Akaike Information Criterion (AIC), Bayesian information criterion (BIC)
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Supplemental Table 2 – Final Model output - Nonlinear mixed-effects model fit by REML:
Fixed effects Coefficient Std Err. Df t-value p-value
Intercept 107.745 4.665 2284 23.097 0.0000
Age >70 vs. Age <=70 -24.492 5.411 2284 -4.526 0.0000
HT (yes vs. no) 0.932 4.466 2284 0.209 0.8346
Diabetes (yes vs. no) 3.299 3.933 2284 0.839 0.4017
Baseline CTCAE -46.190 6.552 2284 -7.050 0.0000
Newdosis > 600 vs. Newdosis <=600 0.868 4.582 2284 0.189 0.8498
Decay rate 0.001 0.000 2284 9.374 0.0000
Output random effects:
Diagonal covariate matrix: estimated standard deviation of 26.17 and 0.001 for b0 and 
b1 respectively.
#Note; interactions tried between Time in weeks and Age, BasCTCAE, HT, Diabetes  and 
NewDosis, do not improve model fit. Use of DMMed/HBA1c60 does not improve model 
fit over use of Diabetes.
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ABSTRACT
In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of the 
dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from 131I treatment. 
We investigated the incidence and duration of hematological toxicity and its risk factors 
in patients treated with PRRT with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE). Also, 
absorbed BM dose estimates were evaluated and compared with the accepted 2 Gy 
dose limit. 
Methods:
The incidence and duration of grade 3 or 4 hematological toxicity (according to CTCAE 
v3.0) and risk factors were analyzed. Mean BM dose per unit (Gigabecquerels) of 
administered radioactivity was calculated and the correlations between doses to the 
BM and hematological risk factors were determined. 
Results:
Hematological toxicity (grade 3/4) occurred in 34 (11 %) of 320 patients. In 15 of the 
34 patients, this lasted more than 6 months or blood transfusions were required. Risk 
factors significantly associated with hematological toxicity were: poor renal function, 
white blood cell (WBC) count <4.0×109/l, age over 70 years, extensive tumor mass and 
high tumor uptake on the OctreoScan. Previous chemotherapy was not associated. The 
mean BM dose per administered activity in 23 evaluable patients was 67 ± 7 mGy/GBq, 
resulting in a mean BM dose of 2 Gy in patients who received four cycles of 7.4 GBq 
177Lu-DOTATATE. Significant correlations between (cumulative) BM dose and platelet 
and WBC counts were found in a selected group of patients. 
Conclusion:
The incidence of subacute hematological toxicity after PRRT with 177Lu-DOTATATE is 
acceptable (11 %). Patients with impaired renal function, low WBC count, extensive 
tumor mass, high tumor uptake on the OctreoScan and/or advanced age are more likely 
to develop grade 3/4 hematological toxicity. The BM dose limit of 2 Gy, adopted from 
131I, seems not to be valid for PRRT with 177Lu-DOTATATE. 
Keywords: 
PRRT, 177Lu-DOTATATE, Bone marrow, Toxicity, Dosimetry
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INTRODUCTION 
In the past two decades, peptide receptor radionuclide therapy (PRRT) with radiolabelled 
somatostatin analogues has been used successfully in patients with somatostatin 
receptor-positive tumors. One of the most frequently used radiopharmaceuticals is 
177Lu-DOTA0-Tyr3-octreotate (177Lu- DOTATATE). Patients with neuroendocrine tumors 
treated with 177Lu-DOTATATE have a radiological response rate of 15 – 35 % [1–5]. 
Generally, PRRT is well tolerated, but the kidneys and bone marrow (BM) are usually the 
dose-limiting organs. 
BM toxicity results from irradiation of and damage to hematopoietic tissue. Grade 3 or 4 
hematological toxicity develops in about 5 – 10 % of patients [6–11]. The nadir normally 
occurs 4 – 6 weeks after each treatment, followed by a recovery phase. The generally 
accepted threshold dose for radiation-induced BM suppression is 2 Gy, adopted from 131I 
therapy studies [12, 13]. However, up to now, no data have been published that confirm 
or reject this BM dose limit for 177Lu-DOTATATE. 
The aim of this study was to analyze short-term hematological toxicity after PRRT with 
177Lu-DOTATATE. Risk factors analyzed included renal function, chemotherapy, baseline 
cytopenia, tumor mass and patient age. In addition, the individual and mean BM doses 
were calculated in a subgroup of patients. 
MATERIALS AND METHODS 
Patients 
The study included 320 Dutch patients who were treated from January 2000 to December 
2007. Inclusion criteria were: patients with neuroendocrine tumor and baseline tumor 
uptake on [111In-DTPA0] octreotide scintigraphy (OctreoScan®; Mallinckrodt, Petten, The 
Netherlands) with accumulation in the tumor at least as high as in normal liver tissue; 
no prior treatment with PRRT; baseline serum hemoglobin (Hb) ≥6 mmol/l; white blood 
cell (WBC) count ≥2×109/l; platelet (PLT) count ≥75×109/l; serum creatinine ≤150 μmol/l 
or creatinine clearance ≥40 ml/min and Karnofsky performance status ≥50. Only Dutch 
patients were selected, because loss to follow-up is limited in these patients. 
This study was part of the ongoing prospective study in patients with neuroendocrine 
tumors treated with 177Lu-octreotate at the Department of Nuclear Medicine, Erasmus 
University Medical Center Rotterdam. The hospital’s medical ethics committee approved 
the study. All patients gave written informed consent for participation in the study. 
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Treatment 
[DOTA0,Tyr3] octreotate was obtained from BioSynthema (St. Louis, MO). 177LuCl3 was 
supplied by IDB-Holland (Baarle-Nassau, The Netherlands) and 177Lu-DOTATATE was 
prepared locally [14]. 
Granisetron 3 mg or ondansetron 8 mg was injected intravenously 30 min before 
infusion of 177Lu-DOTATATE. Infusion of amino acids (2.5 % arginine and 2.5 % lysine, 
1 l) was started 30 min before administration of the radiopharmaceutical and lasted 
for 4 h. The radiopharmaceutical was coadministered for 30 min using a second pump 
system. Cycle dosages of 1.85 GBq (50 mCi) were given in 4 patients, 3.7 GBq (100 mCi) 
in 13 patients, 5.6 GBq (150 mCi) in 14 patients, and 7.4 GBq (200 mCi) in the remaining 
patients, injected over 30 min. The interval between treatments was 6 – 16 weeks. The 
intended cumulative dose was 29.6 GBq (800 mCi). Median cumulative activity was 29.6 
GBq, range 7.4 – 29.6 GBq. However, the dose was lowered if the calculated kidney dose 
was higher than 23 Gy. Other reasons for dose reduction or cessation of further therapy 
were recurrent grade 3 or 4 hematological toxicity and persistent low blood counts. 
Dosimetry 
Biodistribution and dosimetry studies were performed in three subgroups of patients. 
The data on estimated BM doses have been published previously [14–16]. Only patients 
meeting the inclusion criteria, as stated above, and with complete datasets for dosimetry 
were included in the present analysis. The BM dose (Drm) is derived from three sources: 
(1) from the blood circulating through the marrow cavities (rm), (2) from large organs 
and tumors with high radioactivity uptake (h), and (3) from the general distribution of 
radioactivity throughout the remaining whole body (rb): 
 (2.13)
where Ã is the cumulative activity and DF are the dose factors for red marrow to red 
marrow, large organs to red marrow, and remainder of the body to red marrow. The 
contribution to the BM dose from radioactivity distribution within the remainder was 
calculated (and corrected) according to the method of Wessels et al. [17]. 
Calculated dose contributions were based on planar scans (at 24, 96 and 168 h after 
injection), and radioactivity measured in urine (at 1, 6, 24, 48 h after injection) and blood 
samples (at 0, 10, 30, 60, 90, 120, 360 and 1,440 min after injection). A pharmacokinetics 
(PK) compartment model was used to describe the biodistribution of radioactivity 
in organs over time. Organs with physiological uptake (kidneys and abdomen) were 
added to the central (blood) compartment (Figure 1). A single compartment linked 
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to the kidney was able to model the urine data. An additional remainder-of-the-body 
compartment was used to fit the data. Flow in both directions between compartments 
was modeled by kinetic transfer components, k(i,j). The PK compartment model was 
numerically solved using SAAMII software (Simulation Analysis and Modeling; SAAM 
Institute, Seattle, WA). BM dose values were computed using the Olinda/EXM software 
package (Vanderbilt University) and using dose factors for 177Lu [18]. 
Figure 1 – Generalized compartment model for the biodistribution of 177Lu-DOTATATE in 
humans. Compartments (C1 to C5) represent different organs. Flow in both directions between 
compartments is represented by kinetic transfer components, k(i,j). The shaded grey circles 
represent input (radioactivity) data and the open grey circle represents modeled output. Injection 
is a simulated bolus of 177Lu-DOTATATE in the blood compartment. 
Toxicity assessment 
Hematology, and liver and renal function tests were performed during the 6 weeks before 
the first therapy, 4 and 6 weeks after each therapy, and at follow-up visits. Hematological 
toxicity was assessed according to Common Terminology Criteria for Adverse Events 
(CTCAE v3.0) [19]. This version of CTCAE was used because of well-defined criteria for 
thrombocytopenia, leucocytopenia and anemia. Hematological toxicity was modeled 
for toxicity grade 3/4 in PLT count, WBC count, Hb and a combination of all three. The 
duration of grade 3/4 hematological toxicity was defined as the time from the last 
therapy until recovery to toxicity grade 2 or lower. 
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Statistical analysis and parameters 
SPSS software (SPSS 19; IBM, New York, NY) was used for statistical analysis. Distributions 
were examined for normality using the Kolmogorov-Smirnov test. Correlations between 
distributions were evaluated using the χ2 test, t-test and analysis of variance. Spearman’s 
rank correlation coefficient was used for correlation analysis. Regression analysis was 
performed with the binary logistic model. Conditional step- forward and step-backward 
methods were used with the following parameters: classification cut-off 0.5, maximum 
iterations 20, probability for entry 0.05 and removal 0.20. P values <0.05 (for both 
step-forward and step-backward) were considered significant. The following discrete 
baseline variables were included in the analysis: gender, age over 70 years, presence of 
bone metastasis, prior chemotherapy, prior external beam radiotherapy, uptake on the 
OctreoScan, tumor load, chromogranin A >2,000 μg/l, splenectomy, baseline PLT count 
<150×109/l and baseline WBC count <4.0×109/l. The creatinine clearance was estimated 
with the Cockcroft-Gault formula and evaluated as a continuous variable. Similar 
regression analyses were performed setting thresholds for de- creases in PLT count, WBC 
count and Hb of 15 % and 25 % after the first therapy. Univariate analysis was performed 
in a subgroup of patients with transient and persistent grade 3/4 hematological toxicity. 
In the dosimetric subgroups, the correlations between the percentage reductions in 
blood cells (Hb, PLT count, WBC count) after the first therapy and dose to the BM were 
determined using Spearman’s rank correlation coefficients (rs). The median and mean 
doses to the BM per unit (gigabecquerels) of administered radioactivity were calculated 
for each subgroup separately and for all three subgroups combined. 
RESULTS 
In total, 324 patients were evaluated. The patient characteristics are summarized in Table 
1. Four patients were excluded because of unrelated hematological toxicity (internal 
bleeding in three and iron-deficiency anemia in one). 
Toxicity 
Severe subacute hematological toxicity (grade 3/4) occurred 4 to 8 weeks after 
administration in 34 (11 %) of the 320 patients, with thrombocytopenia in 25 (8 %), 
leucocytopenia in 17 (5 %), anemia in 10 (3 %) and pancytopenia (1 %) (Figure 2). 
Two patients were excluded from the analyses for toxicity duration. One patient 
(with grade 4 thrombocytopenia) died 6 weeks after last the treatment due to bowel 
obstruction, and one patient (with grade 3 thrombocytopenia and grade 3 anemia) died 
9 weeks after last the treatment due to progressive disease. Of 30 patients, 15 (50 %) 
had grade 3/4 hematological toxicity lasting more than 6 months or required blood 
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transfusion. The duration of hematological toxicity in these patients is presented in 
Figure 3. 
Table 1 - Baseline characteristics of 320 Dutch patients
Characteristic Number of patients (%)
Male 164 (51) 
Age ≥70 years 62 (19) 
Karnofsky performance status ≤70 46 (14) 
Elevated chromogranin A 237 (74) 
Bone metastasis 72 (23) 
Splenectomy 12 (4) 
WBC count <4.0 × 109/l at baseline PRRT 16 (5) 
Previous therapy 
  Chemotherapy 38 (12) 
  Radiotherapy (external) 32 (10) 
Tumor type 
  Neuroendocrine 278 (87) 
  Other 42 (13) 
Tumor uptake on baseline OctreoScan 
  Equal to or more than normal liver 248 (77) 
  Higher than kidneys 72 (23) 
Tumor mass on baseline OctreoScan 
  Equal to or more than normal liver 264 (82) 
  Higher than kidneys 56 (18) 
Cumulative activity (GBq) 
  ≤22.2 103 (32) 
  ≤29.6 215 (67) 
Kidney function, mean (range) creatinine clearance 
in milliliters per minute, Cockcroft-Gault 99 (35 – 246) 
Baseline parameters that were significantly associated with grade 3/4 hematological 
toxicity were: decreased renal function, WBC <4.0×109/l, age >70 years, extensive tumor 
mass, and tumor uptake on the OctreoScan more than uptake in the kidneys (Table 2). 
No significant association was found for previous chemotherapy. 
Of 30 patients with persistent (more than 6 months) hematological toxicity or who 
required blood transfusions, 15 had significantly more tumor mass on the baseline 
OctreoScan than patients with transient (6 months or less) grade 3/4 hematological 
toxicity. No significant difference in other baseline variables was found between these 
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two sub- groups (data not shown). In patients with decrease in Hb of more than 15 % 
after the first therapy, previous radiotherapy was an additional significant factor in the 
logistic regression analysis (p = 0.005 and p = 0.001 for step-forward and step- backward 
methods, respectively). In patients with a decrease in Hb, PLT count and/or WBC count 
of more than 25 % after the first therapy, decreased renal function at baseline was the 
only significant variable (p<0.05). 
Table 2 - Baseline clinical parameters associated with grade 3/4 hematological toxicity in 34 of 
320 patients treated with a median cumulative dose of 29.6 GBq 177Lu-DOTATATE from logistic 
regression analysis with the stepwise method (step- forward and step-backward).
Variable
Step-forward   Step-backward
Coefficientb p value   Coefficient p value
Any toxicity (Hb/PLT/WBC)
  Creatinine clearance (Cockcroft-Gault)a −0.160 0.028 −0.150 0.044
  Bone metastasis 1.055 0.017 0.912 0.056
  WBC count <4.0×109/l at baselinea 1.828 0.005 1.741 0.011
  Tumor uptake on Octreoscan> kidney uptake 0.867 0.051 1.055 0.023
  Previous radiotherapy Not in predictive equation 1.225 0.074
  Previous chemotherapy Not in predictive equation 1.171 0.161
Hemoglobin
  Age >70 yearsa 1.698 0.045 1.860 0.039
  Extensive tumor massa 2.551 0.002 2.570 0.003
  Previous radiotherapy Not in predictive equation 2.165 0.036
Platelets
  Creatinine clearance (Cockcroft-Gault)a −0.022 0.01 −0.025 0.008
  Bone metastasis 1.268 0.009
  WBC count <4.0×109/l at baseline 1.731 0.016 1.565 0.196
  Extensive tumor mass Not in predictive equation 1.174 0.024
  Previous radiotherapy Not in predictive equation 1.392 0.055
  Previous chemotherapy Not in predictive equation −1.604 0.144
White blood cells
  Age >70 years Not in predictive equation 1.161 0.062
  WBC count <4.0×109/l at baselinea 2.436 0.001 2.531 0.000
  Tumor uptake on Octreoscan > kidney uptakea 1.321 0.022 1.549 0.010
  Previous radiotherapy 1.363 0.068   Not in predictive equation
a Variable statistically significant (p<0.05) in multivariate analyses 
b Logistic coefficient in predictive equation 
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Figure 2 - Venn diagram of hematological toxicity (grade 3/4) in 34 out of 320 patients treated 
with a median cumulative dose of 29.6 GBq 177Lu- DOTATATE. 
Figure 3 – Duration of subacute hematological toxicity (grade 3/4) in 32 of 320 patients treated 
with a median cumulative dose of 29.6 GBq 177Lu-DOTATATE: a any toxicity in 32 patients, b 
thrombocytopenia in 23 patients, c leucocytopenia in 17 patients, and d anemia in 9 patients (NA 
results not available during follow-up, Transfusion patients who received blood cell transfusion 
after grade 3/4 hematological toxicity. Two patients were excluded (see text). 
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Dosimetry 
The dosimetry analysis included 32 patients split into three groups with different cycle 
doses (1.85, 3.7 and 7.3 GBq 177Lu-DOTATATE). Of the 32 patients, 25 patients were 
treated according protocol; in two patients no complete dosimetric data were available. 
The BM dose after the first therapy was determined in 25 patients: 4 patients in group 
1 (cycle dose 1.85 GBq), 7 patients in group 2 (cycle dose 3.7 GBq) and 14 patients in 
group 3 (cycle dose 7.3 GBq). The cumulative dose was 14.8 GBq in 1 patient, 22.2 GBq 
in 9 patients and 29.6 GBq in 15 patients. The median dose (and range) to the BM per 
unit of administered radioactivity in patients in group 1 and group 2 was 69 mGy/GBq 
(54 – 73 mGy/GBq) and 75 mGy/GBq (35 – 139 mGy/GBq), respectively. In group 3 the 
median dose (and range) was 51 mGy/GBq (24 – 116 mGy/GBq) excluding one outlier 
of 331 mGy/ GBq. In this patient the urinary excretion data could not be fitted correctly 
in the compartment model. This resulted in a long residence time of activity in the total 
body and in an exceptionally high BM dose, leading to the exclusion of this patient from 
further analysis (Supplementary Data). Despite a high calculated BM dose, this patient 
did not develop grade 3 or 4 hematological toxicity. 
Data from groups 1, 2 and 3 combined were normally distributed (Kolmogorov-
Smirnov test) allowing calculation of the mean BM dose. The mean BM dose (excluding 
one outlier) per unit of administered activity in the 24 evaluable patients was 0.067 
± 0.007 mGy/MBq. At an activity administration schedule of 4 × 7.4 GBq (which most 
patients received) this would lead to a BM dose of 2.0 ± 0.2 mGy. Three (13 %) of 23 
patients developed grade 3/4 hematological toxicity. No significant difference in BM 
dose was observed between these 3 patients and the other 20. Significant Spearman’s 
rank correlation coefficients and P values (one-tailed) were found in group 3 between 
(cumulative) BM dose and PLT count after the first and last treatments (rS=−0.51 with 
P<0.05 and rS= −0.59 with P=0.02, respectively) and WBC count (rS=−0.70 with P=0.01 
and rS=−0.51 with P<0.05, respectively; Figure 4). No significant correlation between 
(cumulative) BM dose and hemoglobin was found in group 3, and no significant 
correlations were found between (cumulative) BM dose and blood cells in group 1 and 
group 2. 
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Figure 4 - Platelet counts (a,b), white blood cell counts (c, d) and hemoglobin (e, f ) expressed as 
percentages of the baseline values in relation to bone marrow dose in 23 patients after the first 
and last treatments with 177Lu- DOTATATE (  circles group-1, 1.85 GBq, n=4;   squares  group 
2, 3.70 GBq, n=7;  triangles group 3, 7.40 GBq, n=12). Solid lines are linear regression with 95 
% confidence intervals (dotted lines). Significant Spearman’s rank correlation coefficients with 
(one-tailed) P values in group 3: a rS =−0.51 with P<0.05, b rS = −0.59 with P=0.02, c rS=−0.70 with 
P=0.01, d rS=−0.51 with P<0.05. 
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DISCUSSION 
Subacute hematological grade 3/4 toxicity was observed in 34 (11 %) of 320 patients 
receiving 177Lu-DOTATATE. In half of these patients, toxicity persisted for more than 6 
months or blood transfusions were required. This is in accordance with data from other 
groups [5–10]. Long-term hematological toxicities, such as myelodysplastic syndrome 
(MDS) and acute leukemia (AL), have been found in patients receiving PRRT with 177Lu-
DOTATATE [6, 11]. Also in our patient group, MDS and AL were observed, but since these 
events have a rare complex stochastic character, they will be reported in a separate 
study. In a recent study, long-term side effects of PRRT with 90Y-octreotide and/or 
177Lu-octreotate were investigated [6]. The authors found more hematological toxicity 
after PRRT in patients with baseline nephrotoxicity (transient or persistent elevation in 
creatinine). The prolonged circulation time of 177Lu-DOTATATE in patients with a poor 
renal function is probably the most important factor that explains the increased toxicity 
to the BM, as shown by Svensson et al. [20]. Also anemia is common in these patients 
due to a reduction in renal erythropoietin production. In our study, poor renal function 
was also found to be a predictor of hematological toxicity. We also found that a low 
baseline WBC count is a predictor of grade 3/4 hematological toxicity. This is in line 
with the findings of a recent study showing that baseline cytopenia is a predictor of 
hematological toxicity after PRRT [9]. 
From a dosimetric point of view, it has been theorized that patients with a large 
tumor burden and high receptor density have lower amounts of circulating activity 
[21]. Therefore the radiation to normal tissues could be less than in patients with a 
low tumor burden. However, in our study, patients with more tumor mass at baseline 
were significantly more likely to have grade 3/4 hematological toxicity. Furthermore, 
high tumor burden was more frequently found in patients with persistent grade 3/4 
hematological or who required blood transfusion. This suggests that tumor burden 
plays a role in the development and duration of hematological toxicity, in contrast to the 
recently described tumor sink effect [22]. That study showed that internalization of 68Ga-
DOTATATE in the tumor leads to a significant decrease in uptake in healthy tissue, the so-
called tumor sink effect [22]. The authors extrapolated their results and speculated on 
a similar effect for PRRT. However, the main contributing factor for radiation dose to an 
organ (i.e. the BM) from PRRT is the exposure to radiation over time and the organ dose 
cannot be based on a distribution with only one time point. In our limited subgroup of 
patients in whom biodistribution and dosimetry data were available, we were not able 
to demonstrate the tumor sink effect. 
Past chemotherapy was not a clear risk factor in our analyses. This finding can be 
explained by the limited number of patients who received chemotherapy in our series 
(38 of 320 patients, 12 %). In other studies more than 25 % of patients have had a history 
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of chemotherapy [6, 8, 9]. In particular, chemotherapy regimens with alkylating agents 
(e.g. cisplatin, carboplatin, oxaliplatin) or topoisomerase II inhibitors (e.g. etoposide) 
can damage the DNA of hematopoietic cells [23]. A small number (12 %) of patients 
in our study had received this type of chemotherapy in the past, therefore limiting the 
statistical power of this (possible) risk factor. 
A potential protective effect of splenectomy on the development of hematological 
toxicity in patients receiving 177Lu- DOTATATE has recently been reported [9]. The spleen 
is a major reservoir of blood cells and uptake of radioactivity is mainly caused by the 
presence of somatostatin receptors on lymphocytes [14, 24]. Blood cells circulating 
throughout the spleen may be damaged leading to a reduction in peripheral blood cell 
counts. However, in another clinical study with 177Lu-DOTATATE/DOTATOC, no correlation 
was found between dose to the spleen and hematological toxicity during PRRT [25]. In 
our study, none of the 12 patients who had had a splenectomy developed grade 3/4 
hematological toxicity. This supports the idea that splenectomy has a protective effect 
in patients receiving PRRT, but statistical analysis could not be performed due to the 
limited number of patients with splenectomy. 
PRRT using 177Lu-DOTATATE shows similarities to 131I treatment, because of the comparable 
half-life (6.7 and 8.0 days, respectively) and similar energies of the emitted β radiation 
(with average energies of 133 and 182 keV, respectively). Therefore in 2000, we accepted 
a maximum BM dose for PRRT with 177Lu-DOTATATE, which was adopted from clinical 
studies with 131I treatments. The upper BM dose limit was set to 2 Gy, based on early 
work in thyroid cancer patients treated with 131I [12]. In that study, 122 doses of 131I were 
administered to 59 patients with metastasized thyroid cancer. In 14 administrations of 
131I, serious radiation complications were observed (Table 3, original table). The authors 
stated that serious radiation complications per treatment cycle were more frequent 
when the total dose to the blood exceeded 200 rad (2 Gy) with a significance of P = 
0.03 (Table 3). However, only 8 of 14 serious radiation complications were related to 
the BM; the other complications were pneumonitis or vomiting. When we repeated the 
analysis, taking into account only serious BM complications (Table 3, modified table), 
no significantly higher frequency of hematological toxicity for BM radiation doses more 
than 2 Gy could be demonstrated (Fisher’s exact test, P = 0.68). Also, all eight patients 
with radiation complications (related to the BM) had metastatic disease to the bone. 
Bone metastases are a source of radiation after PRRT and could contribute to an increase 
in BM dose. However, in our multivariate analysis, the presence of bone metastases was 
not a risk factor for developing grade 3/4 hematological toxicity. 
Another comment on the study by Benua et al. is that the radiation complications per 
unit administered dose were analyzed and the cumulative BM dose per patient was not 
considered. This resulted in a double count of radiation complications in one patient 
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(after the first and second dose of 131I). In our study, hematological toxicity was counted 
only once per patient since the chance of recurrent hematological toxicity in one patient 
is relatively high. We also analyzed the cumulative BM dose instead of complications 
per administration, considering that multiple sequential treatments reduce the BM 
reserve. In a more recent article, the BM limit was set to 3 Gy for 131I treatment, based 
on 104 treatments in 83 thyroid cancer patients [26]. No permanent BM suppression 
was observed, but two patients required PLT and red blood cell transfusion because of 
pancytopenia. 
Table 3 - Complications in relation to total BM radiation dose reported by Benua et al. [12], and 
with new modifications. Data were derived from patients treated with radioiodine 131I treatment.
Blood total 
radiation (Gy) 
No. of 
doses 
Original tablea 
 
 
 
Modified tableb
Radiation complications Radiation complications 
Severe Fatal Total inpercent Severe Fatal 
Total in
percent
0–0.99 5 0 0 0 0 0 0
1.00–1.99c 24 1 0 4 1 0 4
2.00–2.99 33 5 1 18 3 1 12
3.00–3.99 7 1 1 29 1 0 14
4.00–4.99 9 0 2 22 0 1 11
Over5.00 7 2 0 29 1 0 14
Unknown 37 1 0 3 0 0 0
Total 122 10 4 7 6 2 7
a Original table of Benua et al. [12] 
b Modified table with only serious bone marrow radiation complications 
c Significantly more frequent complications with total dose >200 rad are stated in the original table, but are 
not significant in the modified table
In the past decade, several studies with BM dose estimates using 177Lu-DOTATATE have 
been reported (Table 4). Variations in the reported BM dose estimates can partly be 
attributed to differences in accuracy of dosimetric methods [27]. In a recent Swedish 
study, 200 patients who were treated with 7.4 GBq 177Lu-DOTATATE were analysed 
and BM doses were calculated based on blood-based and organ-based analysis of the 
whole-body images. The authors calculated a maximum BM dose of 0.4 Gy per cycle of 
7.4 GBq, which would result in a cumulative BM dose of 1.6 Gy for four cycles. Our data 
showed an estimated mean BM dose of 2.0 Gy (SD 0.2 Gy) in 184 out of 320 patients 
who received four cycles of 7.4 GBq 177Lu-DOTATATE. Therefore, half of these patients 
(92 of 184) received a BM dose of more than 2 Gy. If the true maximum tolerated dose 
to the BM were 2 Gy, these 92 patients would theoretically be more prone to develop 
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hematological toxicity. However, we found hematological toxicity in only 34 of the 320 
patients. This supports the idea that a higher BM dose limit for PRRT with 177Lu- DOTATATE 
is appropriate. Another argument for a different BM dose maximum is the success 
of retreatment with extra cycles of PRRT without serious hematological side effects 
[28]. In our analysis of this type of retreatment, in which selected patients received a 
cumulative BM dose of approximately 3 Gy, only 5 (16 %) of 32 patients developed grade 
3/4 hematological toxicity after two additional cycles of 177Lu- DOTATATE. In another 
study reversible hepatotoxicity (grade 3/4) was found in 7 (21.2 %) of 33 patients who 
underwent salvage PRRT [29]. In our ongoing study in Erasmus MC, we have treated 
a selected group of patients with multiple additional cycles of 177Lu-DOTATATE with 
cumulative doses up to 59.2 GBq resulting in an estimated mean BM dose of more than 
3 Gy with limited hematological toxicity (unpublished data). 
Table 4 - Overview of reported data on BM dosimetry for PRRT with 177Lu-DOTATATE
Reference Number of patients 
Dosimetric 
method 
Administered 
activity  
(GBq) 
Amino 
acids 
BM dose 
Per unit 
administered 
activity  
(Gy/GBq) 
For four cycles 
of 7.4 GBq (Gy) 
14 5 Planar 1.85 Lys/Arg 0.070 ± 0.009 2.1
36 69 Planar 3–7 Lys/Arg 0.050 ± 0.020 1.5
16 13 Planar 7.47 Lys/Arg 0.01 – 0.13 0.30 – 3.85 
4 16 SPECT/CT 7.4 Vamin 14 0.070 ± 0.020 2.1
2 12 Not reported 3.7 – 7.4 Lys 0.002 – 0.060 0.6 – 1.8 
37 200 SPECT/CT 7.4 Vamin 14 0.006 – 0.050 0.2 – 1.5
This study 25a Planar 1.85 – 7.3 Lys/Arg 0.067 ± 0.007 2
Lys/Arg lysine 2.5%/arginine 2.5 %, Lys lysine 2.5 % 
a Of 320 patients
Several groups have investigated the role of BM dosimetry in radionuclide treatments 
for predicting hematological toxicity. A weak negative correlation (rp = −0.47) between 
neutrophils at nadir and measured whole-body absorbed dose was found in 20 patients 
treated with 131I-MIBG [30]. In a PRRT study with 90Y-DOTATOC, a correlation (R=0.58) 
was found between BM absorbed dose and PLT count reduction at nadir [31, 32]. 
BM dose was calculated in 12 patients based on plasma samples, assuming that the 
activity concentration in the BM was equal to that in the plasma. 86Y-DOTATOC PET was 
performed after therapy and showed uptake in the vertebrae. Taking the radioactivity 
in the spine into the dosimetric calculations, a better correlation (R=0.82) was found 
between BM absorbed dose and PLT count reduction at nadir. However, 24 patients did 
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not demonstrate sufficient uptake of 86Y- DOTATOC in the spine to provide usable BM 
dose measurements. In our study, we found similar correlation coefficients between the 
relative decrease in blood cells and (cumulative) radiation dose to the BM. We found no 
correlation between BM dose and Hb, which can be explained by minimal effects on 
circulating erythrocytes after 2 Gy of irradiation [33]. These weak correlations between 
decreases in blood count and BM dose indicate that current dosimetry cannot fully 
predict hematological toxicity. Additional clinical factors have to be taken into account 
to predict hematological toxicity in PRRT. 
Further research should focus on reporting BM dose in patients receiving PRRT with 
177Lu-DOTATATE. BM dose limits should be explored at the population level with clinical 
toxicity grading (e.g. CTCAE) as outcome. However, current BM dosimetry is imprecise 
and varies due to differences in method of BM dose calculation [34]. Also the absorbed 
BM dose does not reflect the damage done to the hematopoietic stem cell department. 
If BM dosimetry can reflect the actual dose to hematopoietic stem cells, it will have a 
more prominent place in clinical practice during PRRT. In vivo markers might also be an 
option for assessment of BM status after irradiation with PRRT. In a recent article, γ-H2AX 
foci in lymphocytes were successfully used for monitoring ionizing radiation-induced 
DNA double-strand breaks in patients treated with 177Lu-DOTATATE [35]. However, 
the response of γ- H2AX foci varied significantly between patients over time, making 
it less suitable for individual monitoring. In future, BM radiation dose could provide 
information for decision- making in a clinical setting, but at present BM dosimetry plays 
a minor role in clinical practice. Clinical parameters and blood cell count recovery are 
currently the most important criteria for individual PRRT planning. 
CONCLUSION 
The prevalence of subacute hematological toxicity (grade 3 or 4) after PRRT with 177Lu-
DOTATATE is low (11 %). Our dosimetric calculations of the absorbed BM dose support 
the idea that a BM dose limit of more than 2 Gy seems appropriate for PRRT with 177Lu-
DOTATATE. A correlation was found between BM dose and decreases in blood counts, 
but clinical risk factors are currently the most important parameters for prediction of 
clinical toxicity. Patients with impaired renal function, low WBC count, extensive tumor 
mass, high tumor uptake on the OctreoScan and/or those of advanced age are more 
likely to develop grade 3 or 4 hematological toxicity. Our data support the idea that a 
higher BM dose limit of 2 Gy is appropriate for PRRT with 177Lu-DOTATATE.
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SUPPLEMENTAL DATA
Methods
Dosimetry
The method used for calculating the bone marrow (BM) radiation dose takes into 
account the radiation from β-rays of 177Lu-DOTATATE in the blood circulating through the 
trabecular bone, and from penetrating γ-rays from radioactivity dispersed throughout 
the remainder of the body. The absorbed dose (D) to red marrow (rm) can be estimated 
using the MIRD schema. Contributions to the BM dose are from localized in the marrow 
tissues (self-dose) and in the remainder tissues (rm) of the body (cross-dose):
   (2.14)
             (2.15)
where Ã is the cumulated activity and S are the S factor for red marrow to red marrow 
and the remainder of the body to red marrow. 
Our BM dose (Drm) is derived from three source contributions: (1) from the blood 
circulating through the marrow cavities (rm), (2) from large organs and tumors with 
high radioactivity uptake (h) and (3) from the general distribution of radioactivity 
throughout the remaining whole body (rb):
 (2.16)
where Ã is the cumulated activity and DF are the dose factors for red marrow to red 
marrow, large organs to red marrow and remainder of the body to red marrow. 
Contribution to the bone marrow dose from radioactivity distribution within the 
remainder were calculated according to the method by Wessels et al. [17]. Radioactivity 
in the bone marrow first follows the plasma perfusion through the marrow space and 
at later times will be according to the whole body distribution. Both contributions have 
been taken into account in accordance with the bone marrow dosimetry performed by 
Forrer et al. [16], which data are included in the present data set.
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Results
Incomplete dosimetric DATA
Incomplete 1, Patient (Po****)
In this patient no data for urinary clearance was available, therefore it was not possible 
to perform bone marrow dose calculation using the compartment model. 
Supplemental figure 1 - Anterior (A) and posterior (B) planar scans, 24 hr after the 1st therapy of 
patient Po****.  
Incomplete 2, Patient (Me****)
In this patient no blood radioactivity data were available. Consequently no compartment 
modeling was possible and numerical fitting was performed to obtain the cumulated 
activity in the bowel and the remainder of the body. The uptake in the bowel was 
exceptionally high, leading to a residence time of 79 h. As only 41% of the activity was 
cumulatively excreted in the urine at 48 h this lead to a total body residence time of 135 
h. Using the dose conversion factor DF (BM¬remainder) = 2.67 E-7 mGy/MBq.s from 
Olinda [18], this would lead to a bone marrow dose of 0.13 mGy/MBq. 
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Supplemental figure 2 - Anterior (A) and posterior (B) planar scans, 24 hr after the 1st therapy of 
patient Me****.  
Supplemental figure 3 - Time-activity curves for urinary clearance and total bowel uptake of 
177Lu-Dotatate in patient Me****. Only 44% (95%CI: 42-45%) of the radioactivity is measured in the 
cumulative urinary clearance and it shows a half-life of 14 h (12-16 h). The 57% (43-71%) uptake in 
the bowel clears with  239 h (127 – 2183 h) half-life.
Outliers
Outlier, Patient (Ko****) 
The compartmental model failed to fit the urinary excretion data of patient Ko*** 
correctly. The clearance from the bowel was slow with final clearance half-life of 290 
h, leading to a residence time of 33 h. The total body residence time is 72 h, based on 
the numerical fit, this leads to a bone marrow dose of 69 μGy/MBq. This value is 5σ 
above the mean value of 14 ± 10 μGy/MBq. In this case the blood time-activity curve 
determines the bone marrow residence time to be 1.0 h and the contribution to the 
bone marrow dose from the remainder needs to be corrected according to the method 
by Wessels et al. [17]. This leads to a corrected bone marrow dose by the remainder of 
3.1 μGy/MBq, which is still 5σ above the corrected mean value of 0.67 ± 0.46 μGy/MBq.
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Supplemental figure 4 - Anterior (A) and posterior (B) planar scans, 24 hr after the 1st therapy of 
patient Kon****-2.  
Supplemental figure 5 - Time-activity curves for urine, bowel and blood activity in patient Ko***. 
The curves through the data are the result of the compartmental fitting, except for through the 
urine data, where a single-exponential build-up curve was fitted numerically instead.
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ABSTRACT
Peptide Receptor Radionuclide Therapy (PRRT) may induce long-term toxicity to 
the bone marrow (BM). The aim of this study was to analyze persistent dysfunction 
of the hematopoietic system after PRRT with 177Lu-DOTATATE in patients with 
gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 
Methods: 
The incidence and course of persistent hematological dysfunction (PHD) was analyzed 
in 274 (=GEP-NET) out of 367 patients with somatostatin receptor-positive tumors. PHD 
was defined as diagnosis of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia 
(AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic/Myeloproliferative 
neoplasms (MDS/MPN) or otherwise unexplained cytopenia (for more than 6 months). 
Using data from the Dutch cancer registry, the expected number of hematopoietic 
neoplasms (MDS, AML, MPN. MDS/MPN) was calculated and adjusted for sex, age and 
follow-up period. 
Assessment of risk factors was performed in 274 GEP-NET patients with the following risk 
factors: gender, age over 70 years, bone metastasis, prior chemotherapy, prior external 
beam radiotherapy, uptake on the OctreoScan®, tumor load, grade 3-4 hematological 
toxicity during treatment, estimated absorbed BM dose, elevated plasma chromogranin 
A, baseline blood counts and renal function. 
Results: 
We identified 11 (3.7%) out of 274 GEP-NET patients with PHD following treatment 
with 177Lu-DOTATATE: 8 (2.9%) patients developed a hematopoietic neoplasm (4 MDS, 1 
AML, 1 MPN, 2 MDS/MPN) and 3 (1.1%) patients developed BM failure characterized by 
cytopenia and BM aplasia. The median latency period at diagnosis (or first suspicion of a 
hematological malignancy) for 11 patients was 41 (range 15 - 84) months. The expected 
number of hematopoietic neoplasms for our 274 GEP-NET patients was 3.0 resulting in 
a relative risk of 2.7 (CI 0.7 – 10.0). 
No risk factors for PHD could be identified for the GEP-NET patients, including bone 
metastasis and estimated BM dose. Seven patients with PHD developed anemia in 
combination with a rise in mean corpuscular volume.
Conclusion: 
The prevalence of persistent hematological dysfunction after PRRT with 177Lu-DOTATATE 
is 3.7% in our specific patient population. The median time when PHD can develop is 41 
months after the first PRRT cycle. The RR for developing a hematopoietic neoplasm is 
2.7. No risk factors were identified for developing PHD in GEP-NET patients.
Keywords: 
PRRT, 177Lu-DOTATATE, Bone marrow, Toxicity, MDS, Leukemia, Neuroendocrine tumor, 
NET
14802HBergsma_BW_DEF_15/8.indd   136 15-08-17   11:40
2.3 Hematological malignancies after PRRT with 177Lu-DOTA-octreotate
137 
INTRODUCTION
Peptide receptor radionuclide therapy (PRRT) has been in use for twenty-five years as 
second-line therapy in patients with inoperable (metastatic) gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs). Indium-111 radiolabeled somatostatin analogs 
were used in early studies (1,2). Besides encouraging results with regard to symptom 
relief, the reported number of objective responses was low. Myelodysplastic syndrome 
(MDS) or leukemia was reported in half of the NET patients who received a very high 
dosage (>100 GBq) of [111In-DTPA0]Octreotide. PRRT with 177Lu-DOTA0-Tyr3-octreotate 
(177Lu-DOTATATE) results in a better radiological response rate of 15 – 35% (3-6). In 
general, side effects are mild, although serious hematological toxicity has been reported, 
making the bone marrow (BM) the main dose-limiting organ. In 11% of the patients, 
(sub)acute grade 3-4 hematological toxicity is observed after PRRT with 177Lu-DOTATATE 
(7). Also long-term hematological toxicity like acute myeloid leukemia (AML) and MDS 
were reported in 1-2% of the patients treated with 177Lu and/or 90Y based PRRT (8-11). 
Up to now, no in depth report of therapy related long-term hematological toxicity in 
patients treated with 177Lu-DOTATATE has been published. 
The aim of this study was to analyze long-term persistent hematological dysfunction 
(PHD) after PRRT with 177Lu-DOTATATE in GEP-NET patients. Incidence, clinical course 
and predicting factors were evaluated in a large group of GEP-NET patients. 
MATERIALS AND METHODS
Patients
In this study, Dutch patients were analyzed who were treated from January 2000 to 
December 2007. Follow-up data were used up to December 2012 since we expected 
therapy related malignancies within 5 years after therapy and because of changes in our 
follow-up protocol after December 2012. Only Dutch patients were selected, because 
loss to follow-up was limited in these patients. Only GEP-NETs were selected in our 
analysis, since 177Lu-DOTATATE is indicated for this group of patients.
Inclusion criteria were: patients with somatostatin receptor-positive tumors and baseline 
tumor uptake on somatostatin receptor scintigraphy with [111In-DTPA0] octreotide 
(OctreoScan®; Mallinckrodt, Petten, The Netherlands) with accumulation in the tumor 
at least as high as in normal liver tissue; no prior treatment with a radionuclide therapy; 
baseline serum hemoglobin ≥6 mmol/l; white blood cell count ≥2×109/l; platelet count 
≥75×109/l; serum creatinine ≤150 μmol/l or creatinine clearance ≥40 ml/min and 
Karnofsky performance status ≥50. 
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The intensity of tumor uptake and the extent of tumor burden were scored according 
to simple scaling systems (3). 
This study was part of the ongoing prospectively designed study in patients with 
neuroendocrine tumors treated with 177Lu-DOTATATE at the Department of Radiology 
and Nuclear Medicine, Erasmus University Medical Center Rotterdam. The hospital’s 
medical ethics committee approved the study. All patients gave written informed 
consent for participation in the study.
Treatment 
[DOTA0,Tyr3]octreotate was obtained from BioSynthema (St. Louis, MO). 177LuCl3 was 
supplied by IDB-Holland (Baarle-Nassau, The Netherlands) and 177Lu-DOTATATE was 
prepared locally (12). 
Granisetron 3 mg, or ondansetron 8 mg was injected intravenously 30 min before 
infusion of 177Lu-DOTATATE. Infusion of amino acids (2.5 % arginine and 2.5 % lysine, 
1 l) was started 30 min before administration of the radiopharmaceutical and lasted 
for 4 h. The radiopharmaceutical was coadministered for 30 min using a second pump 
system. Cycle dosage(s) of 1.85 GBq (50 mCi) was given in 1 patients, 3.7 GBq (100 mCi) 
in 13 patients, 5.6 GBq (150 mCi) in 12 patients, and 7.4 GBq (200 mCi) in the remaining 
patients, injected over 30 min. The interval between treatments was 6 – 16 weeks. The 
intended cumulative dose was 29.6 GBq (800 mCi) 177Lu-DOTATATE. The median number 
of therapy cycles was 4 (range 1-8) with a median cumulative activity of 29.6 GBq (range, 
7.4–59.2 GBq) of 177Lu-DOTATATE. However, the dose was lowered if the calculated 
kidney dose was higher than 23 Gy. Other reasons for dose reduction or cessation of 
further therapy were recurrent grade 3 or 4 hematological toxicity and/or persistent low 
blood counts. 
Follow-up & Toxicity Assessment 
Hematology, and liver and renal function tests were performed during the 6 weeks 
before the first therapy, 4 and 6 weeks after each therapy cycle, and at follow-up visits. 
Subacute hematological toxicity was assessed according to Common Terminology 
Criteria for Adverse Events v3.0 (13). This version was used because of well-defined 
grades (1 to 5) for adverse events in platelets, leucocytes and hemoglobin.
Patient with PHD were defined as having one or more characteristics: MDS, AML, 
myeloproliferative disorders (MPN), myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) according to the revised WHO 2008 diagnostic criteria (14) or unexplained 
hematological toxicity grade 3-4 (> 6 months) in hemoglobin, platelets and/or white 
blood cells (with/without requirement of multiple blood transfusions). 
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Latency period was defined as the time from the 1st treatment with 177Lu-DOTATATE 
to the date of diagnosis. If no diagnosis was made, the date of the first BM biopsy or 
aspiration was used. In case of no available BM biopsy/aspiration, the date of diagnosis 
was replaced by the date when hematological malignancy was suspected in the 
patient’s medical file.  
The estimated absorbed BM dose was calculated based on a group-averaged estimated 
BM dose in 23 patients (7). Therefore, this mean BM dose per administered activity of 
0.067 ± 0.007 mGy/MBq (7) was multiplied by the individual cumulative injected activity 
of 177Lu-DOTATATE. 
The Netherlands Cancer Registry
The expected number of patients with hematopoietic neoplasms was calculated using 
data of Dutch cancer figures (www.cijfersoverkanker.nl). This database contains the 
statistics on cancer in the Netherlands that  are registered in the  Netherlands Cancer 
Registry, which is managed by the Netherlands Comprehensive Cancer Organization. 
Data on incidence, prevalence, survival,  mortality and risk are available on this 
website. Users can make their own graphs and tables on cancer incidence according to 
localization, region, sex and age. Data are available from 1989 to 2016.
The incidence (number of cancers per 100,000 persons a year) of hematopoietic 
neoplasms was used for four categories; MDS, AML, MPN and MDS/MPN. 
Data were categorized by sex and age (in 5-year cohorts). Average incidence rates (per 
100.000 residents) between 2001-2011 of the four categories were calculated. Expected 
cases per category were compiled, based on the number of patients and years of follow-up 
in our study. Expected numbers were adjusted for sex, age and duration of follow-up period. 
  
Statistics 
The SPSS software (SPSS 19; IBM, New York, N.Y., USA) was used for statistical analysis. 
Distributions were examined for normality using the Kolmogorov-Smirnov and Shapiro-
Wilk test. Correlations between distributions were evaluated using the Chi-squared and 
unpaired-t test. 
PHD was analyzed as a discrete variable. The following baseline variables were 
included in the analysis: gender, age over 70 years, presence of bone metastases, prior 
chemotherapy, prior external beam radiotherapy, uptake on the OctreoScan®, tumor 
load, grade 3-4 hematological toxicity during treatment and plasma chromogranin A 
>2,000 μg/l (ref < 100 μg/l). Continuous variables included in the analysis were: baseline 
hemoglobin, baseline platelet count, baseline white blood cell count and estimated 
absorbed BM dose. The creatinine clearance was estimated with the Cockcroft-Gault 
formula and evaluated as a continuous variable. 
14802HBergsma_BW_DEF_15/8.indd   139 15-08-17   11:40
Chapter 2: Toxicity after PRRT
140 
RESULTS
In total 367 patients with somatostatin receptor-positive tumors were treated of whom 
274 with GEP-NETs, 34 NETs with unknown primary/other location and 59 with other 
tumors. In the group of GEP-NET patients, 22 out of 274 patients did not meet the 
inclusion criteria for various reasons e.g. low tumor uptake, concomitant radiotherapy. 
The median follow-up time of the 274 GEP-NET patients was 29 (range, 0 - 142) 
months. Twenty-six (10%) out of 274 GEP-NET patients had been treated with cytotoxic 
chemotherapy in the past and/or 18 out of 274 patients with external beam radiation 
therapy. Full patient characteristics are summarized in table 1. 
Long-term Hematological Toxicity
We identified 11 patients (6 females and 5 males) with PHD out of 274 GEP-NET 
patients following treatment with 177Lu-DOTATATE (3.7%). Eight patients developed 
a hematopoietic malignancy (4 MDS, 1 AML, 1 MPN, 2 MDS/MPN) and 3 patients 
developed BM failure characterized by cytopenia and BM aplasia (table 2). Two patients 
were excluded since they did not have GEP-NETs (see inclusion criteria); one patient with 
thyroid carcinoma died two weeks after a BM biopsy demonstrating BM hypoplasia. 
Another patient with a NET (unknown primary) developed BM failure most likely due 
to significantly decreased kidney function (GFR < 50 ml/min). Characteristics of the 11 
GEP-NET patients with persistent dysfunction of the hematopoietic system are shown 
in table 3.
The median latency period from initiation of PRRT to the diagnosis of hematopoietic 
disease in 11 out of 274 GEP-NET patients was 41 (range 15-84) months (Figure 1). 
Figure 1 – Median latency time in 11 patients with persistent hematological dysfunction. 
Whisker boxplot of latency time (period between first treatment and date of diagnosis) in 11 
out of 274 GEP-NET patients with persistent hematological dysfunction (PHD) after peptide 
receptor radiotherapy (PRRT) with 177Lu-DOTATATE. Whiskers represent minimum (15 months) 
and maximum (84 months) latency time. The width of the box shows the interquartile range and 
the vertical line in the box is the median (41 months) latency time. 
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Table 1 - Baseline characteristics of 274 Gastroenteropancreatic Neuroendocrine Tumors (GEP-
NETs).
Number of patients (%)
Patient characteristics Yes No
Male 139 (51) 135 (49)
Age ≥ 70 52 (19) 222 (81)
KPS ≤ 70 38 (14) 236 (86)
Elevated Chromogranin A 72 (26) 202 (74)
Bone metastases 59 (22) 215 (78)
Patients who met inclusion criteria 252 (92) 22 (8)
Previous therapy
- Chemotherapy 26 (10) 248 (90)
- Radiotherapy (external) 18 (7) 256 (93)
NET Location 
- Gastrointestinal 172 (63)
- Pancreas 86 (31)
- Bronchus 16 (6)
Tumor uptake on baseline Octreoscan
- Less to normal liver 8 (3)
- Equal or more to normal liver 203 (74)
- Higher than kidneys 63 (23)
Tumor mass on baseline OctreoScan
- Limited and Moderate 223 (81)
- Extensive 51 (19)
Cumulative administered activity 
(177Lu-DOTATATE)
- up to 22.2 GBq 73 (27)
- 22.3 to 29.6 GBq 122 (44)
- 29.7 Gbq to 44.4 GBq 71 (26)
- 44.5 to 59.2 GBq 8 (3)
Age range at first treatment
15-29 1 (0.5)
30-44 31 (11.5)
45-59 109 (40)
60-74 110 (40)
75-89 23 (8)
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In 5 out of 11 patients, PRRT was interrupted and the planned cumulative activity of 29.6 
GBq 177Lu-DOTATATE was not administered. The median cumulative estimated BM dose 
in 263 patients without PHD was 2.0 Gy (range, 0.2 - 4.0 Gy). In the group of GEP-NET 
patients with PHD (n=11), the median BM dose was 1.8 Gy (range, 1.0 -2.0 Gy) (Figure 2). 
Seven out of 11 patients received a BM dose of less than 2.0 Gy.
Table 2 – Classification of 11 out of 274 Gastroenteropancreatic neuroendocrine tumors 
(GEP-NETs) patients with persistent hematological dysfunction (PHD) after peptide receptor 
radiotherapy (PRRT) with 177Lu-DOTATATE. Eight patients were classified according to the World 
Health Organization (WHO) (14).  Three patients were classified as bone marrow failure with 
specific characteristics.
Classification Number of patients
Hematopoietic Neoplasms according to WHO  
Myelodysplastic syndrome (MDS)  
- RAEB-II 1
- RARS 1
- Other 2
Acute myeloid leukemia and related neoplasms (AML)  
- Acute myeloid leukemia with recurrent genetic abnormalities 1
Myeloproliferative Neoplasms (MPN)  
- Myelofibrosis 1
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)  
- Chronic Myeloid Leukemia (CML) 1
- Chronic myelomonocytic Leukemia (CMML) 1
Bone marrow failure characterized by (not WHO)  
- BM hypoplasia 1
- BM aplasia 1
- Pancytopenia 1
A total of 274 (139 male and 135 female) GEP-NET patients were analyzed for calculating 
the expected number of patients with hematopoietic neoplasms. The cumulative 
follow-up was 1113 person years, resulting in an expected number of MDS, AML, MPN 
and MDS/MPN cases of 1.10, 1.27, 0.48 and 0.19 respectively, with a total number of 3.0 
patients based on Netherlands Comprehensive Cancer Organization data (Figure 3). 
The RR is the chance that a hematopoietic neoplasms occurs when exposed (8/274) to 
PRRT, divided by the chance that hematopoietic neoplasms occur when non-exposed 
(3/274). This results in an RR of 2.7 (95% CI 0.7 – 10.0) meaning that patients treated with 
PRRT have more than three times higher risk of developing hematopoietic neoplasms 
than patients not treated with PRRT. 
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Figure 2 – Estimated bonemarrow dose in 11 GEP-NET patients with persistent hematological 
dysfunction. Spikeplot of cumulative estimated bonemarrow (BM) dose in 11 GEP-NET patients 
with persistent hematological dysfunction (PHD) after peptide receptor radiotherapy (PRRT) with 
177Lu-DOTATATE. 
Note the median (and range) estimated BM dose (dashed lines) in 263 NET patients without PHD.
Figure 3 – Expected number of patients (3) with hematopoietic neoplasms and type, based on 
data from The Netherlands Cancer Registry. Observed number of patients (11 out of 274 GEP-NET 
patients) with persistent hematological dysfunction (PHD) after peptide receptor radiotherapy 
(PRRT) with 177Lu-DOTATATE including 8 patients with hematopoietic neoplasms and 3 with 
bonemarrow failure. 
 Myelodysplastic Syndrome (MDS),  Acute Myeloid Leukemia (AML),  Myeloproliferative 
Neoplasms (MPN) + Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN) and  Bone 
Marrow failure.
Figure 4 – Course of hemoglobin (Hb) and mean corpuscular volume (MCV)  in patient 
no. 185 diagnosed with myelodysplastic syndrome (MDS)/Myeloproliferative disease (MPN) after 
peptide receptor radiotherapy (PRRT) with 177Lu-octreotate. Time zero is the date of the last PRRT 
cycle. A decline in Hb (upper red arrow) was followed by an increase in MCV (lower red arrow).
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Table 4 – Results of analysis in 367 patients with somatostatin positive tumors after peptide 
receptor radiotherapy (PRRT) with 177Lu-DOTATATE (177Lu). Persistent hematological dysfunction 
(PHD), Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs), Bonemarrow (BM), Not 
calculated (NC) because of low statistical power. 
Characteristic All patients
Lung + GEP-
NET
Non GEP-
NETs*
Total number of patients 367 274 93
PHD patients 13 11 2
Prevalence 3.5% 3.7% 2.2%
Median latency period (and range) in months 36 (5 - 84) 41 (15 – 84) 5.8 (5 – 7)
Median FU time (and range) in months 24 (0 - 143) 29 (0 - 142) 12 (0 – 116)
Cumulative median BM dose (and range) in Gy:
without PHD 2.0 (0.2 - 4.0) 2.0 (0.2 - 4.0) 1.5 (0.2 – 3.9)
with PHD 1.5 (1.0 - 2.0) 1.76 (1.0 – 2.0) 1.2 (1.0 – 1.5)
Expected number of MDS/leukemia 4.4 3.0 <1
Follow-up in years 1309 1113  
Relative Risk (RR) and 95% Confidence Interval 1.9  (1.0 - 3.6) 2.7 (0.7 – 10.0)  
Significant Risk factors - Baseline WBC was 
significantly lower 
(p=0.01) in the 13 NET 
patients with PHD.
None NC
  - Subacute 
hematological toxicity 
grade 3-4 during 
PRRT was marginally 
significantly (p=0.053) 
different in patients 
with PHD.
 
Remark - Including a non GEP-
NET patient* treated 
with 131I, resulting in 
BM failure, 5 months 
after the first PRRT 
cycle.
 
* Patients with non GEP-NET, e.g. NET unknown primary, thyroid carcinoma, paraganglioma.
Risk Factors and Course
Risk factor assessment was performed in 274 GEP-NET patients, including 11 GEP-NET 
patients with PHD. The presence of bone metastases or prior chemotherapy was not 
more prevalent in NET patients with PHD as compared to those without PHD. For the 
other defined risk factors (gender, age over 70 years, prior external beam radiotherapy, 
uptake on the OctreoScan®, tumor load, grade 3-4 hematological toxicity during 
treatment, estimated absorbed BM dose, elevated plasma chromogranin A, baseline 
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blood counts and renal function), no significant differences were found between GEP-
NET patients with and patients without PHD. 
Seven patients with PHD had anemia in combination with an elevated mean corpuscular 
volume, for example patient no. 185 (Figure 4).
Incidence of PHD, expected number of hematopoietic neoplasms and risk assessment 
was also performed in all 367 patients with somatostatin receptor-positive tumors, see 
table 4. 
DISCUSSION
MDS covers a heterogeneous group of myeloid malignancies and occurs in 2-4 
individuals per 105 persons per year in the Dutch population (15). AML and related 
precursor neoplasms occur in 3-4 individuals per 105 persons per year in the European 
population (16). The incidence of myeloid neoplasms and leukemia are strongly 
determined by age and sex. Also exposure to radiation increases the frequency of 
hematological malignancies (17).
The total observed incidence of hematopoietic neoplasms after PRRT is a summation 
of de novo incidence (e.g. without exposure to radiation) and therapy-related (with 
radiation exposure) incidence. The total number of patients with PHD after PRRT is 
significantly higher than we would expect, based on the expected number of (de novo) 
hematopoietic neoplasms. Our incidence of PRRT related PHD is 3.7%, however this 
percentage is patient-group dependent since sex, age and previous (chemotherapeutic) 
treatments influence the incidence of hematopoietic neoplasms. In a large retrospective 
analysis of a 90Y-DOTATOC phase II trial, only 2 (<1%) out of 1109 patients developed 
myeloproliferative diseases (10). Considering the number of patients and mean follow-
up of 23 months in this study, one would expect an incidence of more than 2 de novo 
hematopoietic neoplasms alone. Therefore the reported number of myeloproliferative 
events after PRRT in this study does not seem accurate. Bodei et al. found in a large 
retrospective study of 807 NET patients treated with 177Lu and/or 90Y-labelled 
somatostatin analogs, an incidence of MDS and acute leukemia of 3.3% (8). This is in 
line with our findings. In the same retrospective study of Bodei et al. a mean latency 
time of 45 and 57 months was reported between start of PRRT and the development of 
MDS or leukemia, respectively (8). Our median latency period was 41 months, which is 
approximately the same as reported by Bodei et al. (8). 
PRRT with 177Lu-DOTATATE has significant similarities to therapy with radioiodine 
(131I), like the physical decay characteristics and the human biodistribution in blood 
and BM. In patients with thyroid cancer treated with radioiodine (131I), a leukemia 
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incidence of 0.2 - 0.3% is observed in comparison to the general population (18,19). In 
a comprehensive meta-analysis the pooled RR for development of leukemia increased 
2.5-fold in patients treated with 131I as compared with thyroid cancer survivors not 
treated with radioiodine (20,21). In our study, we found a RR in our GEP-NET patients 
treated with 177Lu-DOTATATE, which was similar to that in thyroid cancer patients treated 
with 131I. However, the number of de novo (=expected) MDS and leukemia cases is age 
dependent. Therefore, the incidence can vary between studies in patient populations 
with a different age distribution. Also in the radio immunotherapy, myelosuppression 
is the primary toxicity and raised concerns about the risk of treatment-related MDS or 
acute leukemia. In the database of the radioiodine (131I) labeled monoclonal antibody 
(Bexxar), 35 (3.5%) out of 995 non-Hodgkin lymphoma patients developed MDS or 
acute leukemia (22). Whereas, clinical studies with the yttrium-90 or indium-111 labeled 
monoclonal antibody (Zevalin), reported an incidence of 2.3% and the malignancies 
were diagnosed 23 months after radioimmunotherapy (23).
In our study, we did not find a difference in cumulative estimated BM dose between 
patients with or without PHD. This is in line with BM dose calculation of Bodei and 
colleagues (8), for a comparison see Figure 5. However, about half of our patients with 
PHD, did not receive the intended cumulative administered activity of 29 GBq 177Lu-
DOTATATE. These patients were also excluded for salvage therapy with 177Lu-DOTATATE, 
therefore creating a bias in our results. Despite this selection bias, about 30% of our 
patients received a cumulative injected dose of > 30 GBq with an estimated BM dose 
of more than 2 Gy. However, none of these patients developed PHD. Therefore, the 
cumulative administered activity of 177Lu-DOTATATE and estimated BM dose is currently 
not a dominant factor for predicting PHD after PRRT with 177Lu-DOTATATE using our 
treatment regimen. 
In general, signs and symptoms in patients with MDS are non-specific. Many patients 
are asymptomatic at diagnosis and only come to the physician’s attention based 
upon abnormalities found on routine blood counts (e.g., anemia, neutropenia, and 
thrombocytopenia) (24). First, common causes of anemia have to be excluded, like 
nutrient deficiencies (iron, folate, and vitamin B12) and anemia secondary to renal 
failure (25). In our patient group, the red blood cells are the most frequently affected cell 
line followed by a reduction in platelets and/or white blood cells. In more than half of 
our patients, we observed a decrease in Hb combined with a rise in mean corpuscular 
volume. The decrease in red blood cells reflects the imbalance between their production 
and survival, whereas the increased mean corpuscular volume represents an increase in 
size resulting from an abnormal blood cell production. 
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Figure 5 – Comparison of hematological malignancies and cumulative dose to the bonemarrow. 
A. Whisker and scatter plot of cumulative estimated bone marrow dose in 11 patients (including 5 
AML/MDS patients O) with persistent hematological dysfunction (PHD) and 263 patients without 
PHD. B. Whisker and scatter plot of bonemarrow dose in 3 patients with AML/MDS (O) and 28 
patients without AML/MDS. Data of dosimetry analysis in a subgroup of 807 patients adopted 
from bodei et al. (8). Whiskers represent minimum and maximum (estimated) bone marrow dose 
in Gy. The height of the box shows the interquartile range and the horizontal line in the box is the 
median (estimated) bone marrow dose in Gy.
In another paper, we have identified several risk factors for (sub)acute hematological 
toxicity following PRRT with 177Lu-DOTATATE, like: impaired renal function, low white 
blood cells, extensive tumormass, high tumoruptake on the OctreoScan® and/or 
advanced age (7). As for long-term hematological toxicity, Bodei et al. reported the 
following risk factors associated with MDS and leukemia after PRRT with 177Lu-DOTATATE 
(8): previous chemotherapy, tumor invasion of the BM, platelet toxicity grade and other 
previous myelotoxic therapies. In our study, we could not identify any risk factors for 
GEP-NET patients who develop PHD after PRRT with 177Lu-DOTATATE. However, analysis 
in all 367 patients with somatostatin receptor positive tumors positive demonstrated 
a significantly lower white blood cells in patients with PHD (table 4). Also a trend was 
observed, where subacute hematological toxicity (grade 3-4) during PRRT was more 
frequent in patients with PHD in comparison to patients without PHD. 
In a recent study, a high incidence (20%) of MDS/AML after chemotherapy and PRRT 
with 177Lu-DOTATATE was reported in a small group of metastatic GEP-NET patients 
(26). A critical response was written about the limited (biased) group of patients in this 
study (27). The high dose of alkylating chemotherapy was the main contributing factor 
for development of MDS/AML in these patients. In our study, the number of patients 
treated with chemo(embolization)therapy prior to PRRT is low. Therefore, the statistical 
power of this (possible) risk factor is limited in our study. 
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CONCLUSION
The prevalence of therapy-related persistent hematological dysfunction after PRRT with 
177Lu-DOTATATE in GEP-NET patients was 3.7% implying a RR of 2.7. The median latency 
time to disease development was 41 months.
In the group of GEP-NET patients, no risk factors could be identified for the development 
of therapy-related persistent hematological malignancies. Anemia combined with a rise 
in MCV occurred in half of the patients with therapy-related hematological malignancies 
after PRRT with 177Lu-DOTATATE. 
SUPPLEMENTAL DATA
Materials and Methods
Uptake and Extent Scale
The intensity of tumor uptake on OctreoScan® and the extent of tumor burden is to be 
scored according to simple scaling systems, see Supplemental figures 1 and 2. 
1) <Liver
 (Excluded) 2) ≈ Liver 3) > Liver
4) Very intense
 (>>Kidneys, spleen)
Supplemental figure 1 - Tumor uptake scaling system; 1. Uptake less than the liver (excluded) 
2. Uptake equal to the liver 3. Uptake more than the liver 4. Uptake more than kidneys and/or 
spleen.
 
1) Limited 2) Moderate 3) Extensive
Up to 5 sites in one part of the 
body (head/neck, chest, upper 
abdomen, lower abdomen)
Multiple sites in up to 2 sites of 
the body. Neither qualifying for 
limited nor for extensive.
Many tumor sites in ≥ 2 parts of 
the body. 
Supplemental figure 2 - Tumormass on OctreoScan; 1. Limited tumor mass is up to 5 sites in 
one part of the body (head/neck, chest, upper abdomen, lower abdomen) 2. Moderate tumor 
mass is multiple sites in up to 2 sites of the body, neither qualifying for limited nor for extensive 
3. Extensive tumor mass is many tumor sites in ≥ 2 parts of the body. Usually a combination of 
extensive liver and lymph node involvement or diffuse skeletal metastases. Diffuse liver metastasis 
with limited abdominal involvement does not qualify.
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Method - The Netherlands Cancer Registry
The expected number of patients with dysfunction of the hematopoietic system was 
calculated using the website of Dutch cancer figures (www.cijfersoverkanker.nl). 
The incidence (number of cancers per 100,000 persons a year) was used for four 
categories with the following selection criteria:
1. Myelodysplastic Syndrome (MDS) – the selected tumor group was “MDS and 
Myelodysplastic/myeloproliferative disorders” with subgroup “Myelodysplastic 
Syndrome”.
2. Acute myeloid leukaemia (AML) – the selected tumor group was “Acute Myeloid 
Leukaemia” including all subgroups.
3.  Myeloproliferative disorders (MPN) - the selected tumor group was “Myeloproliferative 
disorders” with subgroup “Myeloproliferative neoplasm, other”.  
4. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) - the selected tumor 
group was “MDS and Myelodysplastic/myeloproliferative disorders” with subgroup 
“Myelodysplastic/Myeloproliferative disorders” plus tumor group “Myeloproliferative 
disorders” with subgroup “Chronic Myeloid Leukaemia”.
Incidence data extracted from the website, sorted by 5-years age category and sex can 
be found in supplemental table 1 - 10. Expected numbers were adjusted for sex, age and 
duration of follow-up period.
Patient age, sex and follow-up characteristics in all 367 and 274 Gastroenteropancreatic 
Neuroendocrine tumors (GEP-NETs) patients with expected number of expected 
number of hematopoietic neoplasms can be found in supplemental table 11 - 14. 
Method – Relative Risk
The Relative risk (RR), it’s standard error and 95% confidence interval are calculated 
according to Altman (28). 
The relative risk or risk ratio is given by
         (2.17)
where a is the number of exposed patients with a positive (bad) outcome, b is the 
number of exposed patients with a negative (good) outcome, c is the number of non-
exposed patients with a positive (bad) outcome and d is the number of non-exposed 
patients with a negative (good) outcome. 
   
(2.18)
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with a 95% confidence interval of 
  to    (2.19)
Where zeros cause problems with computation of the relative risk or its standard error, 
0.5 is added to all cells (a,b,c,d) (29,30).
Results
In total 367 patients were treated of whom 324 patients met the inclusion criteria. Forty-
three patients were off-protocol for various reasons (see Supplemental table 15). The 
tumor type of 93 non GEP-NET patients can be found in Supplemental table 16. Patient 
characteristics of all 13 patients with persistent hematological dysfunction (PHD) can 
be found in Supplemental table 17. Calculations of the relative risk can be found in 
Supplemental table 18.
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Supplemental Table 11 – Patient age, sex and follow-up characteristics in 367 patients. Age 
category (Age-Cat), Follow-up (FU)
Age-Cat Age Total no. Male Female FU in yrs. FU-Male FU-Female
1 0-4 0 0 0 0.0 0.0 0.0
2 5-9 0 0 0 0.0 0.0 0.0
3 10-14 0 0 0 0.0 0.0 0.0
4 15-19 0 0 0 0.0 0.0 0.0
5 20-24 0 0 0 0.0 0.0 0.0
6 25-29 0 0 0 0.0 0.0 0.0
7 30-34 14 7 7 20.6 7.1 13.4
8 35-39 12 2 10 28.2 7.0 21.3
9 40-44 29 14 15 53.9 15.3 38.5
10 45-49 38 20 18 228.2 59.9 168.3
11 50-54 44 23 21 135.8 68.0 67.8
12 55-59 66 33 33 173.6 85.3 88.3
13 60-64 62 34 28 317.7 108.3 209.4
14 65-69 34 14 20 145.2 73.5 71.7
15 70-74 39 19 20 104.2 51.2 53.0
16 75-79 22 13 9 73.5 42.9 30.6
17 80-84 6 4 2 20.9 11.9 9.0
18 85-89 1 0 1 7.0 4.3 2.7
19 90-94 0 0 0 0.0 0.0 0.0
20 95-99 0 0 0 0.0 0.0 0.0
Total 0-99 367 183 184 1308.8 534.7 774.1
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Supplemental Table 12 - Expected number of hematological malignancies in 367 patients; 
Myeloproliferative Neoplasms (MPN), Chronic Myeloid Leukemia (CML), Myelodysplastic/
Myeloproliferative neoplasms (MDS/MPN). Myelodysplastic Syndrome (MDS) and Acute Myeloid 
Leukemia (AML).
Age-Cat Age MPN  (without CML) CML MDS/MPN MDS AML
1 0-4 0.000 0.000 0.000 0.000 0.000
2 5-9 0.000 0.000 0.000 0.000 0.000
3 10-14 0.000 0.000 0.000 0.000 0.000
4 15-19 0.000 0.000 0.000 0.000 0.000
5 20-24 0.000 0.000 0.000 0.000 0.000
6 25-29 0.000 0.000 0.000 0.000 0.000
7 30-34 0.000 0.001 0.000 0.000 0.002
8 35-39 0.000 0.002 0.000 0.000 0.004
9 40-44 0.001 0.006 0.000 0.002 0.015
10 45-49 0.005 0.043 0.004 0.042 0.111
11 50-54 0.010 0.033 0.006 0.035 0.094
12 55-59 0.044 0.078 0.026 0.146 0.291
13 60-64 0.080 0.137 0.076 0.345 0.600
14 65-69 0.044 0.047 0.047 0.280 0.243
15 70-74 0.051 0.044 0.065 0.358 0.283
16 75-79 0.028 0.033 0.042 0.298 0.171
17 80-84 0.002 0.003 0.004 0.029 0.016
18 85-89 0.000 0.000 0.000 0.001 0.000
19 90-94 0.000 0.000 0.000 0.000 0.000
20 95-99 0.000 0.000 0.000 0.000 0.000
Total 0-99 0.265 0.425 0.271 1.536 1.831
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Supplemental Table 13 – Patient age, sex and follow-up characteristics in 274 
Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs) patients. 
Age-Cat Age Total no. Male Female FU in yrs FUMale FUFemale
1 0-4 0 0 0 0.0 0.0 0.0
2 5-9 0 0 0 0.0 0.0 0.0
3 10-14 0 0 0 0.0 0.0 0.0
4 15-19 0 0 0 0.0 0.0 0.0
5 20-24 0 0 0 0.0 0.0 0.0
6 25-29 0 0 0 0.0 0.0 0.0
7 30-34 6 3 3 9.4 5.8 3.6
8 35-39 7 1 6 23.1 6.3 16.8
9 40-44 19 10 9 38.3 9.7 28.6
10 45-49 26 13 13 203.2 45.7 157.5
11 50-54 36 19 17 108.2 49.4 58.8
12 55-59 47 23 24 144.6 75.5 69.1
13 60-64 53 29 24 298.0 94.8 203.2
14 65-69 28 12 16 125.9 63.6 62.4
15 70-74 29 15 14 87.8 46.9 40.9
16 75-79 18 11 7 54.1 36.5 17.6
17 80-84 5 3 2 16.2 9.5 6.8
18 85-89 0 0 0 4.3 3.8 0.5
19 90-94 0 0 0 0.0 0.0 0.0
20 95-99 0 0 0 0.0 0.0 0.0
Total 0-99 274 139 135 1113.2 447.3 665.8
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Supplemental Table 14 – Expected number of hematological malignancies in 274 patients; 
Myeloproliferative Neoplasms (MPN), Chronic Myeloid Leukemia (CML), Myelodysplastic/
Myeloproliferative neoplasms (MDS/MPN). Myelodysplastic Syndrome (MDS) and Acute Myeloid 
Leukemia (AML).
Age-Cat Age MPN (without CML) CML MDS/MPN MDS AML
1 0-4 0.000 0.000 0.000 0.000 0.000
2 5-9 0.000 0.000 0.000 0.000 0.000
3 10-14 0.000 0.000 0.000 0.000 0.000
4 15-19 0.000 0.000 0.000 0.000 0.000
5 20-24 0.000 0.000 0.000 0.000 0.000
6 25-29 0.000 0.000 0.000 0.000 0.000
7 30-34 0.000 0.000 0.000 0.000 0.000
8 35-39 0.000 0.001 0.000 0.000 0.002
9 40-44 0.000 0.003 0.000 0.002 0.007
10 45-49 0.003 0.027 0.002 0.020 0.070
11 50-54 0.006 0.021 0.004 0.028 0.060
12 55-59 0.026 0.046 0.015 0.085 0.173
13 60-64 0.063 0.109 0.060 0.354 0.474
14 65-69 0.031 0.034 0.034 0.172 0.175
15 70-74 0.033 0.028 0.043 0.235 0.184
16 75-79 0.019 0.022 0.028 0.184 0.113
17 80-84 0.001 0.002 0.003 0.019 0.010
18 85-89 0.000 0.000 0.000 0.000 0.000
19 90-94 0.000 0.000 0.000 0.000 0.000
20 95-99 0.000 0.000 0.000 0.000 0.000
Total 0-99 0.183 0.292 0.190 1.100 1.268
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Supplemental Table 15 - 43 out of 367 off-protocol with reason:
Reason Number of patients
Low uptake (on first post therapy scan) 14
Concomitant Radiotherapy 6
Diagnostic 4
Previous 111In-PRRT 3
Low Karnofsky score 3
Poor renal function 3
Low baseline Hb, platelets or WBC 3
Previous 90Y-PRRT 2
No pathology available 2
Hb tranfusion prior to PRRT 1
Previous 131I-therapy 1
Patient was not able to give fully consent 1
Totaal 43
Supplemental Table 16 - 93 out of 367 patients with Non GEP-NETs:
Type of tumor Number of patients
NET - thorax/chest 2
NET - unknown primary 28
NET - other locations 4
Tyroid carcinoma 19
Paraganglioma 14
Feochromocytoma 2
Meningioma 4
Hurthecell carcinoma 6
SCLC 1
Grawitz pancreas 1
Mamma carcinoma 3
Erdheim chester 1
HCC 2
Prostaat carcinoma 1
Esthesioneuroblastoom 1
Melanoma 2
Meduloblastoma 1
Rectum carcinoma 1
Totaal 93
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Supplemental Table 18 – Calculations for the relative risk (RR) in all 367 patients and 274 
Neuroendocrine gastroenteropancreatic tumors (GEP-NETs).
All 367 patients 274 GEP-NET patients
Exposed group
Number with positive (bad) outcome (a): 8 8
Number with negative (good) outcome (b): 359 266
Control group
Number with positive (bad) outcome (c): 4.4 3
Number with negative (good) outcome (d): 362.6 271
Relative Risk 1.82 2.67
95% Confidence Interval 1.26 to 2.62 0.72 to 9.95
Z statistic 3.22 1.46
Significance level P = 0.0013 P = 0.1442
NNT (Harm) 101.81 54.800
95% Confidence Interval 254.25 (Harm)  
to 63.65 (Harm)
23.99 (Harm) to ∞  
to 192.77 (Harm)
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ABSTRACT
The spleen is the only lymphoid tissue directly interposed in the blood circulation and 
receives a high-absorbed dose during treatment with PRRT. However, little is known 
about the clinical consequences. The aim of this study was to examine the correlation 
between the cumulative radiation dose to the spleen, changes in spleen volume and 
peripheral blood counts after multiple cycles of PRRT. 
Methods: 
Data of spleen volume, spleen dosimetry and leucocyte count (total and differential) 
were collected at baseline, 3 months and 12 months after completion of initial 
treatment cycles and within 3 months after re-treatment. Only patients who received a 
cumulative dose of 30 GBq and an extra dose for retreatment of 15 GBq were included 
in the analysis. Patient medical files were reviewed for the occurrence and type of 
documented infections. 
Results: 
Significant smaller splenic volumes were measured (p<0.001, r= -0.55) 12 months 
after initial treatment with 177Lu-Octreotate, compared to baseline. An increasing 
decline in volume was observed after re-treatment when compared to 12 months 
follow-up (p<0.001, r= -0.43). An overall decline of 55% in volume was observed. The 
median absorbed dose to the spleen was 52 Gy (23-110 Gy), no minimum threshold 
for spleen volume reduction was found. A decline in White Blood Count (WBC), total 
and differential, was observed in all patients after treatment. Lymphocyte count was 
only decreased after re-treatment in comparison to the blood counts after 12 months, 
(p<0.001, r=-0.81). 
No correlation was found between the absorbed spleen dose and decrease in WBC 
count or lymphocyte count. There was also no association between spleen volume 
and difference in lymphocyte count at 12 months follow-up and at 3 months after re-
treatment. Evaluation of the medical files demonstrated no infection of patients caused 
by a pneumococcal, meningococcal and/or Haemophilus influenzae type b based 
bacteria.
Conclusion: 
Administration of multiple cycles of PRRT reduces spleen volume and lymphocyte 
count. Reduction in spleen volume combined with a decrease in lymphocyte count does 
not have clinical consequences. No increased risk of infection, based on encapsulated 
bacteria, was found. 
Key words:
PRRT, 177Lu-Octreotate, Spleen, Dosimetry, Volume, toxicity
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INTRODUCTION
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin 
analogues is increasingly being used in patients with metastasized and/or inoperable 
neuroendocrine tumors. Since the introduction of PRRT in the late nineties, an increase 
in clinical experience has supported the growth in knowledge regarding the (side)
effects of PRRT.
After PRRT with 177Lu-octreotate, physiological accumulation of the radiopeptide can be 
found in the liver, kidneys, spleen and occasionally in the pituitary gland. Uptake of the 
radioligand can also be seen in neuroendocrine tumours because of their rich expression 
of the somatostatin receptor (sst), particular subtype 2 (1,2). Dosimetric analysis also 
indicates high-absorbed doses to the spleen and kidneys (1,3). The absorbed doses to 
the spleen are in the range of dose limits, generating deterministic radiation effects. 
However, clinically observed radiation-induced toxicities are low.
Coinfusion of amino acids during PRRT lowers the absorbed dose to the kidneys and 
reduces renal toxicity (4,5). Accumulation of the radioligand in the pituitary gland can 
induce transient inhibitory effects on spermatogenesis in male patients and can lead 
to a decrease of gonadotropin levels in post-menopausal females (6). However, little is 
known about the clinical consequence of a high-absorbed dose to the spleen. 
The spleen is the only lymphoid tissue directly interposed in the blood circulation and 
fulfills an important immunological, moreover it acts as reservoir for platelets, red and 
white blood cells (7). Up to now, the bone marrow is considered as one of the main 
dose limiting organs for PRRT. Interestingly, Svensson et al. recently found a correlation 
between total absorbed spleen dose and decrease in hemoglobin, but such a correlation 
was not observed for spleen dose and white blood cell and/or platelet count (8). These 
findings contradict the results of an earlier study done by Kulkarni et al., they found 
no relation between hematological toxicity and absorbed spleen dose after PRRT with 
177Lu-DOTATATE or 177Lu-DOTATOC (9).
The combination of radiation exposure to the bone marrow and the spleen after PRRT 
may lead to a different hematological response compared to irradiation of only the 
bone marrow, like in radioiodine (131I) therapy in patients with thyroid cancer.
The aim of this study was to explore the correlation between cumulative mean absorbed 
spleendose, the changes in spleen volume and change in peripheral blood counts after 
multiple cycles of PRRT. Since the spleen has an important immunological role, changes 
in leucocyte count and vulnerability to infectious disease were also taken into account.
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MATERIALS AND METHODS
Patients
The study included Dutch patients who were treated from January 2000 to October 
2010. Only patients who completed initial treatment followed by re-treatment after 
renewed progressive disease were selected.
Inclusion criteria were: patients with neuroendocrine tumor and baseline tumor 
uptake on [111In-DTPA0] octreotide scintigraphy (OctreoScan®; Mallinckrodt, Petten, The 
Netherlands) with accumulation in the tumor at least as high as in normal liver tissue; 
no prior treatment with PRRT; baseline serum hemoglobin (Hb) ≥6 mmol/l; white blood 
cell (WBC) count ≥2×109/l; platelet (PLT) count ≥75×109/l; serum creatinine ≤150 μmol/l 
or creatinine clearance ≥40 ml/min and Karnofsky performance status ≥50. Only Dutch 
patients were selected, because loss to follow-up is limited in these patients. 
This study was part of the ongoing prospective study in patients with neuroendocrine 
tumors treated with 177Lu-octreotate at the Department of Nuclear Medicine, Erasmus 
University Medical Center Rotterdam. The hospital’s medical ethics committee approved 
the study. All patients gave written informed consent for participation in the study. 
Treatment
[DOTA0,Tyr3] octreotate was obtained from BioSynthema (St. Louis, MO). 177LuCl3 was 
supplied by IDB-Holland (Baarle-Nassau, The Netherlands) and 177Lu-octreotate was 
prepared locally (1). Granisetron 3 mg or ondansetron 8 mg was injected intravenously 
30 min before infusion of 177Lu-octreotate. Infusion of amino acids (2.5 % arginine and 
2.5 % lysine, 1 l) was started 30 min before administration of the radiopharmaceutical 
and lasted for 4 h. The radiopharmaceutical was coadministered for 30 min using a 
second pump system. The intended cumulative dose for the initial treatment was 30.0 
GBq, given in 4 cycles. Two additional cycles of 7.4 GBq (=re-treatment) were given after 
renewed progressive disease.
Data acquisition & statistical analysis
Data on spleen volume, spleen dosimetry and leucocyte count (total and differential) 
collected at baseline, 3 months and 12 months after completing the initial treatment 
cycles and within 3 months after finishing re-treatment was analyzed. Spleen volume 
was based on diagnostic CT-scans and volume was calculated using MeVisLab software 
(version 2.4, MeVis Medical Solutions AG, Bremen, Germany). An MD reviewed patient 
medical files for the occurrence and type of documented infections.
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A nonparametric test for dependent samples was used to assess changes in spleen 
volume and leucocyte count; p-values ≤ 0.05 were considered significantly different. 
Correlations between mean absorbed dose to spleen, spleen volume and leucocyte 
count were tested using binary logistic regression and linear regression tests (SPSS 
version 20; Inc., Chicago, IL).
Dosimetry
Dosimetric calculations were performed according to the MIRD scheme (10). The mean 
absorbed dose (D(rT, TD)), to target tissue (rT) can be calculated over a dose-integration 
period (TD) from a uniformly distributed compound within a source tissue (rS):
  (2.20)
       (2.21)
where  is the time-integrated activity (no. of nuclear transformations) in  over 
 and  is the absorbed dose rate in  per nuclear transformation in . 
Highest physiological uptake of the radiopeptide was observed in the kidneys and 
spleen. Therefore 
 (2.22)
where Dspl is the radiation dose to the spleen (spl), Ã is the cumulative activity and DF are 
the dose factors for the specific organs. Since contribution of cross-dose from gamma 
radiation of the surrounding organs to the absorbed spleen dose is limited (11), we can 
further reduce equation (2.23) to  
    (2.23)
After the first therapy cycle of initial treatment, planar whole body scans were 
performed at 24, 96 and 168 hours after the administration of the radiopharmaceutical. 
A monoexponential curve was fitted through the spleen conjugate-view background 
corrected time-activity data (Excel, Microsoft). Time-integrated activity coefficients 
(TIAC) in the spleen and other organs with physiological uptake were acquired by 
integration of the exponential curve folded with the 177Lu decay curve (with half-life 
T1/2=6.647 d). 
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After the second and sequential therapy cycles, planar whole body scans were 
performed at 24 hours after the administration of the radiopharmaceutical. Splenic dose 
calculations for second and sequential therapy cycles were calculated by normalization 
of the monoexponential function (calculated after the fi rst initial treatment) and the 
amount of radioactivity measured at the whole body scan (table 1). The resulting organ 
TIACS were used as input for the Olinda/EXM dosimetry software with correction for 
the actual spleen mass, by modifying the standard spleen masses (female: 150g, male: 
183g) with the measured spleen mass taking a density of 1 g/cm3.
Table 1 - Methods of splenic dose calculations after diff erent therapy cycles with 177Lu-Octreotate.
Table	1	-	Methods	of	splenic	dose	calculations	after	different	therapy	cycles	with	177Lu-
Octreotate.	
	
	
	RESULTS
A total of 35 of 67 patients completed the full treatments and had complete follow-up 
at the required time points. Thirty-fi ve patients were analyzed, see table 2 for the patient 
and treatment characteristics. Overall, patients received a total of 6 PRRT cycles, with a 
minimum of 5 and maximum 7 therapy cycles. Median follow-up was 37.7 (range 21.4 
- 68.5) months. 
Complete dosimetric data was available in 27 patients. The median absorbed dose to 
the spleen was 52 Gy (23-110 Gy). No minimal threshold for the induction of a spleen 
volume reduction was found.
Median splenic volumes at baseline and during follow-up are summarized in table 3. 
Signifi cant smaller splenic volumes (Wilcoxon signed rank test; p<0.01, r= -0.58) were 
measured at 12 months follow-up after initial treatment in comparison to baseline 
measurements. Also, signifi cant changes (Wilcoxon signed rank test; p<0.01, r= -0.55) 
were observed after re-treatment with 177Lu-Octreotate in comparison to baseline 
measurements. Likewise, splenic volumes after 12 months follow-up and after re-
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treatment were significantly different (Wilcoxon signed rank test; p<0.01, r= -0.43). 
Figure 1 shows the absolute change in volume per individual patient. In two cases the 
spleen increased in size between 12 months follow-up and retreatment. However, in 
both patients a volume reduction was observed at the 12 months follow-up CT-scan. 
An example of spleen volume loss on CT-scan in two patients is displayed in figure 2.
Table 2 - Characteristics of 35 (16 male and 19 female) Dutch patients with complete data of 
initial- and retreatment. 
Characteristic Value (and range)
Initial Treatment
- Age at initial treatment (years) 57 (39-72) 
- Cumulative activity initial treatment (GBq) 29.9 (22.4 - 30.5) 
Interval initial treatment to re-treatment (months) 30.5 (10.5 -59.5) 
Retreatment
- Age at re-treatment in (years) 60 (41 -76) 
- Cumulative activity re-treatment (GBq) 44.9 (36.3 - 46.4) 
- Cumulative absorbed dose to the spleen (Gy) 52 (23 - 110)
Table 3 - Median splenic volume at different times during initial- and re-treatment.
Measured at Median (and range) volume in ml
Initial treatment
- Baseline 219 (44 – 508)
- 3 months follow-up 173 (37 – 471)
- 12 months follow-up 152 (31 – 410)
Retreatment
- ≤ 3 months follow-up 122 (20 – 386)
A persistent decrease in WBC (total and differential) occurred in all patients. However, 
only lymphocyte count was persistently decreased after re-treatment in comparison 
to 12 months counts, Wilcoxon signed rank test; p<0.00, r=-0.81 (table 4). Other blood 
counts did not show a significant change. No correlation was found between absorbed 
spleen dose and decrease in WBC count (p= 0.18) or lymphocyte count (p= 0.46). Also 
spleen volume and lymphocyte count alterations were not significantly correlated at 12 
months follow-up (p= 0.58) and at 3 months after re-treatment (p= 0.33).
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Figure 1 - Absolute change in splenic volume (in cm3) measured in 35 patients treated with 177Lu-
Octreotate. Baseline spleen volumes were compared to spleen volumes at 12 months follow-up 
after initial treatment (  blue bars) and 6 weeks or 3 months follow-up after re-treatment with 
PRRT (  orange bars).
Figure 2 - Images of CT-scans in two patients (A & B) at baseline, 12 months after initial treatment 
and ≤ 3 months after re-treatment with 177Lu-Octreotate. The spleen (white arrow) appears smaller 
on CT-scan after multiple cycles of PRRT. 
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Table 4 - Overview of absolute Blood Counts (and ranges) in 35 patients treated with 177Lu-
Octreotate. Comparison of 3, 12 months follow-up (FU) to baseline blood counts and 3 months 
after re-treatment to 12 months FU blood counts. 
 Measured at Leucocytes Basophils Eosinophils Neutrophils Lymfocytes Monocytes
Initial treatment            
Baseline 6.10  
(5.20, 7.60)
0.04 
(0.00, 0.07)
0.12 
(0.08, 0.22)
4.12 
(2.29, 5.25)
1.54 
(1.13, 1.98)
0.49 
(0.36, 0.63)
3 Months FU 3.50 
(2.80, 4.30)
0.00 
(0.00, 0.03)
0.09 
(0.05, 0.17)
2.33 
(1.76, 2.88)
0.66 
(0.47, 0.85)
0.36 
(0.28, 0.46)
12 Months FU 4.40 
(3.60, 5.60)*
0.00 
(0.00, 0.04)*
0.11 
(0.04, 0.14)*
2.81 
(2.29, 3.64)*
0.92 
(0.70, 1.31)*
0.42 
(0.30, 0.52)*
Retreatment            
3 Months FU 4.20 
(3.10, 5.20)
0.00 
(0.00, 0.04)
0.10 
(0.06, 0.18)
2.74 
(2.08, 3.55)
0.76 
(0.47, 0.91)**
0.43 
(0.34, 0.50)
Significant differences are indicated by an * and an ** respectively.    
Evaluation of the medical files showed no diagnosis of patients with an infection caused 
by a pneumococcal, meningococcal and/or Haemophilus influenzae type b based 
bacteria (Table 5).  
Table 5 - Reported infections in 35 patients during/after PRRT with 177Lu-Octreotate.
n=
Common Cold 9
Herpes Zoster 1
Influenza 7
Sinusitis 2
Urinary Tract Infection 4
DISCUSSION
The first objective of this study was to explore correlations between cumulative mean 
absorbed dose to the spleen and changes in spleen volume or peripheral blood counts 
after multiple cycles of PRRT. The second objective was an exploration of the clinical 
consequences regarding the change in splenic volume. 
In the 1930s and 1940s, the radiocontrast agent Thorotrast, containing the radioactive 
compound thorium dioxide (ThO2), was used in medical radiography. Thorium is 
retained in the body and emits harmful α-radiation and can induce alterations in 
splenic volume. The compound lost its clinical application due to a high lifetime risk 
of developing hemangioendothelioma and/or cholangiocarcinomas originating in the 
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liver (12,13). Our study demonstrates that multiple administrations with PRRT, based 
on β-emitting radionuclide 177-Lutetium-Octreotate, will result in significant spleen 
volume reduction. No significant dose-dependent relationship between the mean 
absorbed dose to the spleen and volume decline was found. Svensson et al. recently 
published a similar observation of spleen volume decline after treatment with 177Lu-
Octreotate (8). However, two patients in our study had a spleen volume increase after 
retreatment, although a decrease in volume was seen at the 12 months follow-up CT-
scan after the initial cycles with PRRT. Both patients suffered from an increase in ascites 
at the start of retreatment; therefore it is likely that the increase in spleen volume was 
due to portal hypertension caused by progressive disease. 
The decrease in spleen volume can be explained by fibrotic changes in the splenic 
tissue, a hypothesis that is in line with earlier studies (14,15). In one of the two studies, 
histological analyses of surgical pancreas NET specimens after neoadjuvant PRRT was 
performed, in the other study a hyalinization of tumor tissue was observed in patients 
who underwent external radiotherapy for Hodgkin’s disease. 
Currently, little is known about the clinical impact of changes in spleen volume after 
PRRT. Normally, the spleen has a role of eliminating pitted erythrocytes, damaged or 
aged blood cells and fulfills an important immunological role in the production of 
antibodies and filtering out blood borne pathogens (7). Several medical conditions 
can induce splenic atrophy and compromise the splenic function as an immunological 
barrier against encapsulated bacteria. Splenic atrophy puts patients at risk of developing 
an Overwhelming Post-Splenectomy Infection (OPSI) (16-18). OPSI is a serious disease 
that can present as sepsis, meningitis or pneumonia and has high mortality rates within 
the first 24 hours (19). Evidence suggests that hyposplenic state can be iatrogenically 
induced after external beam radiotherapy. Analysis of a historic cohort of patients 
who underwent postoperative chemoradiotherapy for gastric cancer demonstrated a 
radiation-induced reduction of spleen volume. Moreover, an incidence and mortality 
rate of pneumonia and sepsis was observed, comparable to that in patients with a 
hyposplenic and/or post-splenic state (20). 
Our study demonstrates a persistent decrease in complete lymphocyte count after the 
administration of 177Lu-Octreotate. However, we cannot determine the mechanism of 
action, whether the observed toxicity is an effect of targeted and prolonged irradiation 
of the spleen, a known reservoir of white blood cells, or of transient bone marrow 
irradiation. Radioactive iodine (RAI) does not specifically accumulate in the spleen, 
therefore irradiation of the bonemarrow and spleen may be different. Studies in 
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patients with differentiated thyroid cancer who underwent RAI with 131I demonstrated a 
transient decrease of the total WBC and lymphocyte count after treatment up to 1 year. 
Lymphocyte subset analyses demonstrated a prolonged B-cell lymphopenia. However, 
none of the studies reported severe clinical consequences (21-24). These studies support 
the hypothesis that the decrease in blood cells is mainly caused by irradiation of the 
bone marrow and in a less extend caused by irradiation of the spleen. Interestingly, 
patients who underwent splenectomy were protected against hematological toxicity 
after 177Lu-Octreotate (25).
In our patients, multiple cycles of PRRT with 177Lu-Octroetate induce atrophy of the spleen 
and a persistent lower complete lymphocyte, compared to baseline measurements. An 
interesting question is whether patients are prone to develop a hyposplenic state after 
PRRT. 
In the current standard of Centers for Disease Control and Prevention [CDC] 2016, the 
consensus is to immunize patients with 13-valent pneumococcal conjugate vaccine 
(PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), Haemophilus 
influenzae type b (Hib) vaccine and Meningococcal vaccine if patients are at risk of 
developing an OPSI. The highest incidence of OPSI after splenectomy is observed within 
24 months (26). During follow-up of patients in our study with a median of 38 months, 
no hospitalization was required. Also no infection, based on capsulated bacteria, or 
OPSI was observed. Therefore it is unlikely that patients develop a hyposplenic state 
after PRRT with 177Lu-Octreotate.
CONCLUSION
Administration of multiple cycles of PRRT with 177Lu-Octreotate induces splenic volume 
loss and a decrease in lymphocyte count without clinical consequences. There is no 
increased risk for developing an infection based on encapsulated bacteria in patients 
receiving PRRT with 177Lu-Octreotate.
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INTRODUCTION 
Prostate cancer (PCa) is the most common cancer in American men and in European 
males (particularly beyond 70 years of age) (1). About one American man in seven and 
one European in eight will be diagnosed with PCa during his lifetime. Diagnosis of 
primary PCa is mainly based on transrectal ultrasound (TRUS) guided biopsies, which 
has a limited sensitivity after one procedure. Therefore multiple biopsies are required for 
a reliable outcome. Also, the role of CT, (f )MRI and PET/CT in the diagnosis and staging 
of PC is not well established because of variations in sensitivity/specificity in different 
patient groups (2,3). 
In women, breast cancer (BC) is the most frequent type of cancer with 1.67 million new 
cases in the year 2012 (4). In 2015, the number of new cases of BC in men and women 
were 105 and 17,060, respectively, in the Netherlands (5). Mammography is the most 
widely used technique of imaging BC, but has several limitations leading to a significant 
amount of false positive and false negative findings (6). False positive results lead to 
unnecessary additional tests and anxiety in the patient (7,8), whereas false negative 
results may cause a delay in diagnosis and treatment (7). When a suspicious lesion is 
detected by mammography, occasionally additional imaging with ultrasound or MRI 
is required in a select group of patients (9). Ultrasound and MRI enhance the overall 
sensitivity, but the specificity is not increased (9). 
Targeted nuclear imaging can offer an interesting opportunity to improve the 
diagnostic imaging yield in prostate- and breast cancer, which could lead to better 
patient management. The upcoming paragraphs will briefly summarize targeted 
nuclear imaging in prostate and breast cancer, whereas Chapter 3.2 will report a novel 
PET radiotracer [68Ga]SB3 in patients with prostate and breast cancer. 
Targeted nuclear imaging and therapy
Targeted nuclear imaging and treatment is based on targeting receptors/proteins, 
which are overexpressed on cancer cells using radioligands. These radioligands consist 
of a peptide (which links to the receptor), linker/chelators (for stabilization) and the 
radionuclide (used for imaging and/or therapy) Figure 1. Several radioligands for imaging 
(e.g. 111In-pentreotide also known as Octreoscan) and therapy (e.g. 177Lu-DOTATATE) 
have been successful developed for targeting the somatostatin receptor (sst). In the 
clinic, these two radioligands improved imaging and formed new therapeutic options 
for patients with neuroendocrine tumors (chapter 1.1 & 1.2).
In the past decades, new targets have been identified for prostate and breast cancer 
(Table 1). Receptor positive tumor can be visualized (and the tumor can possibly be 
treated) with novel radioligands, following the success of sst in neuroendocrine tumors. 
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Figure 1 - Structure of somatostatin analogue with binding to the receptor and cell; radionuclide, 
chelator, linker, ligand and receptor (on the cell membrane). 
Table 1 - An overview of malignancies and the target options on the cell membrane. Somatostatin 
receptor (sst), Prostate Specifi c Membrane Antigen (PSMA) and gastrin releasing peptide receptor 
(GRPR).
Malignancy originating from: Targets options 
Neuroendocrine cell sst
Prostate PSMA, GRPR
Breast sst, GRPR
Lung sst, GRPR
PSMA
Prostate-specifi c membrane antigen (PSMA) is signifi cantly overexpressed in PCa cells, 
therefore it is an attractive target in the clinical and diagnostic fi eld. PSMA (also known 
as folate hydrolase I or glutamate carboxypeptidase II), is a transmembrane 750-amino-
acid type II glycoprotein that is primarily expressed in normal human prostate epithelium 
but is overexpressed in prostate cancer (10), including metastatic disease (11,12). Since 
almost all prostate cancers express PSMA, it is an attractive target for prostate cancer 
imaging and therapy. Also, PSMA expression is further increased in poorly diff erentiated, 
metastatic, and hormone-refractory carcinomas (13,14). Recently, PSMA ligands with 
68Ga, 99mTc and radioiodine have been developed, enabling their use for PET or SPECT 
imaging and therapy. In the past, an 111In-capromab pendetide (ProstaScint) labelled 
ligand of the intracellular epitope of PSMA was used for imaging of PSMA expression 
(15). However, 111In-capromab pendetide only binds to the intracellular domain of PSMA 
which is only accessible in dying, apoptotic or dead tumor cells. ProstaScint has also a 
low sensitivity because of poor resolution of scintigraphic gamma cameras. 
14802HBergsma_BW_DEF_15/8.indd   190 15-08-17   11:40
3.1 Introduction 
191 
New PSMA-based PET imaging agents have been developed like Glu-NH-CO-NH-Lys-
(Ahx)-68Ga[HBED-CC] (68Ga-PSMA). In more than 1000 patients 68Ga-PSMA have been 
given for different clinical indications, such as initial assessment and recurrence of 
disease. 68Ga-PSMA is able to detect a significant uptake in more than 60% of recurrent 
PCa patients with a PSA level < 1 ng/ml and has a detection rate of >80% in those with a 
PSA higher than 2ng/ml (16). However, Afshar-Oromieh et al (17) presented some critical 
notes regarding 68Ga-PSMA: there is no relationship between an increase in PSA level 
and an increase in tumor detection. Also no correlation was found between Gleason 
score and uptake on 68Ga-PSMA. However patients with an androgen deprivation 
therapy at the time of 68Ga-PSMA-ligand PET/CT more frequently showed a positive PET 
scan compared to patients without such treatment, making 68Ga-PSMA imaging a good 
candidate for assessment of recurrent disease. 
GRPR
The gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor with 7 
transmembrane spanning domains and is part of the mammalian bombesin receptor 
family. GRPR’s ligand, gastrin releasing peptide (GRP), cascades various biological and 
pharmacological responses, like smooth muscle contraction in the gastrointestinal tract 
and urogenital system (18). Expression of the GRPR has been reported in various types 
of cancer, like prostate, breast and lung cancer (18).
High GRPR expression (85–100 %) has been documented in primary and well-
differentiated PC, the expression drops (to 50%) in androgen-refractory bone metastases 
(19-23). GRPR is also expressed in primary BC (62-74%), whereas all metastases originating 
from GRPR-positive primaries retain high levels of receptor expression (24-26). 
Originally, radiolabeled analogs for targeting of GRPR-positive tumor sites were derived 
from the bombina bombina frog, containing an active tetradecapeptide, bombesin 
(27,28). At that time, internalization was considered essential for prolonged lesion 
retention, which would eventually translate into greater diagnostic sensitivity and 
therapeutic efficacy. However, this principle has been challenged by accumulating 
evidence on the superior performance of radiolabeled GRPR antagonists versus their 
agonist-based counterparts (29,30). For example, the radioantagonist [99mTc]DB1 has 
displayed higher uptake and retention in GRPR-expressing tumors in combination 
with a much faster background clearance (including the GRPR-rich pancreas) than the 
radioagonist [99mTc]DB4 (29). Another advantage of radioantagonists is their greater 
inherent biosafety. GRPR agonists (like 177Lu-AMBA) elicit pharmacological effects after 
receptor binding and are less tolerated by patients (31), whereas GRPR antagonist do 
not elicit side effects. 
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In the chapter 3.2, we introduce the [99mTc]DB1 mimic [68Ga]SB3, whereby the 99mTc-
binding acyclic tetraamine unit has been replaced by the chelator DOTA to allow 
labeling with the PET radiometal 68Ga. The new PET tracer has been characterized in 
GRPR-positive cells and animal models using the [67Ga]SB3 surrogate. Furthermore, 
a first-in-man clinical evaluation of [68Ga]SB3 has been per- formed in patients with 
recurrent PC or BC.
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ABSTRACT
Gastrin-releasing peptide receptors (GRPR) represent attractive targets for tumor 
diagnosis and therapy because of their overexpression in major human cancers. 
Internalizing GRPR agonists were initially proposed for prolonged lesion retention, 
but a shift of paradigm to GRPR antagonists has recently been made. Surprisingly, 
radioantagonists, such as [99mTc]DB1 (99mTc-N4’-DPhe
6,Leu-NHEt13]BBN(6–13)), displayed 
better pharmacokinetics than radioagonists, in addition to their higher inherent 
biosafety. We introduce here [68Ga]SB3, a [99mTc]DB1 mimic-carrying, instead of the 99mTc-
binding tetraamine, the chelator DOTA for labeling with the PET radiometal 68Ga. 
Methods:
Competition binding assays of SB3 and [natGa]SB3 were conducted against [125I-Tyr4]BBN 
in PC-3 cell membranes. Blood samples collected 5 min postinjection (pi) of the [67Ga]SB3 
surrogate in mice were analyzed using high-performance liquid chromatography (HPLC) 
for degradation products. Likewise, biodistribution was performed after injec- tion of 
[67Ga]SB3 (37 kBq, 100 μL, 10 pmol peptide) in severe combined immunodeficiency 
(SCID) mice bearing PC-3 xenografts. Eventually, [68Ga]SB3 (283 ± 91 MBq, 23 ± 7 nmol) 
was injected into 17 patients with breast (8) and prostate (9) cancer. All patients had 
disseminated disease and had received previous therapies. PET/CT fusion images were 
acquired 60–115 min pi. 
Results: 
SB3 and [natGa]SB3 bound to the human GRPR with high affinity (IC50: 4.6 ± 0.5 nM and 1.5 
± 0.3 nM, respectively). [67Ga]SB3 displayed good in vivo stability (>85 % intact at 5 min 
pi). [67Ga]SB3 showed high, GRPR-specific and prolonged retention in PC-3 xenografts 
(33.1 ± 3.9%ID/g at 1 h pi – 27.0 ± 0.9%ID/g at 24 h pi), but much faster clearance 
from the GRPR-rich pancreas (≈160 %ID/g at 1 h pi to <17 %ID/g at 24 h pi) in mice. In 
patients, [68Ga]SB3 elicited no adverse effects and clearly visualized cancer lesions. Thus, 
4 out of 8 (50 %) breast cancer and 5 out of 9 (55 %) prostate cancer patients showed 
pathological uptake on PET/CT with [68Ga]SB3. 
Conclusion: 
[67Ga]SB3 showed excellent pharmacokinetics in PC-3 tumor-bearing mice, while [68Ga]
SB3 PET/CT visualized lesions in about 50 % of patients with advanced and metastasized 
prostate and breast cancer. We expect imaging with [68Ga]SB3 to be superior in patients 
with primary breast or prostate cancer. 
Keywords: 
PET/CT tumor imaging, 68Ga radiotracer, Gastrin-releasing peptide receptor antagonist, 
Prostate cancer, Breast cancer
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INTRODUCTION 
Prostate (PC) and breast cancer (BC) rank first in incidence among men and women 
diagnosed with cancer in Western countries and are linked to considerable morbidity 
and mortality in the metastatic stages of the disease [1, 2]. Accordingly, the non-
invasive and reliable diagnosis and staging of these cancers remain compelling medical 
requirements. This is reflected in the high number of inconclusive biopsies, which are 
associated with much patient discomfort and anxiety, and with an increase in healthcare 
costs [3, 4]. On the other hand, conventional imaging techniques, such as MRI, CT, 
ultrasound, or even established nuclear medicine procedures (e.g., 18FDG/PET) remain 
of limited diagnostic value because of their low specificity [5–8]. 
In this respect, receptor-targeted tumor imaging may represent an attractive alternative 
for diagnosing primary and/or disseminated disease with high specificity and sensitivity. 
This approach holds great promise in cases of PC and BC, owing to the high density 
expression of the gastrin-releasing peptide receptor (GRPR) target in pathological 
lesions. In particular, high GRPR expression has been documented in primary and well-
differentiated PC (85–100 %), which, however, drops (50 %) in androgen-refractory bone 
metastases [9–13]. GRPR is also expressed in primary BC (>60 %), whereas all metastases 
originating from GRPR-positive primaries retain high levels of receptor expression [14–16]. 
Originally, radiolabeled analogs of the frog tetradecapeptide bombesin (BBN) have 
been developed for the in vivo targeting of GRPR-positive tumor sites, mainly owing 
to their ability to internalize rapidly and massively into cancer cells [17, 18]. At that 
time, internalization was considered essential for prolonged lesion retention, which 
would eventually translate into greater diagnostic sensitivity and therapeutic efficacy. 
However, this rationale has been challenged by accumulating evidence on the 
unexpectedly superior performance of radiolabeled GRPR antagonists in visualizing 
GRPR-positive tumors in vivo versus their agonist- based counterparts [19, 20]. Thus, 
the radioantagonist [99mTc]DB1 has displayed higher uptake and retention in GRPR-
expressing tumors in combination with a much faster background clearance (including 
the GRPR-rich pancreas) than the radioagonist [99mTc]DB4 [19]. A further significant 
advantage of radioantagonists is their greater inherent biosafety. In contrast to agonists, 
GRPR antagonists do not elicit pharmacological effects after receptor binding and are 
consequently better tolerated after intravenous (iv) injection to patients [21]. 
In the current work, we introduce the [99mTc]DB1 mimic [68Ga]SB3 (Figure 1), whereby 
the 99mTc-binding acyclic tetraamine unit has been replaced by the chelator DOTA to 
allow labeling with the PET radiometal 68Ga. The new PET tracer has been characterized 
in GRPR-positive cells and animal models using the [67Ga]SB3 surrogate. Furthermore, a 
first-in-man clinical evaluation of [68Ga]SB3 has been per- formed in a small number of 
patients with recurrent PC or BC employing PET/CT. 
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Figure 1 - Chemical structure of [67/68Ga]SB3 
Table 1 - Characteristics and scan results in the subgroup of 8 breast cancer (BC) patients 
Patient Age Final Initial Year of 
Previous therapy  
[68Ga]SB3 
(number) (years) diagnosis stage diagnosis scan
2 55 BC T2N1M0 1999 Mast2, chem +
3 70 BC LC
T1N2M1  
Stage IV 
1988  
2008 Mast2, rad Chem +
5 49 BC T1N1M0 2001 Mast2, chem, rad, horm, sam, imm +
6 48 BC T1N0M0  T3N0M1 
Left: 1998  
Right: 2007 Mast2, chem, horm, rad, sam +
8 60 BC T3N0M1  TxNxMx 
Left: 1993  
Right: 1999 Left: mast1 Right: mast1 − 
9 51 BC TxNxMx 1994 Mast2, chem, rad, imm − 
11 69 BC  T2N1M0 2004 Mast, chem, rad, imm − 
14 40 BC  T2N1M0 1999 Mast2, chem − 
MATERIALS AND METHODS 
SB3 and [67/68Ga]SB3 
The DOTA-conjugated GRPR antagonist SB3 (DOTA-p-aminomethylaniline-diglycolic 
acid-DPhe-Gln-Trp-Ala-Val- Gly-His-Leu-NHEt) was obtained from PiChem and labeled 
with 67Ga or 68Ga, as detailed in the Supplementary material; quality control of the 
radiolabeled product (Figure 1) is also presented therein. 
In vitro assays 
Human androgen-independent prostate adenocarcinoma PC-3 cells (LGC Promochem) 
endogenously expressing the GRPR [22] were used in biological assays. Competition 
binding experiments with SB3 and [natGa]SB3 were conducted in PC-3 cell membranes 
using [125I-Tyr4]BBN as the radioligand and [Tyr4]BBN as reference (Supplementary 
material). In brief, the radioligand (~40,000 cpm per assay tube, at a 50 pM concentration) 
was incubated at 22 °C for 1 h and the assay conducted as previously reported [23]. IC50 
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values were calculated using nonlinear regression for a one-site model and represent 
mean ± SD values from three independent experiments performed in triplicate. 
The cell association of [67Ga]SB3 in PC-3 cells was tested during a 1-h incubation 
period at 37 °C. Briefly, confluent PC-3 cells were seeded in six-well plates (~1.0 × 106 
cells per well) 24 h before the experiment. Approximately 300, 000 cpm of [67Ga]SB3 
(corresponding to 2 pmol total peptide in 150 μL of 0.5 % BSA/PBS supplemented 
with Haemaccel®) was added alone (total) or in the presence of 1 μM [Tyr4]BBN (non-
specific) and the experiment was per- formed as before [24]. Results were calculated as 
percentage internalized plus membrane bound activity versus total added activity per 
million cells. 
Stability and biodistribution of [67Ga]SB3 in mice 
Blood collected 5 min pi of [67Ga]SB3 in healthy mice was analyzed using high-
performance liquid chromatography (HPLC) (Supplementary material). 
For biodistribution studies, a≈150-μL bolus containing a suspension of ≈ 1.5 × 107 
freshly harvested human PC-3 cells in saline was subcutaneously injected into the 
flanks of female severe combined immunodeficiency (SCID) mice (15 ± 3 g, 6 weeks of 
age on the day of arrival; NCSR “Demokritos” Animal House Facility). The animals were 
kept under aseptic conditions and 2–3 weeks later developed well-palpable tumors 
at the inoculation sites (80–150 mg). A 100-μL bolus (37 kBq, 10 pmol total peptide; 
in saline/EtOH 9/1 v/v) of [67Ga]SB3 was injected into the tail vein and biodistribution 
was conducted for the 1-, 4-, and 24-h pi time intervals; for in vivo GRPR-blockade a 
separate 4-h animal group received excess [Tyr4]BBN (40 nmol [Tyr4]BBN in 50-μL vehicle 
coinjected with the radioligand). Biodistribution data were calculated as percentage 
injected dose per gram of tissue (%ID/g) with the aid of suitable standards for the 
injected dose [24]. 
Statistical analysis using the unpaired two-tailed Student’s t test was performed to 
compare values between the control and the in vivo GRPR-blockade animal groups at 4 
h pi; values of P < 0.05 were considered statistically significant. 
All animal experiments were carried out in compliance with European and national 
regulations and after approval of protocols by national authorities. 
Patient selection and administration of [68Ga]SB3 
Seventeen patients (9 men and 8 women; age range, 40–74 years) with advanced PC or 
BC were iv injected with [68Ga]SB3 (Supplemental table 1). The iv injection of [68Ga]SB3 
(mean administered activity of 283 ± 91 MBq associated with a peptide mass of 23 ± 
0.7 nmol) was followed by the iv administration of furosemide (20 mg). Initial diagnosis 
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using the classification of malignant tumors (TMN) was made using histopathology and 
tomography. All patients had had confirmed metastases to distant organs at last imaging 
and had demonstrated evident progression of tumor disease, e.g., a rise in tumor 
markers (PSA, CEA, Ca15-3 or CA-125) and/or progression on recent imaging (CT, MRI, 
and/or PET). Hematological (Hb, WBC, and platelets), liver (ALAT, AP, and γ-GT), and renal 
functions (s-creatinine and eGFR) were measured before [68Ga]SB3 injection. Heart rate, 
blood pressure, and oxygenation were monitored throughout administration. Patients 
were asked to report side effects (dizziness, vomiting, abdominal discomfort) during 
injection and imaging. At the follow-up visits they were asked to report side effects. In 
three patients (numbers 4, 7, and 17) with recurrent PC an [18F]fluoromethylcholine PET/
CT scan was conducted. Written informed consent was obtained from all patients in 
accordance with German regulations for the administration of radiolabeled substances 
to humans. Data recording in a database was approved by all patients and by the local 
ethics committee. 
Imaging protocol 
All patients were scanned on a dual-modality PET/CT tomography scanner (Biograph 
duo; Siemens Medical Solutions). The CT component consists of a two-row spiral CT 
system and the PET component is based on a full-ring lutetium orthosilicate (LSO) PET 
system. Acquisition started 60–115 min pi. PC patients were requested to empty their 
bladder immediately before the PET/CT examination. They were positioned head first 
supine on the common patient handling system with the arms raised. 
First, a topogram was acquired over 1,024 mm axially. Coaxial whole-body imaging 
ranges were defined on the topogram, covering an area from the skull to the upper 
thighs. CT was performed in spiral mode using a continuous acquisition at 130 kVp, 
115 mAs, 4-mm collimation, 5-mm slice width, a table feed of 8 mm per rotation at 0.8-s 
rotation time, and 2.4-mm slice spacing. During the CT acquisition patients were asked 
to hold their breath in normal expiration. Three-dimensional PET emission scanning 
started in the caudocranial direction. An emission scan time of 2–3 min per bed position 
was used for all patients, with a total emission scan time of 24 min. 
Data acquisition and interpretation 
[68Ga]SB3 scans were acquired from July 2009 until March 2010. After scatter and 
attenuation correction, PET emission data were reconstructed using an attenuation-
weighted ordered subsets maximization expectation (OSEM) approach with two 
iterations, 8 subsets on 128 × 128 matrices and a 5- mm Gaussian postreconstruction 
filtering. 
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The CT images were evaluated on a Syngo viewing station by a skilled radiologist. Two 
experienced nuclear medicine physicians assessed the PET/CT images using E.soft 
(Syngo-based nuclear medicine software from Siemens Medical Solutions). Scintigraphic 
findings were compared with previous diagnostic examinations. [68Ga]SB3 scans were 
defined as positive when focal, not physiological, accumulation of the radiotracer was 
found. 
The maximum intensity projection (MIP) images were visually inspected and each single 
transversal slice was viewed from head to mid-thigh in combination with the CT image. 
Slice number and anatomical localization were recorded when focal and abnormal 
tracer uptake was found. PET/CT fusion images were used for measurements of SUVmax 
in different organs/structures. Manually selected regions of interest (ROIs) were drawn 
on a single slice using the software provided by E.soft. SUVmax was calculated for the 
following organs: pancreas, kidney parenchyma, esophagogastric junction (EGJ), blood 
activity (blood pool), liver, lung, kidneys, and gluteus muscle. 
RESULTS 
In vitro studies 
Both SB3 and [natGa]SB3 were able to displace [125I-Tyr4]BBN from GRPR sites on PC-3 
membranes in a monophasic and dose-dependent manner (Figure 2). Incorporation of 
Ga3+ favored receptor binding, as evident from the pertinent IC50 values of 4.6 ± 0.4 nM 
(SB3) and 1.5 ± 0.3 nM ([natGa]SB3). During 1-h incubation of [67Ga]SB3 with PC-3 cells 
at 37 °C, 22.2 ± 1.2 % of added radioactivity remained on the cell membrane, with only 
5.5 ± 0.4 % detected within the cells, as consistent with an antagonist profile [19, 24]. In 
the presence of excess [Tyr4]BBN, these values dropped to 1.5 ± 0.1 % and 0.4 ± 0.1 % 
respectively, suggesting GRPR specificity. 
Stability and biodistribution of [67Ga]SB3 in mice 
After entering the bloodstream of mice [67Ga]SB3 remained >85 % stable, as revealed by 
HPLC analysis of blood samples collected 5 min pi (Figure S3). This stability was found 
to be superior to previously reported values of GRPR-targeting radioligands [24–26]. 
The biodistribution of [67Ga]SB3 in SCID mice bearing human PC-3 xenografts is shown 
in Figure 3 for the 1-h, 4-h, and 24-h pi time points, with a separate 4-h animal group 
representing in vivo GRPR-blockade. The tracer rapidly cleared from blood, showing 
no retention in the kidneys. Likewise, background radioactivity declined with time, 
including GRPR-rich tissues, such as the mouse pancreas. In particular, the initially 
high pancreatic uptake of [67Ga]SB3 at 1 h pi (≈160% ID/g) gradually dropped at the 
later time points (≥100% ID/g at 4 h and ≈ 17% ID/g at 24 h pi), as consistent with a 
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GRPR radioantagonist profi le. Conversely, the uptake of [67Ga]SB3 in the GRPR-positive 
xenografts remained remarkably high over time (33.1±3.9%ID/g at 1 h pi, 34 ± 6.9% 
ID/g at 4 h pi, and 27.1 ± 0.9% ID/g at 24 h pi). Uptake in tumor and mouse pancreas 
was signifi cantly reduced in the animals treated with excess [Tyr4]BBN, confi rming GRPR 
specifi city. 
Figure 2 - Displacement of [125I-Tyr4]bombesin (BBN) from gastrin- releasing peptide receptor 
(GRPR) sites in PC-3 cell membranes by increasing concentrations of:  SB3 (IC50 = 4.6 ± 0.4 nM); 
 [natGa]SB3 (IC50 =1.5 ± 0.3 nM); reference:  [Tyr
4]BBN (IC50 =1.7 ± 0.0.3 nM). 
Results represent the average IC50 values ± SD of three independent experiments performed in 
triplicate.
Figure 3 – Biodistribution of [67Ga]SB3 in severe combined immunodefi ciency (SCID) 
mice bearing human GRPR-positive 140 PC-3 xenografts. Data are expressed as %ID/g and 
represent mean±SD, n=4, for  1 h,   4 h and  24 h pi; a separate  4-h animal group represents 
in 40 vivo GRPR-blockade. 
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Safety, tolerability, and physiological distribution of [68Ga]SB3 in patients 
No local or systemic adverse eff ects were found. During injection, one patient had 
high blood pressure (RR 180/130), most likely due to anxiety. In this patient, diastolic 
and systolic pressure returned to normal levels within 1 h. The highest physiological 
uptake of [68Ga]SB3 was found in the pancreas head (mean SUV 47.7). Mean SUVmax 
in the kidneys and at the EGJ was 5.4 and 3.3 respectively. High activity at the EGJ was 
previously described in preliminary clinical data with the GRPR agonist [68Ga]AMBA [27]. 
An overview of the biodistribution is found in Figure 4 (Supplemental table 2). 
Figure 4 - SUVmax ± SD in regions of interest (ROI) of [
68Ga]SB3 scans, including values for normal 
organs (n=17 patients) and for [68Ga]SB3-positive lesions in 9 patients. 
PET/CT results 
A total of 71 lesions in 9 patients with positive [68Ga]SB3 scans were recorded 
(Supplemental table 2). Mean SUVmax of these lesions in 9 patients was 4.2 (range 0.7–
17.8). Thirty-eight lesions in group 1 (BC) were positive, with a median SUVmax of 2.0 
(range 0.6–7.8). Thirty-three positive lesions in group 2 (PC) were positive, with a median 
SUVmax of 4.4 (range 1.7– 17.8; Figure 4; Supplemental tables 1-3). 
The characteristics of 8 BC and 9 PC patients injected with [68Ga]SB3 are presented in 
Tables 1 and 2 respectively. Four BC patients (50 %) and 5 of the 9 PC patients (55 %) 
had positive lesions visualized by [68Ga]SB3. Abnormal focal uptake on the [68Ga]SB3 
scan was seen in 2 patients. The fi rst patient showed uptake on the left side in the 
supraspinatus muscle (SUVmax 2.2) and proximal adductor muscles (SUVmax 2.4), which 
was attributed to local shoulder infl ammation. The second patient showed local uptake 
in the prostate (SUVmax 4.7), which was negative on other imaging modalities and 
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attributed to calcifi cations in this tissue. One patient showed exceptionally high uptake 
on the [68Ga]SB3 scan in several metastatic lymph nodes compared with the follow-up 
scan performed with [18F]fl uoromethylcholine (Figure 5). 
Figure 5 - Top [68Ga]SB3 PET/CT and bottom 18F-choline PET/CT scan in a prostate cancer (PC) 
patient (number 4), demonstrating GRPR-positive and choline-avid lymph node metastases 
respectively: right to the aortic bifurcation (B–D, straight arrow) and right iliac lymph node 
metastasis at the level of the S1 vertebra (E, F, curved arrow). A MIP; B, F fused axial PET/CT 
images; C, E axial CT images; D fused coronal PET/CT image. 
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The mean PSA level of PC patients was 64 ± 81 ng/mL (range 1.5–215 ng/mL). Four out 
of 5 patients with a positive [68Ga]SB3 scan had elevated PSA levels (≥10 ng/mL). One 
out of 4 patients with a negative [68Ga]SB3 scan had normal PSA levels (Table 2). 
Interestingly, osseous metastases could be well visualized in BC patients, as shown in 
Figure 6 for patient number 6. 
Table 2 - Characteristics and scan results in the subgroup of 9 prostate cancer (PC) patients 
Patient Age Final Initial Year of 
Previous therapy 
PSA [68Ga]SB3 
(number) (years) diagnosis stage diagnosis (ng/ml) scan
1 59 PC TxNxM1 2006 Rad, chem 89 +
4 74 PC T1N0M0 2003 Horm, nephr, rad 40 +
7 70 PC T4N1M0 2005 Prost, rad, horm, phos 182 +
10 70 PC T3N1Mx 2002 Prost, rad, chem 215 +
12 53 PC TxNxM1 2004 Lymph, horm 4 -
13 71 PC T4N0M0 2001 Prost, horm 2 -
15 61 PC T4NxM1 2006 Horm, rad, chem 32 -
16 54 PC TxNxM1 2009 Horm, phos 7 -
17 69 PC T3N0Mx 2004 Prost, rad 5 +
 
Figure 6 - [68Ga]SB3 scan in a breast cancer (BC) patient (number 6), demonstrating GRPR-
positive bone metastasis in the skull: frontal bone on the left side (B, SUVmax 2.4) and bone marrow 
metastasis in the right proximal femur (D, arrow, SUVmax 7.8), both negative on CT (C, E). A MIP; B 
fused axial PET/CT image; C, E axial CT images; D fused coronal PET/CT image. 
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DISCUSSION 
The overexpression of GRPR in PC and BC offers promising opportunities for staging, 
monitoring, and potentially also for radionuclide therapy of these tumors with the 
application of GRPR-specific radiopeptide probes [9, 10, 14, 17, 18]. A great number 
of GRPR-directed radioligands studied in the past two decades are analogs of BBN, 
displaying agonistic activity at the GRPR. While internalization of radiolabeled GRPR 
agonists was originally considered advantageous for in vivo tumor targeting, injection 
into patients was soon linked to undesirable pharmacological effects, raising biosafety 
concerns [21]. Recent studies on GRPR radioantagonists with better inherent biosafety 
have inadvertently brought to light their superior tumor targeting efficacy and faster 
background clearance compared with agonists. Based on the well- characterized GRPR 
antagonist, [99mTc]DB1 [19], we introduce here its DOTA-modified mimic, SB3, which can 
be labeled with 68Ga (Figure 1). We have thus designed a new 68Ga-radiotracer suitable 
for PET and complementary to the existing SPECT radiotracer [99mTc]DB1. In addition, 
we have evaluated the novel PET radiotracer first in in vitro and animal GRPR-positive 
models and then in BC and PC patients, following an integrated “bench-to-patient” 
approach. 
At the preclinical level, both SB3 and [natGa]SB3 exhibited high affinity for the human 
GRPR expressed on PC-3 cells (Figure 2). Moreover, [67Ga]SB3 strongly and specifically 
bound onto the membrane of PC-3 cells, internalizing poorly, as expected for a GRPR-
radioantagonist [19, 24]. Of great advantage is the stability of [67Ga]SB3 in the mouse 
blood- stream (Supplemental figure 3), favoring sufficient delivery to tumor sites, in 
contrast to the rapid in vivo catabolism previously reported for GRPR radioligands by 
neutral endopeptidase and possibly other enzymes [24, 26, 28]. High uptake of [67Ga]
SB3 was observed in PC xenografts in mice at 1 h pi (Figure 3), which remained at high 
levels up to 24 h pi. At the same time, values in the GRPR-rich mouse pancreas, although 
very high at the initial time points, declined rapidly over time. Likewise, back- ground 
radioactivity cleared rapidly over time, leading to an attractive overall profile. On the 
other hand, the tumor uptake of [67Ga]SB3 surpassed the values previously reported 
for [99mTc]DB1 in the same animal model at all time points [19]. Tumor retention in 
particular was clearly superior for [67Ga]SB3 (27.1±0.9%ID/g) compared with [99mTc]DB1 
(5.4±0.7%ID/g at 24 h pi). 
This attractive preclinical profile prompted us to further evaluate [68Ga]SB3 in a first-in-
man study including a small number of PC and BC patients. Several pilot clinical studies 
with GRPR radioligands have been reported, including both PC and BC patients [13, 
17, 21, 27]. However, most of these radioligands were BBN-based receptor agonists. A 
64Cu-labeled GRPR radioantagonist, 64Cu-CB-TE2A-AR06 [(64Cu-4,11-bis(carboxymethyl)-
1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)-PEG4-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-
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LeuNH2], was recently studied in four patients with newly diagnosed PC using PET/
CT. The radiotracer showed favorable tumor-to-normal organ ratios over time [29]. 
The most promising clinical results in 11 primary PC patients scheduled for radical 
prostatectomy were presented for the GRPR radioantagonist, [68Ga]BAY86-7548 (68Ga-
DOTA-4-amino-1-carboxymethyl-piperidine-DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-
NH2). Sensitivity and specificity of 88 % and 81 % were reported [30]. In the case of BC, 
no data have hitherto been provided on the diagnostic efficacy of a GRPR antagonist-
based radioligand in patients. Good diagnostic sensitivity was demonstrated in early-
stage BC patients during clinical evaluation of a series of 99mTc- radiotracers based on 
BBN, which were performed during the last decade [31–33]. In most of these studies, 
however, osseous involvement was not visualized, although the primary tumor and 
lymph node metastases were well visualized. 
In the clinical part of our study, we have included patients with progressive disseminated 
disease for the evaluation of uptake in tumor metastases. For example, bone metastases 
were well visualized in patient number 6 with BC (Figure 6), highlighting the promising 
imaging qualities of [68Ga]SB3. As our patients have a long history of recurrent disease, 
other (nuclear) imaging modalities were available and were additionally used for 
lesion detection. In one patient, [68Ga]SB3 clearly demonstrated better performance in 
comparison with [18F]fluoromethylcholine PET/CT (Figure 5). However, the total number 
of positive [68Ga]SB3 scans was lower compared with other studies, presumably as a 
result of recurrent, extensive disease history and previous therapies in our patients. 
It should be noted that GRPR is strongly upregulated in most of the primary prostate 
cancers that are still confined to the prostate, particularly in well-differentiated prostate 
tumors. On the other hand, a significant decline in GRPR expression is observed in the 
advanced androgen-independent stages of PC [9, 10, 12]. Recently, an inverse correlation 
was reported between GRPR expression vs high PSA values and high Gleason score [11]. 
Results were obtained from screening multiple prostate samples for GRPR expression 
in 530 patients, with most of the primary carcinoma specimens (77 %) acquired after 
radical prostatectomy. For BC, GRPR expression has been correlated with estrogen 
receptor levels [16, 34]. 
Despite the fact that all patients in our study had disseminated recurrent disease and 
many had a history of previous therapies, including anti-hormonal therapy, potentially 
leading to a state of androgen/estrogen independence and consequently to a higher 
number of negative scans with [68Ga]SB3, we still found positive scans in about 50 % of 
cases, both in BC and in PC. This indicates the potential value of GRPR as a biomarker 
for monitoring after therapy. A preclinical study in nude mice with xenografted BC did 
indeed demonstrate better visualization and monitoring of hormone treatment with 
the bombesin agonist 68Ga-AMBA vs 18F-FDG [35]. It is reasonable to assume that a 
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higher number of [68Ga]SB3 scans would have been positive in early BC and PC cases. 
This hypothesis is currently under investigation in a clinical study in patients with 
primary PC initiated at Erasmus MC. 
The benefi t of choline PET/CT was recently shown in the preoperative staging of PC 
patients with an intermediate or high risk of extracapsular disease, leading to a diff erent 
therapeutic treatment in 19 out of 130 patients (15 %) [36]. [68Ga]SB3 could be used 
in addition to conventional imaging for upstaging nearby lymph nodes and/or distant 
metastases. In patients with local recurrent PC, choline PET/CT can be used to delineate 
local sites of recurrence. However, irradiation planning for the treatment of single 
lymph node metastases on the basis of choline PET/CT remains controversial owing 
to its limited lesion-based sensitivity in primary nodal staging [37]. Furthermore, the 
detection rate of choline-PET/ CT is poor in patients with low PSA levels (<3.0 ng/ml) 
[37]. PET/CT with [68Ga]SB3 may be valuable in this group of PC patients and could 
improve radiation treatment planning by enhancing the target volume to, for example, 
lymphatic drain- age sites. 
Prostate-specifi c membrane antigen (PSMA) is another interesting target for imaging. 
PSMA is expressed in normal and malignant prostatic epithelium with high expression 
in poorly diff erentiated metastatic carcinomas [38, 39]. Small molecule PSMA inhibitors 
demonstrated good imaging characteristics in patients with androgen-independent PC 
with bone metastasis, but have a lower sensitivity in patients with primary PC [40]. GRPR 
expression, on the other hand, is higher in the early stages of PC, in contrast to PSMA 
(Figure 7). A comparative study of [68Ga]SB3 and a PSMA-targeted PET radiotracer in 
patients with primary or recurrent PC would therefore be of utmost interest for further 
evaluation and clinical use. 
Figure 7 - Graphical representation of imaging characteristics for gastrin- releasing peptide 
receptor (GRPR) and prostate-specifi c membrane antigen (PSMA) in PC as a function of histological 
diff erentiation grade and androgen receptor (AR) expression. 
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CONCLUSION 
We introduce here a new GRPR antagonist suitable for labeling with 68Ga. Preclinical 
experience with the [67Ga]SB3 surrogate revealed the most attractive radiotracer 
qualities, such as high GRPR-affinity, good in vivo stability, and excellent targeting 
efficacy in human GRPR-positive xenografts in mice. First clinical data with [68Ga]SB3 
PET/CT in patients with disseminated PC and BC showed encouraging results, as lesions 
were visualized in about 50 % of the patients, despite their advanced disease. The 
number of positive [68Ga]SB3 scans is expected to be higher in patients with primary PC 
and BC. This prospect favors the application of [68Ga]SB3 as an attractive tool for PC and 
BC staging, monitoring, and eventually patient stratification for radionuclide therapy 
with [177Lu/90Y/213Bi]SB3.
SUPPLEMENTAL DATA
Preparation of [natGa]SB3 
SB3 (600 μg) was incubated with a threefold molar excess of natGa(NO3)3·9H2O (Alfa-
Ventron) in acetate buffer (pH 4) at 90 oC 30 min. The excess natGa was then scavenged 
by addition of EDTA. Complete natGa-metalation of SB3 was verified by analytical HPLC, 
performed on a Waters Chromatograph coupled to a 996 photodiode array UV detector 
(Waters) and a Gabi gamma detector (Raytest RSM Analytische Instrumente GmbH). For 
analysis, an XBridge Shield RP18 (5 μm, 4.6 mm × 150 mm, Waters) cartridge column 
coupled to the respective 2-cm guard column was used. The column was eluted at 1 
mL/min flow rate with a linear gradient of 0.1% aqueous trifluoroacetic acid (TFA) 
solution and acetonitrile (MeCN), starting from 20% MeCN with 1% increase of MeCN/
min; tR(SB3) = 15.4 min and tR([
natGa]SB3) = 16.2 min. 
Preparation of [125I-Tyr4]BBN 
[Tyr4]BBN (PSL GmbH) and 125I (MDS Nordion) were used for the preparation of [125I- Tyr4]
BBN. Radioiodination was performed by the chloramine-T methodology, as previously 
described [41,42]. The forming sulfoxide (Met14=O) was reduced by dithiothreitol and 
[125I- Tyr4]BBN was isolated in non-carrier added form by HPLC. Methionine was added to 
the purified radioligand solution to prevent re-oxidation of Met14 to the corresponding 
sulfoxide and the resulting stock solution in 0.1% BSA-PBS was kept at −20 °C; aliquots 
thereof were used for competition binding assays (specific activity of 2.2 Ci/μmol). 
Samples were measured for radioactivity in an automatic well-type gamma counter 
(NaI(Tl)] crystal, Canberra Packard Auto-Gamma 5000 series instrument). 
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Preparation and Quality Control of [67/68Ga]SB3 
Lyophilized SB3 was dissolved in HPLC-grade H2O (2 mg/mL) and 50 μL aliquots thereof 
were stored in Eppendorf Protein LoBind tubes at –20 °C. For labeling, 67GaCl3 in dilute 
HC1 at an activity concentration of 18.4–27.5 GBq/mL was provided by (MDS Nordion). 
[67Ga]SB3 was obtained at specific activities of 3.7–7.4 MBq 67Ga/nmol SB3. Briefly, 3–15 
nmol of SB3 were mixed with 50–150 μL of 1 M pH 4.0 sodium acetate buffer and 5–15 μL 
of 67GaCl3 (11–111 MBq). The mixture was incubated at 90 oC for 30 min and Na2-EDTA 
(0.1 M, pH 4.0) was added to a final concentration of 1 mM. For HPLC analysis, elution 
with a linear gradient was applied with 0.1% TFA/MeCN, starting from 20% MeCN and a 
0.5% increase per min at 1 mL/min flow rate. 
The radiochemical labeling yield (RCY) exceeded 98% and the radiochemical purity 
(RCP) of [67Ga]SB3 was >99% (Supplemental figure 1). 
Supplemental figure 1 - Radioanalytical trace of [67Ga]SB3 labeling reaction mixture by HPLC 
(the radiopeptide tR is indicated by the arrow). 
All reagents used for the preparation of [68Ga]SB3 were purchased from commercial 
sources. Cartridges used for separation chemistry were bought from Varian and solutions 
were prepared with ultrapure water (Merck). All experiments were performed with a 
68Ge/68Ga generator from Obninsk (Eckert & Ziegler Europe) or an IGG100 68Ge/68Ga 
generator (Eckert & Ziegler Europe) eluate. [68Ga]SB3 was prepared using either the 
cation-exchange method in hydrochloric acid/acetone [43] or the NaCl based method 
[S4]. In the first method [44], the SCX cartridge (Varian, Bond Elut-SCX, 100 mg, 1 mL) 
was preconditioned with 1 mL 5.5 M HCl and 10 mL water prior to the elution step. In 
the NaCl based method [44], the 68Ge/68Ga generator was eluted with 0.1 M HCl (10 mL 
in total) and 68Ga was collected almost quantitatively on a SCX cartridge. The activity 
was eluted, with minimal loss (1-2%), using a mixture of 12.5 μL of 5.5 M HCl and 500 μL 
of 5 M NaCl (Ultrapur, Merck) into a solution of 400 μL 1 M ammonium acetate buffer 
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(pH 4.5), 40 μg of SB3, and 3.0 mL water. The end pH was 3.7 ± 2. The reaction was 
completed after heating the solution for 7 min at 90 °C. A final purification step using 
a C-18 solid phase extraction cartridge was not needed. The RCY after sterile-filtration, 
expressed as percentage of the activity originally present and not decay-corrected, 
was approximately 65%. The final product was neutralized with 2 mL of sterile sodium 
phosphate buffer (Braun) and then diluted for dose administration. 
Supplemental figure 2 - Radioanalytical HPLC of [68Ga]SB3 labeling reaction mixture (the 
radiopeptide tR is indicated by the arrow).
Supplemental figure 3 - Radiochromatogram of HPLC analysis of mouse blood collected 5 min 
pi of [67Ga]SB3 (>85% detected intact); the tR of the parent radiopeptide is indicated by the arrow.
The quality control combined TLC and HPLC methods. For TLC, ITLC-SG strips (Varian) 
were run using MeCN/H2O 1:1 as mobile phase. For HPLC analyses the system applied 
included a Jasco PU-1580 pump of a quaternary gradient unit (Jasco LG-1580-04), a 
gamma detector (Biostep IsoScan LC) and a multi-wavelength detector (Jasco MD 
1510). A RP-18 column (LiChroCART 250-4, LiChrospher 100, RP-18e; 5 μm, 250 mm × 4 
mm was eluted at 1.2 mL/min with the following gradient system: from 0-2 min 100% 
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A, 2-15 min to 100% B, whereby A: 0.1% TFA in 5/95 MeCN/H2O and B: 0.1% TFA in 95/5 
MeCN/H2O. The RCP, as determined by HPLC and expressed as the percentage of activity 
in the [68Ga]SB3 peak versus total activity, was >99%. As shown in Supplemental figure 
2, the main peak for [68Ga]SB3 eluted at tR 10.0 min, whereas no free 
68Ga (tR 2.3 min) was 
detected. 
HPLC Analysis of Mouse Blood Samples 
[67Ga]SB3 was injected as a 100 μL bolus (11-22 MBq, 3 nmol total peptide) in the tail 
vein of male Swiss albino mice (30 ± 5 g, NCSR “Demokritos” Animal House Facility). 
Mice were anesthetized and blood (0.5-1 mL) was collected from the heart at 5 min post 
injection (pi). Blood samples were prepared for HPLC analysis, as previously described 
[45]. The Symmetry Shield RP18 (5 μm, 3.9 mm × 20 mm) column was eluted at a flow 
rate of 1.0 mL/min with the following gradient: 100% A to 90% A in 10 min and from 
90% A to 60% for the next 60 min; (A= 0.1% aqueous TFA (v/v) and B = MeCN). The 
position of the intact radiopeptide was determined by coinjection with the [67Ga]SB3 
reference in the HPLC. The amount of [67Ga]SB3 detected intact at 5 min pi in mouse 
circulation exceeded 85% (Supplemental figure 3). 
Patient Data and Scan Results 
Patient selection and characteristics are summarized in Supplemental table 1. 
An overview of the SUVmax biodistribution of [
68Ga]SB3 in 17 patients is found in 
Supplemental Table 2, whereas the localization of [68Ga]SB3 positive lesions in 9 patients 
is listed in Supplemental Table 3. 
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Supplemental table 2 - SUVmax biodistribution in 17 patients injected with [
68Ga]SB3.
Organ Mean SUVmax
Standard 
deviation
Range
Pancreas  
- Head 48.7 22.2 14.7 – 90.9
- Corpus 43.8 23.0 6.4 – 84.5
- Tail 41.6 22.2 5.5 – 78.7
Kidneys (Parenchyma) 5.4 1.2 3.5 – 5.1
Oesophagogastric junction (OGJ) 3.5 0.8 2.1 – 5.1
Blood activity (Blood pool) 2.6 0.6 1.7 – 4.1
Liver 1.9 0.5 1.0 – 2.9
Lung 0.7 0.2 0.3 – 1.1
Background (M. Gluteus) 0.6 0.3 0.2 – 1.2
[68Ga]SB3 positive lesions (n=71 in 9 patients) 3.7 3.2 0.6-17.8
Supplemental table 3 - Localisation of 71 [68Ga]SB3 positive lesions  in 4 patient with breast 
cancer (BC) and 5 patients with prostate cancer (PC).
Organ
Number of positive lesions in
Group 1 BC Group 2 PC
Skull 2 0
Thorax 3 0
Liver 4 0
Abdomen 2 0
Lymph nodes 3 16
Skeletal lesions 24 17
Total lesions 71
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SUMMARY 
Neuroendocrine tumors (NET) are rare neoplasms with differences in clinical 
presentation, course and prognosis. The age-adjusted incidence varies between 3-6 
new cases per 100.000 persons per year (1). Most of the NETs express the somatostatine 
receptor, which can be utilized for imaging and therapy. Radiolabelled somatostatin 
analogs (like 111Indium-DTPA0]octreotide, OctreoScan®) bind to the somatostatin 
receptor and the emitted gamma-rays can be detected by an positron (PET) or photon 
emission computed tomography (SPECT) scanner). 
Radiolabeled somatostatin analogs can also be used for peptide receptor radionuclide 
therapy (PRRT) in NET patients. In the ’90, PRRT with high amounts of 111In-octreotide 
was administered to NET patients, resulting in an improvement of quality of life. 
However, tumor response rates were low and serious side effects were reported in 
patients receiving PRRT with 111In-octreotide. However, the new DOTA chelators enabled 
the use of other radionuclides, like 90Yttrium (90Y) and 177Lutetium (177Lu). Since 2000, NET 
patients are treated with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE). Other medical 
centers started using 90Y based somatostatin analogs, like [90Y-DOTA0,Tyr3]octreotide 
(90Y-octreotide).
Other tumors also have receptors that can be used for imaging and therapy. Prostate 
and breast cancer express the Gastrin-releasing Peptide Receptor (GRPR) on the cell 
surface. The radiolabelled Gastrin-Releasing Peptide (GRP) has a high affinity with the 
membrane receptor (GRPR) and can be used for imaging. In the future, radiolabeled GRP 
analogs might be used for PRRT in patients with extensive metastasized breast- and 
prostate cancer, in analogy to PRRT in NET patients. 
In this thesis, the most important (long-term) side effect after PRRT with 177Lu-DOTATATE 
will be discussed (Chapter 2). Furthermore, a first-in-man clinical evaluation of a new 
radiolabelled GRP compound with (68Gallium, 68Ga), [68Ga]SB3, will be presented in 
patients with metastasized prostate- and breast-cancer (Chapter 3)
Chapter 1.1 is an introduction to NETs containing epidemiology, diagnostics and 
different treatment options. Also an overview is presented regarding dosimetry for 
PRRT and the clinical parameters for assessment of the side effects.
Chapter 1.2 is an overview of the current literature on PRRT. In the past 20 years, 
PRRT with radiolabeled somatostatin analogs has been administered to patients 
with somatostatin receptors positive tumors. In the department of nuclear medicine 
& radiology at the Erasmus MC, PRRT with 177Lu-DOTATATE have been successfully 
administered in NET patients resulting in a complete and partial remission of 30%. In 
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general, PRRT is well tolerated, however the kidneys and bone marrow are the most 
important dose limiting organs.
177Lu-DOTATATE is mainly excreted by and partially reabsorbed in the kidneys, which 
can cause radiation damage to the glomeruli (renal filters). Therefore amino acids are 
given during PRRT to reduce the absorption of 177Lu-DOTATATE in the kidneys. Despite 
administration of amino acids during PRRT, an annual loss of renal function can be 
observed, particular in patients with diabetes mellitus, hypertension and alkylating 
chemotherapy in the past (2,3). In Chapter 2.1, the incidence of renal toxicity, associated 
risk factors (like hypertension, diabetes mellitus, administered dose and radiation 
dose to the kidneys) and renal function during follow-up was analyzed in 209 patients 
treated with 177Lu-DOTATATE. Also the radiation dose to the kidneys was calculated 
and compared with the accepted dose limits adopted from radiotherapy. A non-linear 
effect regression model was used for assessment of the risk factors. Only 1% of the 
treated patients had a grade 2 renal toxicity, no grade 3-4 renal toxicity was observed. 
The annual decline in renal function was 3.4 ± 0.4%. No risk factors could be identified 
which had a significant effect on the fitted non-linear model. The mean radiation dose 
to the kidneys was 20.1 ± 4.9 Gy. In the radiotherapy, the maximum accepted dose to 
the kidneys is 18 Gy.
In conclusion, the incidence of renal toxicity in patients treated with 177Lu-DOTATATE 
is low and no grade 3-4 renal toxicity is observed. Moreover, no patients had a annual 
decline in renal function of more than >20%. Our data supports the idea that the radiation 
dose threshold, adopted from external beam radiotherapy and PRRT with 90Y-labelled 
somatostatin analogues, does not seem valid for PRRT with 177Lu-DOTATATE.
Irradiation and damage to the bone marrow after PRRT with 177Lu-DOTATATE lead to 
hematological toxicity (decrease in cell count). In Chapter 2.2 (sub)acute hematological 
toxicity after PRRT is outlined in 320 patients treated with 177Lu-DOTATATE. First of 
all, the incidence and duration of hematological toxicity (according to CTCAE v3.0) is 
discussed and risk factors assessment is performed. Also the mean radiation dose to 
the bone marrow per administered 177Lu-DOTATATE is calculated, based on 32 patients 
with individualized dosimetry. The median radiation dose to the bone marrow of 320 
patients is compared to the accepted dose limit of 2 Gy, adopted from patients treated 
with radioiodine (131I). Thirty-four (11%) patients developed grade 3-4 hematological 
toxicity, including 15 patients with hematological toxicity for more than 6 months 
or required blood transfusions. The risk factors associated with hematological 
toxicity are: low renal function, advanced age (> 70 years), decreased WBC count (< 
4.0·109/l), metastasized disease and high tumor uptake on OctreoScan®. Surprisingly, 
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previous treatment with chemotherapy was not associated with grade 3-4 (sub)acute 
hematological toxicity, while other studies identified previous chemotherapy as a risk 
factor (3-5). A possible explanation for this difference could be given by the fact that we 
have a limited number of patients in our study with previous chemotherapy in the past. 
The average radiation dose to the bone marrow was 67 ± 7 mGy/GBq, which is equal to 
a cumulative bone marrow dose of 2 Gy when four cycles of 7.4 GBq 177Lu-DOTATATE are 
given. Hematological toxicity after PRRT with 177Lu-DOTATATE is mild, however patients 
with associated risk factors are at risk. The BM dose upper limit of 2 Gy, adopted from 131I 
therapy, seems not to be valid for PRRT with 177Lu-DOTATATE. 
Long-term side effects of the bone marrow after PRRT with 177Lu-DOTATATE are identified 
by the rise in hematological neoplasms. Myelodysplastic syndrome (MDS) and acute 
myeloid leukemia (AML) are the most frequently found hematological neoplasms after 
irradiation. MDS and AML are acquired in only 2-3% of the patients treated with PRRT, 
however the exact mechanisms and correlations are ambiguous. Several factors that 
might contribute to the development of MDS after PRRT with 177Lu-DOTATATE are; AML, 
cumulative administered activity, duration/number of PRRT treatments, CTCAE toxicity 
grade during PRRT in hemoglobin, platelets and white blood cells (3). Chapter 2.3 
deals with the incidence, course and predicting factors in patients with (suspicion of ) 
hematological neoplasms after PRRT with 177Lu-DOTATATE. Based on data from the Dutch 
cancer registration, the expected number of ‘de novo’ hematological neoplasms is 3 
patients. Eight (2%) patients were diagnosed with hematological neoplasms, according 
to the World Health Organization (WHO) (6) and 5 (1.5%) patients with bonemarrow 
failure (not classified according to WHO). The relative risk for developing hematological 
neoplasms after PRRT in GEP-NET patients is 3.6 times higher than without treatment. 
The median latency time of hematological neoplasms is 41 (range 15 – 84) months after 
the last PRRT cycle in GEP-NET patients. Sub acute hematological toxicity grade 3 or 
4 during PRRT is a marginally significant risk factor for the development of persistent 
hematological dysfunction after PRRT.
The spleen is the only lymphoid organ, since it is directly connected to the main blood 
circulation, which receives a high radiation dose during PRRT. The clinical consequences 
of this exposure to radiation are unknown. Therefore, Chapter 2.4 discusses the change 
in spleen size and the blood cell counts after (re)treatment with 177Lu-DOTATATE. In 35 
patients, treated with a cumulative injected dose of 45 GBq 177Lu-DOTATATE, spleen 
volumes were measured at baseline and during follow-up. The radiation dose to the 
spleen was calculated in 27 patients, according to Medical Internal Radiation Dose 
(MIRD) scheme. The spleen was significantly smaller (55%) after the first and the second 
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series of PRRT cycles compared to baseline volumes. The median absorbed dose to the 
spleen was 52 (range 23 – 110) Gy. No minimal dose threshold was observed for spleen 
reduction. In all patients, a reduction in white blood cell count was observed after PRRT 
with 177Lu-DOTATATE. No correlation was found for: absorbed spleen dose, number 
of white blood cells, number of lymphocytes and/or spleen volume. None of the 
patients had an infection with a specific group of bacteria (Streptococcus pneumoniae, 
Haemophilus influenzae type B, Neisseria meningitidis).
In analogy with PRRT in NET patients, PRRT can also be used in other tumor types. 
Prostate carcinoma is the most common cancer in men, whereas for women breast 
cancer has the highest incidence rate. Chapter 3.1 gives an introduction regarding 
targeted nuclear imaging and therapy in prostate- and breast cancer. The two tumors 
types express the Gastrin-Releasing Peptide Receptor (GRPR) on the cell membrane. 
Therefore, GRPR is an attractive molecular target for complementary radioligands. 
Preclinical studies demonstrated better imaging characteristics for GRPR antagonists, 
like [99mTc]DB1, in comparison to GRPR agonists (7,8). Moreover, GRPR antagonists have 
a higher inherent safety profile, since they do not elicit pharmacological effects after 
binding. In chapter 3.2 we present a different version of [99mTc]DB1, namely [68Ga]SB3, 
which is investigated in a (pre)clinical setting. Competitive- and bindings experiments 
on PC-3 cel membranes demonstrated a high affinity of SB3 with the humanlike GRP 
receptor. There was good in vivo stability and long tumor retention of the radioligand in 
mice. After the encouraging preclinical results, [68Ga]SB3 was administered to 17 patients 
with extensive prostate- and breast cancer. Uptake of [68Ga]SB3 was the highest in the 
GPRR-rich pancreas. [68Ga]SB3 PET scans were positive in 4 out of 8 patients with breast 
cancer and 5 out of 9 patients with prostate cancer. In one patient with prostate cancer, 
uptake on [68Ga]SB3 PET/CT was higher than 18F-choline PET/CT. In conclusion, good 
visualization of the tumor lesions was possible with [68Ga]SB3 in 50% of the patients 
with metastasized prostate- and breast-cancer. Therefore [68Ga]SB3 can be a potential 
candidate for stage and monitoring of patients with prostate- or breast cancer. 
Chapter 4.2 is the final chapter of this thesis in which new developments and future 
perspectives are discussed regarding PRRT in patients with NET, prostate cancer and 
breast cancer. 
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SAMENVATTING
Neuroendocriene tumoren (NETs) zijn zeldzame tumoren met grote verschillen in 
presentatie, beloop en prognose. De incidentie ligt tussen de 3-6 nieuwe gevallen per 
100.000 inwoners per jaar (1). Het grootste gedeelte van de NETs hebben somatostatine 
receptoren op hun celoppervlak en deze kunnen gebruikt voor beeldvorming en 
therapie. Radioactief gelabelde somatostatine analogen (zoals 111Indium-DTPA0]
octreotide, OctreoScan®;) binden aan de somatostatine receptor en de uitgezonden 
gammastralen kunnen worden gebruikt voor beeldvorming van NETs. Naast visualisatie 
van NETS is tevens therapie mogelijk met radioactief gelabelde somatostatine 
analogen, wat ook wel bekend staat onder de naam Peptide Receptor Radionuclide 
Therapie (PRRT). Tussen 1990-2000 werd PRRT met hoge dosis 111In-octreotide gegeven 
bij patiënten met NETs en dit resulteerde in een verbetering van klachten. Echter, de 
bijwerkingen waren fors en de mate van tumorverkleining teleurstellend. Door het 
gebruik van een ander verbindingsmolecuul (een DOTA chelator i.p.v. DTPA) werd het 
mogelijk om andere radionucliden te gebruiken, zoals 90Yttrium (90Y) en 177Lutetium 
(177Lu). Vanaf 2000 wordt PRRT in Rotterdam verricht met [177Lu-DOTA0,Tyr3]octreotaat 
(177Lu-DOTATAAT). 90Y gebaseerde somatostatine analoga, zoals [90Y-DOTA0,Tyr3]
octreotide, worden meer gebruikt in andere centra.
Ook andere soorten tumoren hebben receptoren die gebruikt kunnen worden voor 
beeldvorming en therapie. Prostaat- en borst tumoren brengen onder andere de 
Gastrin-Releasing Peptide Receptor (GRPR) tot expressie op het celoppervlak. Het 
radioactief gelabelde Gastrin-Releasing Peptide (GRP) bindt in hoge mate aan de 
membraan receptor GRPR en kan waardevol zijn voor het visualiseren van prostaat- en 
borstkanker. Wellicht zou het mogelijk zijn om radioactieve GRP analogen te gebruiken 
voor therapie bij uitgebreide gemetastaseerde borst- en prostaatkanker, in analogie 
met PRRT voor NET patiënten. 
 
In dit proefschrift worden de belangrijkste korte en lange termijn bijwerkingen van 
PRRT met 177Lu-DOTATAAT beschreven (Hoofdstuk 2). Daarnaast beschrijven we de 
eerste resultaten van een nieuw radioactief (68Gallium, 68Ga) gelabeld GRP radioligand, 
genaamd [68Ga]SB3, bij patiënten met gemetastaseerde prostaat- en borstkanker 
(Hoofdstuk 3). 
Hoofdstuk 1.1 is een algemene inleiding over NETs, inclusief bespreking van de 
epidemiologie, diagnostiek en de verschillende behandelingen. Daarnaast wordt 
een overzicht gegeven van de stralingsmodellen voor PRRT en belangrijke klinische 
parameters voor bijwerkingen. Hoofdstuk 1.2 geeft een overzicht van de literatuur over 
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PRRT. In de afgelopen 20 jaar is PRRT met gelabelde somatostatine analoga toegepast  bij 
patiënten met somatostatine receptor-positieve tumoren. Op de afdeling Radiologie  & 
Nucleaire Geneeskunde van het Erasmus MC wordt PRRT met 177Lu-DOTATAAT succesvol 
toegepast bij patiënten met NETs met een kans op complete en partiële remissies van 
30%. Over het algemeen wordt PRRT goed verdragen, echter de nieren en beenmerg 
zijn de belangrijkste dosis-limiterende organen.  
De nieren zijn belangrijk voor het uitscheiden van de toegediende 177Lu-DOTATAAT uit 
het lichaam, dit kan echter stralingsschade aan de glomeruli (nierfilters) veroorzaken, 
omdat de nieren het radiopeptide ook opnemen in bepaalde cellen. Er worden daarom 
aminozuren toegediend tijdens de PRRT om de absorptie van 177Lu-DOTATAAT in de 
nieren te verminderen. Ondanks de toediening van de aminozuren tijdens PRRT kan er, 
met name bij patiënten met slecht gereguleerde diabetes mellitus (suikerziekte), hoge 
bloeddruk en alkylerende chemotherapieën in de voorgeschiedenis, een belangrijk 
jaarlijks verlies van nierfunctie ontstaan (2,3). Hoofdstuk 2.1 beschrijft de incidentie 
van niertoxiciteit, geassocieerde risicofactoren (o.a. hypertensie, diabetes mellitus, 
toegediende dosis en stralingsdosis op de nieren) en de nierfunctie tijdens follow-up in 
209 patiënten behandeld met 177Lu-DOTATAAT. Tevens is de stralingsdosis op de nieren 
berekend en vergeleken met de geaccepteerde dosislimieten in de radiotherapie. Een 
“non-linear effect regression model” is gebruikt om de risicofactoren te onderzoeken. 
De eerste bevinding was dat in slechts 1% van de behandelde patiënten een  graad 2 
nier-toxiciteit voorkwam en er werd geen graad 3 of 4 nier-toxiciteit geobserveerd. De 
jaarlijkse percentuele vermindering in nierfunctie was 3.4 ± 0.4%. Daarnaast konden 
er geen risicofactoren worden geïdentificeerd die een significant effect hadden op het 
gebruikte niet-lineaire model. De gemiddelde stralingsdosis op de nieren was 20.1 ± 4.9 
Gy. In de radiotherapie is de geaccepteerde dosislimiet op de nieren 18 Gy .   
We concludeerden dat de incidentie van nierschade bij patiënten behandeld met 177Lu-
DOTATAAT laag is en dat er geen graad 3 of 4 nier-toxiciteit is geobserveerd. Tevens 
waren er geen patiënten met een jaarlijkse nierfunctiedaling van >20%. Ons onderzoek 
ondersteunt de hypothese dat de bekende en vastgestelde stralingsdosisgrenzen uit de 
radiotherapie niet van toepassing zijn voor PRRT met 177Lu-DOTATAAT.
Hematologische (beenmerg en bloedcellen) toxiciteit na PRRT met 177Lu-DOTATAAT is 
het gevolg van bestraling en schade aan het beenmerg. In Hoofdstuk 2.2 wordt dieper 
ingegaan op de (sub)acute hematologische toxiciteit na PRRT met 177Lu-DOTATAAT bij 
320 patiënten. Ten eerste wordt de incidentie en duur beschreven van hematologische 
toxiciteit volgens CTCAE v3.0 en worden geassocieerde risicofactoren onderzocht. 
Tevens wordt er een gemiddelde stralingsdosis naar het beenmerg per toegediende 
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hoeveelheid 177Lu-DOTATAAT berekend op basis van individueel berekende 
stralingswaarden bij 32 patiënten. De gemiddelde stralingsdosis van de gehele 
groep patiënten wordt vergeleken met de gangbare dosis norm op het beenmerg 
van 2 Gy bij patiënten behandeld met radioactief Jodium-131. Vierendertig (11%) 
patiënten ontwikkelden hematologische graad 3 en/of 4 toxiciteit, waarbij bij 15 van 
de 34 patiënten de toxiciteit langer dan 6 maanden duurde, of er noodzaak ontstond 
om bloedtransfusies te geven. De risicofactoren geassocieerd met hematologische 
toxiciteit zijn: slechte nierfunctie, leeftijd (> 70 jaar), verminderd aantal witte 
bloedcellen (< 4.0·109/l), uitgebreid gemetastaseerde ziekte en hoge tumoropname op 
OctreoScan®. Verwonderlijk is dat voorgaande behandelingen met chemotherapie niet 
geassocieerd zijn met graad 3-4 (sub)acute hematologische toxiciteit, terwijl dit door 
andere onderzoeksgroepen wel is beschreven (3-5). Een verklaring hiervoor kan zijn 
dat een beperkt aantal patiënten in onze studie chemotherapie in de voorgeschiedenis 
heeft ontvangen. In onze studie is de gemiddelde stralingsdosis op het beenmerg 67 
± 7 mGy/GBq, dit komt neer op  een beenmerg dosis van 2 Gy wanneer vier cycli van 
7.4 GBq 177Lu-DOTATAAT worden toegediend. Bovenstaande onderzoeksresultaten 
onderstrepen dat de (sub)acute hematologische toxiciteit na PRRT met 177Lu-DOTATAAT 
aanvaardbaar is, echter patiënten met risicofactoren hebben een verhoogde kans op 
hematologische toxiciteit. De gebruikelijke beenmerg dosislimiet van 2 Gy lijkt hierdoor 
niet van toepassing op PRRT met 177Lu-DOTATAAT. 
Lange termijn effecten op het beenmerg door PRRT uiten zich door het ontstaan van 
hematologische neoplasmata. De twee meest voorkomende zijn myelodysplastisch 
syndroom (MDS) en Acute myeloïde leukemie (AML). Zij worden slechts gezien bij  2-3% 
van de behandelde patiënten. De precieze mechanismen en risicofactoren in relatie tot 
PRRT blijven echter onbegrepen. Enkele mogelijke factoren voor het ontstaan van MDS 
na PRRT met 177Lu-DOTATAAT zijn: acute leukemie, cumulatieve geïnjecteerde activiteit 
en duur/aantal behandelingen PRRT, toxiciteit graad in hemoglobine, bloedplaatjes 
en witte bloedcellen (3). Hoofstuk 2.3 behandelt de incidentie, het beloop en de 
voorspellende factoren van patiënten met (verdenking op) hematologische neoplasmata 
na PRRT met 177Lu-DOTATAAT. Op basis van cijfers uit de Nederlandse kankerregistratie 
(NKR) verwachten we 4.3 patiënten met een ‘de novo’ hematologische maligniteit. Er 
waren 8 (2%) patiënten gediagnosticeerd met hematologische maligniteit volgens de 
World Health Organization (WHO) (6) en 5 (1.5%) patiënten met langdurig beenmerg 
falen zonder WHO classificatie. Het relatieve risico op het krijgen van hematologische 
neoplasmata na PRRT is 3.6 keer hoger dan zonder behandeling. De mediane latente 
periode van hematologische neoplasmata ligt op 36 (bereik 5 - 84) maanden na laatste 
PRRT behandeling. Subacute hematologische toxiciteit graad 3 of 4 tijdens PRRT met 
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177Lu-DOTATAAT is de enige marginale risicofactor geassocieerd met het ontstaan van 
hematologische neoplasmata na PRRT.   
De milt is het enige lymfoïde orgaan dat, gezien het direct op de bloedcirculatie is 
aangesloten, een hoge stralingsdosis ontvangt tijdens PRRT behandeling. De klinische 
consequenties voor deze hoge blootstelling aan straling zijn onbekend. Daarom is 
Hoofstuk 2.4 gewijd aan de verandering in miltgrootte en bloedwaarden na (her)
behandeling met PRRT. Bij 35 patiënten behandeld met een cumulatief geïnjecteerde 
dosis van 45 GBq 177Lu-DOTATAAT werd het miltvolume opgemeten en op verschillende 
tijdstippen vervolgd. De stralingsdosis op de milt werd berekend in 27 patiënten 
volgens het Medical Internal Radiation Dose (MIRD) schema. De milt was evident 
(55%) kleiner geworden na de eerste serie behandelingen PRRT en na een tweede 
serie herbehandelingen ten opzichte van het volume vooraf aan PRRT. De mediaan 
geabsorbeerde dosis naar de milt was 52 (bereik 23 – 110) Gy en er leek geen minimale 
drempelwaarde voor de 177Lu-DOTATAAT dosis te zijn voor miltreductie. Bij alle patiënten 
trad er een verlaging op van het aantal witte bloedcellen na behandeling. Er werd geen 
onderlinge relatie aangetoond tussen: geabsorbeerde miltdosis, verlaging van aantal 
witte bloedcellen, aantal lymfocyten en/of miltgrootte. Geen van de onderzochte 
patiënten had een infectie met een bepaalde groep bacteriën (Streptococcus 
pneumoniae, Haemophilus influenzae type B, Neisseria meningitidis).
Naar analogie van PRRT bij NET-patiënten kan de therapie tevens worden gebruikt bij 
andere tumoren. Prostaat kanker is bij mannen de meest voorkomende ziekte en bij 
vrouwen is dit borstkanker. Hoofdstuk 3.1 geeft een introductie over doelgerichte 
nucleaire beeldvorming en therapie bij prostaat- en borstkanker. Beide type 
tumoren brengen de Gastrin-Releasing Peptide Receptor (GRPR) tot expressie op het 
celoppervlak. Hierdoor is de GRPR een aantrekkelijk doelwit waar radioliganden voor 
gemaakt kunnen worden. Onderzoek heeft aangetoond dat beeldvorming met GRPR 
antagonisten, zoals [99mTc]DB1, beter is dan met GRPR agonisten (7,8). Daarnaast zijn 
GRPR antagonisten veiliger, omdat ze geen farmacologische effecten veroorzaken 
na binding. In Hoofdstuk 3.2 wordt een variant van [99mTc]DB1, genaamd [68Ga]SB3, 
beschreven, die in preklinische en klinische onderzoeken onderzocht is. Competitie en 
bindingsexperimenten op PC-3 celmembranen toonden een hoge affiniteit van SB3 met 
de menselijke GRPR. Er was een goede in vivo stabiliteit en langdurige tumorretentie 
van het radioligand bij muizen. Na de gunstige preklinische resultaten werd [68Ga]SB3 
toegediend aan 17 patiënten met uitgebreide prostaat- of borstkanker. De stapeling 
van [68Ga]SB3 was het hoogste in de GRPR-rijke pancreas. [68Ga]SB3 PET scans waren 
positief bij 4/8 patiënten met borstkanker en 5/9 patiënten met prostaatkanker. Bij één 
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patiënt met prostaatkanker was de stapeling van [68Ga]SB3 PET/CT zelfs hoger dan die 
van 18F-choline  gemeten door middel van PET/CT. Wij konden concluderen dat [68Ga]SB3 
de  tumorlaesies goed visualiseert bij ongeveer 50% van de patiënten met uitgebreide 
prostaat- en borstkanker. Dit maakt dat [68Ga]SB3 een potentieel geschikt radioligand is 
voor het stageren en monitoren van prostaat- en borstkanker bij patiënten.   
Tot slot worden in Hoofdstuk 4.2 de resultaten van de artikelen in dit proefschrift 
besproken in het kader van de nieuwe ontwikkelingen en toekomstige therapeutische 
opties van PRRT bij patiënten met NET en prostaat- en borstkanker.
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PRRT in NET patients
In Chapter 1, the past and current status of peptide receptor radionuclide therapy 
(PRRT) for patients with neuroendocrine tumors (NETs) has been discussed (see Figure 
1). Chapter 2 outlined the (long-term) side eff ects of PRRT in patients. In 2017, an 
important phase III study (NETTER-1) was published, reporting the safety and effi  cacy 
of 177Lu-DOTATATE in patients with neuroendocrine tumors (NETs). This randomized 
control trial validated the experience that was gained over the past two decades and 
demonstrated that PRRT with 177Lu-DOTATATE has matured into a full treatment modality. 
However, new challenges and future improvements remain in the fi eld of PRRT.
Figure 1 – Timeline of PRRT in the past 25 years. Peptide Receptor Radionuclide Therapy (PRRT), 
NETest® is a circulating tumor molecular marker test for neuroendocrine tumor, Food and Drug 
Administration (FDA), European Medicines Agency (EMA). References (1-14).
Recently, a blood gene transcript analysis in NET patients has demonstrated an 
advantage in the early detection of residual disease (15). Also the measurement of 
circulating transcripts can predict the therapeutic effi  cacy of PRRT in NET patients (16). 
New biomarkers, like CTCs (circulating tumor cells), or circulating tumor DNA, as well 
as genetic profi ling of tumors might play a more prominent role in the future in the 
management of NET patients, in analogy with genomic tests in breast cancer patients 
(17).
The increasing number of treatment options for patients with GEP-NETs raised questions 
regarding timing, sequencing, and selection of therapies. Since there is limited data 
available, clinical judgment continues to play a critical role in the management of 
patients with GEP-NETs. Well-diff erentiated tumors may dediff erentiate to high-grade 
neoplasms, requiring more aggressive treatments (18). Treatment-related characteristics 
such as drug tolerability and therapy goals (tumor shrinkage versus delay of progression) 
are also important in defi ning treatment strategy. An interesting example of sequential 
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therapy is the ongoing HEPAR Plus trial, which evaluates radiological anti-tumor 
response after 166Ho-radioembolization (166Ho-RE) (19) and previous PRRT with 177Lu-
DOTATATE.  
Targeted alpha therapy is another and interesting form of PRRT, where the radionuclide 
177Lutetium is replaced with an alpha emitter, like in 213Bi-DOTATOC (20). However, limited 
data on alpha therapy in NET patients are still available. Also patients with recurrent 
metastasized prostate cancer could benefit from alpha therapy (21,22). However, since 
the physical characteristics of α-particles are different from dose of β-particles, (long-
term) toxicity profiles might also be different compared to PRRT with 177Lu-DOTATATE. 
All somatostatin analogs that are currently used in the clinic (i.e., DOTA-TATE, DOTA-
TOC, DOTA-NOC) are receptor agonists, inducing internalization of the receptor-ligand 
complex upon their binding to the receptor. PRRT with the somatostatin receptor 
antagonist 177Lu-DOTA-JR11 has demonstrated a higher tumor dose, compared to 
177Lu-DOTATATE (11). Interestingly, the two radiocompounds, 68Ga-DOTA-JR11 and 177Lu-
DOTA-JR11 are currently evaluated in an ongoing study in NET patients (ClinicalTrials.
gov NCT02609737). Little information is still available on the (long-term) toxicity of 
these new compounds.
Dosimetry
In this thesis, dosimetry was based on planar (2-dimensional) scans as well as radioactivity 
measured in urine and blood. Large errors have been reported when using this method 
of internal dose calculations and these uncertainties will obscure dose-effect relations. 
Therefore, MIRD pamphlet no. 23 reported that patient-specific dosimetry should be 
performed using quantitative SPECT (23). However, accurate dosimetry for PRRT is time-
consuming and not patient-friendly, since multiple scans need to be performed after 
each therapy cycle. Ideal dosimetry practice would entail simple, accurate dosimetry 
with minimal burden for the patient. Therefore we performed the first steps in a 
feasibility study for surrogate bonemarrow dosimetry, resulting in a lutetium dosimetry 
brace (LDB) placed on the upper thigh, see Figure 2 (24). This LDB can provide the 
kinetics, which leads to complete dose information when combined with SPECT/CT for 
the spatial distribution of the radionuclide. Currently, it is technical feasible to make 
a LDB with off the shelf electrical components. However, further development of the 
brace is needed. A future pilot study can explore ease of use and first clinical dosimetric 
results in comparison to full patient specific dosimetry. Not only dosimetry of the bone 
marrow but also of tumor lesions is feasible with this device. 
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Figure 2 – Feasibility analysis of lutetium dosimetry brace (LDB) (24).
Current dosimetry in PRRT faces a fundamental problem since both the dose calculation 
models and the toxicity dose thresholds are often based on idealized situations. The 
influences of low dose rates and inhomogeneous radiation exposure on dose response 
effects like secondary cancer induction are not well known. Large multi-cohort 
studies are needed to show incidence of second primary malignancies and with only 
retrospective cohort-based dosimetry available no clear indication of a dependency 
with absorbed dose can be found, let aside a clear safe threshold dose. 
Radiobiological parameter values in tumors are affected by tumor type and by a number 
of tumor biology-specific factors that include the hypoxic and metabolic or proliferative 
fraction of the tumor. The radiation sensitivity of neuroendocrine tumors has not been 
established. Therapies with 90Y-DOTATOC and 177Lu-DOTATATE did show significant 
reduction in volume after absorbed doses of more than 200 Gy (25,26). However, the 
large gap between this 200 Gy dose and the typical 70-80 Gy curative dose with external 
beam radiotherapy can be explained by the difference in dose rate and homogeneity. 
The study of Konijnenberg et al. (27) demonstrated a great impact on heterogeneity in 
renal dose distribution. In pancreatic NETs, extensive degenerative changes are seen 
microscopically after PRRT with 177Lu-DOTATATE (28). These changes of sclerosis and 
hyalinization modify the degree of homogeneity, influencing the absorbed dose to the 
tumor after consecutive cycles of PRRT.
Factors that play a role in the tumor dose after PRRT are more complex than in the 
external beam exposure field; Receptor-expressing tumor tissue is getting a high 
absorbed dose and it is intermingled with stromal tissue getting a lower cross-dose. 
At low tumor doses (< 200 Gy) the cross-dose to the interstitial stromal cells will be 
too low to create damage and subsequent reduction in volume, but might induce a 
immunological response, resulting in volume reduction. This concept was demonstrated 
in a case report, where immunotherapy was combined with radiation therapy and 
elicited a significant response, both within and outside the field of radiation.
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Depending upon the scale of the dosimetry calculation, the radiobiological parameters 
will vary across the normal tissue or tumor volume. To address this problem, new 
fundamental radiobiological research has to be done. 
With PRRT using 177Lu-DOTATATE, most published data are based on a fixed treatment 
schedule using 4 consecutive cycles of 7.4 GBq. This approach strongly relies on a 
cohort-based average dose treatment planning and is acceptable when the absorbed 
doses in organs at risk do not show much variation or when no toxicity is observed. Since 
the absorbed dose to the kidneys and bone marrow does show a variation between 
patients, this fixed dose regime reduces side effects but also potentially undertreats 
certain patients, resulting in a loss of effectiveness. In Sweden, implementation of 
patient-specific dosimetry has been applied in a large group of patients treated with 
177Lu-DOTATATE (29). However, this study used the conservative dose thresholds for the 
bone marrow and kidneys adopted from external beam radiotherapy (EBRT) resulting 
also in an under treatment in certain patients, despite these conventional dose 
thresholds, 50% of the patients received more than 4 therapy cycles. The effectiveness 
of PRRT might improve if a minimum target dose to the tumor is specified. In a recent 
study from Uppsala University Hospital (30), this approach resulted in confirmation of 
old results with 90Y-DOTATOC (25). 
Dosimetry might also be used as a tool for further exploration of different treatment 
schedules in Peptide Receptor Radionuclide Therapy (PRRT). In the study of Sarnelli 
et al. (31), clinical data was used to derive representative absorbed doses for several 
treatment schemes for PRRT with different radionuclides (like 177Lu, 90Y). Both uniform 
and non-uniform activity distributions were considered for the kidneys and potential 
uptake reduction and inter-patient radiosensitivity variability were investigated for 
tumors. Normal-Tissue-Complication-Probability (NTCP) and Tumor-Control-Probability 
(TCP) were evaluated. For all 177Lu-schemes the renal toxicity risk is negligible while for 
some 90Y-schemes the NTCP is not zero. In case of tumor uptake reduction with cycles 
the treatment efficacy is reduced with a BED loss up to 46%.
The publication by Sarnelli et al. (31) has some limitations, since fundamental 
radiobiological data is currently not known e.g. for calculating the inter-patient 
radiosensitivity for tumors. Also no data about cumulative dose to the kidneys after 
PRRT with different radionuclides (like 90Y, 177Lu) is at hand. Therefore the article by 
Sarnelli et al. (31) is more a theoretical exercise and presents a set of tools for future 
dosimetric modeling. 
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Gastrin-releasing peptide receptor radioligands
In Chapter 3 the gastrin releasing peptide receptor (GRPR) radioligand successor of 
99mTc-Demobesin-1, 68Ga-SB3 was introduced. This radiolabelled GRP receptor antagonist 
successfully localized early-stage lesions. However, in breast and prostate cancer 
patients with more advanced disease stages (including those who underwent multiple 
previous anticancer treatments), 68Ga-SB3 did not visualize all known lesions. Our results 
are in line with previous reports on the GRPR-expression levels during prostate cancer 
propagation and its relation to androgens (32-34). Therefore, in a subsequent ongoing 
study only patients with primary and therapy-naïve prostate cancer were included (35). 
Moreover, the intensity of tumor uptake was related to GRPR expression, determined in 
(surgically) excised biopsy material from patients. Preliminary results indicate that the 
effective targeting of 68Ga-SB3 seems higher in patients with primary prostate cancer 
than in patients with more advanced disease. The radiocompound labeled with 111In 
and 177Lu has also been investigated in mice, demonstrating a lower in vivo stability 
and an inferior uptake in prostate cancer xenografts as compared to 68Ga-SB3 (36). SB3 
seems therefore restricted to PET imaging of GRPR tumors. However in mice,  111In/177Lu-
SB3 coinjected with the protease inhibitor phosphoramidon achieved tumor uptake 
comparable to 68Ga-SB3. Other research groups have demonstrated that coadministration 
of key enzyme inhibitors can effectively prolong the survival of these radiolabeled 
peptides in vivo in the circulation, resulting in a effective transport to their target (37).
In the quest of radioligands with higher stability, a novel GRPR antagonist, NeoBOMB1 
was developed (38), based on a well-characterized GRPR antagonist (39). NeoBOMB1 
was labeled with 68Ga (for PET), 111In (for SPECT), and 177Lu (for radionuclide therapy). 
GRPR affinity and in vivo stability of the radiocompounds showed comparable behavior 
in prostate cancer models. Moreover, prostate cancer lesions were successfully visualized 
with 68Ga-NeoBOMB1 PET/CT in men. 
Another interesting target in prostate cancer is the prostate-specific membrane 
antigen (PSMA), which is expressed at the cell membrane of normal prostate cells, but 
is significantly up-regulated in primary and metastatic prostate cancer. 18F and 68Ga-
labeled small molecule PSMA inhibitors, demonstrated fast blood clearance and rapid 
and high tumor uptake in metastatic prostate cancer (43,44). The German retrospective 
multicenter study using 177Lu-PSMA-617 demonstrated favorable safety and high 
efficacy exceeding those of other third-line systemic therapies in prostate cancer 
patients. Future phase II/III studies are planned to further elucidate the survival benefit 
of this new therapy in patients with metastatic castration-resistant prostate cancer 
patients.
14802HBergsma_BW_DEF_15/8.indd   239 15-08-17   11:40
Chapter 4: Summary, discussion and future
240 
Figure 3 – Timeline of Gastrin Releasing Peptide Receptor (GRPR) radioligands recent past and 
future. Prostate-specific membrane antigen (PSMA). References; (40),(36,41),(42),(38).
The most widely used 68Ga-labeled bombesin analog in a clinical setting is  68Ga-
RM2/68Ga-BAY 86-7548 
(45). Recently a comparative study was performed between 68Ga-RM2 PET/MR imaging 
with 68Ga-PSMA-11 PET/CT in a small group of patients with recurrent prostate cancer 
(46). The study highlighted the differences in biodistribution between the 2 PET 
radiopharmaceuticals; PSMA-11 is excreted both renal and hepatobiliary, whereas 
RM2 is excreted mainly renal, which might have implications in the detection of pelvic 
and abdominal lesions. The two radiopharmaceuticals demonstrated similar, but not 
identical uptake patterns of distribution in the suspected lesions, demonstrating the 
difference between PSMA and GRPR in the course of the disease. 
Future studies have to be performed to compare the ability of GRPR agents to visualize 
primary and metastatic prostate cancer. Because of the heterogeneity of prostate 
cancer, it is likely that several imaging probes will prove clinically useful for imaging 
various types and stages of prostate cancer.
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List of abbreviations 
LIST OF ABBREVIATIONS
[99mTc]DB1 99mTc-(N′ )-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu- NHEt)
[99mTc]DB4 99mTc-N4-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val- Gly-His-Leu-
Nle-NH2
5-FU 5-Fluorouacil
5-HIAA 5-Hydroxy Indole Acetic Acid
68Ga-DOTATATE Gallium-68 labelled Octreotate
111In Indium-111
131I Iodine-131
177Lu Lutetium-177
177Lu-DOTA(-)TATE 177Lu-Octreotate
177Lu-Octreotate 177Lu-[DOTA0, Naphthyl3,Thr8]octreotate 
90Y Yttrium-90
μmol Micromolar
AA Amino Acid(s)
AL Acute Leukemia
AF Alkaline Phosphatase
ALAT (ALT) Alanine Amino-Transferase
AML Acute Myeloid Leukemia
ANOVA Analysis of Variance
Arg Arginine
ASAT (AST) Asparatate Transaminase
BED Biologically Effective Dose
Bq Becquerel. Conversion to Ci is obtained as follows: 1 mCi=37 MBq.
BSA Body Surface Area
C-G Cockcroft-Gault 
CgA Chromogranin A
Ci Curie. Has been replaced by the SI-unit Becquerel (Bq).
CI Confidence Interval
CLR Creatinine Clearance
CT Computed Tomography
CTCAE Common Terminology Criteria for Adverse Events
DOTA        1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
DOTA(-)NOC [DOTAo,Naphthyl3]octreotate
DOTA(-)TATE [DOTA0, Naphthyl3,Thr8]octreotate 
DOTA(-)TOC [DOTA0,Tyr3]octreotide
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List of abbreviations 
DLT Dose Limiting Toxicity 
EBRT External Beam Radiation Therapy
ECF Extracellular Fraction
ENETS European Neuroendocrine Tumor Society
Erasmus MC Erasmus Medical Center
EUS Endoscopic Ultrasound
exMDRD Extended Modification of Diet in Renal Disease
FDA Food and Drug Administration (USA)
FDG [18F]-Fluorodeoxyglucose
G1 Grade 1
G2 Grade 2
G3 Grade 3
Gamma-GT Gamma Glutamyl Transpeptidase
GBq Gigabecquerel (109 Bq) 
GEP Gastro-Entero-Pancreatic
GEP-NET(s) Gastro-Entero-Pancreatic Neuroendocrine Tumor(s)
GFR Glomerular Filtration Rate
GI Gastrointestinal
Gy Gray (J/kg)
h Hour
Hb Hemoglobin
HbA1c Glycosylated Hemoglobin
HPF High Power Field
HPLC High Performance Liquid Chromatography
HR Hazard Ratio
IA Infused Activity (Radioactivity)
IC50 inhibiting concentration 50% 
ICRP International Commission on Radiological Protection
IFN-α Interferon-alfa
IFN-β Interferon-beta
iv intravenous
keV Kilo Electron Volt
Ki-67 Ki-67 labeling index (using MIB-1 antibody)
L Litre(s)
LAR Long-Acting Release/Repeatable
LDH Lactate Dehydrogenase
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List of abbreviations 
LDST Low-Dose Short Synacthen
LH Luteinizing Hormone
LTB Low Tumor Burden
LQ Linear Quadratic (model)
Lys Lysine
Luthatera 177Lu-octreotate, [177Lu-DOTA0,Tyr3]octreotate
MBq Megabecquerel (106 Bq)
mCi milliCurie 
MCNP Monte Carlo Neutral Particle Transport
MDRD Modification of Diet in Renal Disease
MDS Myelodysplastic Syndrome
MDS/MPN Myelodysplastic/Myeloproliferative neoplasms
MIBG Metaiodobenzylguanidine
MIRD Medical Internal Radiation Dose Committee (part of the SNM)
mmol Millimolar
mo Months
MPN Myeloproliferative Neoplasms
MRI Magnetic Resonance Imaging
mSv milliSievert 
MTC Medullary Thyroid Carcinoma
mTOR mammalian Target of Rapamycin
n Number (of Patients)
NA Not Available
NaCl Sodium Chloride
NaI Sodium Iodide
NEC Neuroendocrine Carcinoma
NET Neuroendocrine Tumor
NR Not Reported
NSE Neuron-specific Enolase
NQ Not quantifiable
Octreoscan® 111In-[DTPA0]octreotide 
OS Overall Survival
PD Progressive Disease
PET Positron Emission Tomography
PET/CT Positron Emission Tomography/Computed Tomography
PFS Progression-Free Survival
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List of abbreviations 
PHD Persistent Hematological Dysfunction
PK Pharmacokinetics
PR Partial Response
PSA Prostate Specific Antigen
PRRT Peptide Receptor Radio(nuclide)therapy
RADAR Radiation Dose Assessment Resource
RECIST Response Evaluation Criteria in Solid Tumors
RFA Radiofrequency Ablation
ROI Region of Interest
RP-HPLC Reverse Phase High Performance Liquid Chromatography
RR Relative Risk
SCLC Small Cell Lung Carcinoma
SD Standard Deviation
SD Stable Disease
SI-unit International System of Units
SPECT Single Positron Emission Computed Tomography
SPSS Statistical Package for Social Sciences
SRS Somatostatin Receptor Scintigraphy
SSA Somatostatin Analog
sst Somatostatin receptor 
sst1-5 Somatostatin receptor subtype 1-5
TACE Transcatheter Arterial Chemoembolization
TNM Tumor, Lymph Node, Metastasies
ULN Upper Limit of Normal
WB Whole Body
WBC White Blood Cells
WHO World Health Organization
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LIST OF SYMBOLS
Table 1 – Symbols used in dosimetric equations.
Symbol Meaning
sf Surviving fraction of cells
D Absorbed dose
α, β Tissue specific constants
T Time
g(T)  Dimensionless function, which describes the probability of lethal 
combinations of reparable events over time (T)
D(T) Absorbed dose over time (T)
BED Biological Effective Dose
RE Relative effectiveness and 
N Number of given fractions
P(D) Probability of a clinical effect as a function of absorbed dose (D)
D50
Absorbed radiation dose which leads to 50% cure/complication 
probability
Drm Absorbed dose to the bone marrow
k Slope of the dose-response curve
hn, rS, rs Irradiation source
hk, k, rT, rt Irradiated target
D(rT, TD), D(rT) Mean absorbed dose to target tissue (rT) over a dose integration period (TD)
dose factors for red marrow to red marrow
TD Dose integration period
, , , Time-integrated activity = number of nuclear transformations
Time-integrated activity (number of nuclear transformations) in an 
irradiation source (rS) over a dose integration period (TD)
Time-integrated activity in the bone marrow
S Absorbed dose rate
Absorbed dose rate in the irradiated target (rT, rt) per nuclear 
transformation in the irradiation source (rS, rs)
C1-9 Compartments (or organs) 1 to 9
k(i,j) 
Kinetic transfer components between the indicated compartments i and j 
(organs)
Dkidneys Absorbed dose to the kidneys
Akidneys Number of nuclear transformations in kidneys
Absorbed dose rate for the kidneys
rm Red marrow = bone marrow
h large organs and tumors with high radioactivity uptake
Absorbed self-dose to the bonemarrow 
Absorbed cross-dose to the bonemarrow 
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List of symbols
Table 2 – Symbols used in renal function equations & statistics.
Renal
CLR Creatinine clearance in ml/min
Estimated average Creatinine clearance in ml/min
age Age of patient in years
weight, body-weight Weight of patient in kg
s-creat Serum creatinine in µmol/l
b0 Estimated average CLR at time 0 when all other covariates are zero
b1 Estimated average change in CLR in percent/time
factor1, factor2 Constants
time Time in weeks
GFR, Cx Glomerular Filtration Rate in ml/min, based on 24-h urine collection 
Ucreatinine Concentration creatinine in urine in µmol/l
V Urine production in ml/min
c-CLR Estimated creatinine clearance (CLR) in ml/min/ 1.73 m2 according to 
Cockcroft-Gault
BSA Body surface area according to Du Bois and Du Bois
height Height of patient in cm
BUN Patient’s Blood Urea Nitrogen in mmol/l
Alb Patient’s Albumin g/l
Statistics
95%CI 95% Confidence Interval
a Number of exposed patients with a positive (bad) outcome
b Number of exposed patients with a negative (good) outcome
c Number of non-exposed patients with a positive (bad) outcome
d Number of non-exposed patients with a negative (good) outcome
p Probability value for a given statistical model
R2 Correlation Coefficient (Pearson-R Squared)
Rspearman, rs Spearman’s rank correlation coefficient
rp Pearson correlation coefficient
RR Relative Risk
SE Standard error
Χ2 Chi-squared test
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